[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f0U5uEL9iqVebtMcKio1w2LtRoM3bzjG8hnGACAuGtek":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"University of Southern California",[4],775,false,157,17,1368764,74,524,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Obesity",26,{"name":18,"count":19},"Depression",16,{"name":21,"count":22},"Stage IIIA Breast Cancer",13,{"name":24,"count":25},"Colorectal Cancer",11,{"name":27,"count":25},"Stage II Breast Cancer",{"name":29,"count":25},"Stage IIIB Breast Cancer",{"name":31,"count":32},"Cancer",10,{"name":34,"count":32},"Malignant Neoplasm",[36,41,46,51,56,61,66,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03526159","Gentamicin for Junctional Epidermolysis Bullosa","2020-07-30","Gentamicin Sulfate",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT02495896","Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","2021-04-01","Cisplatin",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT03257761","Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer","2021-09-27","Durvalumab",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03657641","Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer","2023-02-27","Pembrolizumab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT05487807","Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia","2025-08-31","Nicotine patch",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06658054","Erector Spinae Plan Block (ESPB) with Dexmedetomidine and Dexamethasone in Lumbar Spine Fusion","2025-11","Adjuvant analgesia",{"nctId":67,"briefTitle":68,"date":69,"intervention":55},"NCT02717156","Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors","2025-11-21",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05623501","Phase I, Dose-Escalation Study of Dihydromyricetin (DHM) to Treat Alcohol-Associated Liver Disease","2025-12-31","Dihydromyricetin",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT06701071","Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation","2026-03","Clomiphene Citrate",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04988256","Cyclosporine Vs Steroids in DRESS","2026-04-30","Cyclosporine",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,119,137,167,189,217,235,355,465,538,576,607,629,707,784,815,851,878,896,914,939,957,984,1013,1031,1059,1077,1095,1121,1147,1175,1193,1219,1237,1271,1297,1315,1333,1358,1384,1408,1470,1492,1548,1604,1644,1692,1714,1736,1771,1789,1819,1840,1866,1884,1909,1934,1956,1974,1992,2010,2028,2046,2064,2082,2100,2118,2136,2154,2192,2214,2236,2254,2279,2304,2346,2376,2401,2419,2445,2469,2497,2515,2533,2557,2582,2600,2627,2645,2669,2691,2717,2741,2759,2777,2795,2813,2831,2856,2874,2892,2916,2934,2959,2977,3003,3030,3048,3075,3103,3130,3159,3177,3195,3213,3231,3249,3276,3302,3408,3461,3499,3524,3551,3576,3594,3621,3639,3664,3682,3707,3732,3758,3864,3906,3944,3978,4004,4030,4052,4084,4119,4141,4163,4191,4213,4235,4274,4296,4318,4336,4364,4382,4400,4418,4436,4462,4487,4510,4536,4559,4577,4595,4619,4643,4667,4693,4711,4737,4755,4773,4791,4816,4839,4864,4882,4900,4918,4936,4954,4972,4990,5008,5026,5044,5069,5096,5114,5139,5157,5175,5193,5215,5238,5265,5283,5301,5325,5343,5368,5392,5410,5432,5450,5472,5498,5516,5534,5567,5585,5603,5621,5639,5660,5684,5710,5740,5770,5788,5810,5835,5857,5875,5893,5911,5936,5954,5980,6007,6033,6051,6076,6094,6121,6144,6168,6186,6207,6229,6247,6275,6293,6311,6329,6347,6372,6397,6419,6441,6464,6487,6505,6527,6550,6573,6597,6625,6643,6661,6679,6703,6721,6739,6757,6775,6808,6853,6876,6894,6916,6940,6961,6985,7008,7032,7050,7078,7096,7120,7175,7193,7219,7237,7255,7273,7291,7312,7336,7354,7377,7399,7424,7442,7460,7478,7496,7520,7545,7576,7599,7617,7635,7653,7676,7699,7724,7745,7769,7795,7821,7839,7864,7894,7938,7975,7997,8026,8048,8085,8143,8170,8195,8213,8231,8254,8279,8297,8315,8338,8362,8386,8408,8431,8456,8474,8492,8510,8528,8546,8575,8593,8619,8637,8655,8673,8695,8718,8742,8767,8790,8808,8831,8856,8874,8899,8923,8941,8959,8983,9007,9028,9049,9073,9091],{"intervention":65,"totalTrials":94,"cells":95},1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":117},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":94,"soonestReadout":64},[107],{"nctId":62,"briefTitle":63,"status":108,"phases":109,"primaryCompletion":64,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":115},"NOT_YET_RECRUITING",[90],"2026-11","2024-11",46,[114],"Lumbar Degenerative Disease",[65,116],"Control",{"trials":118,"activeCount":98},[],{"intervention":116,"totalTrials":94,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":135},{"trials":122,"activeCount":98},[],{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":98},[],{"trials":130,"activeCount":94,"soonestReadout":64},[131],{"nctId":62,"briefTitle":63,"status":108,"phases":132,"primaryCompletion":64,"completion":110,"start":111,"enrollment":112,"conditions":133,"interventions":134},[90],[114],[65,116],{"trials":136,"activeCount":98},[],{"intervention":138,"totalTrials":94,"cells":139},"Zolpidem Tartrate 10 mg",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":165},{"trials":141,"activeCount":98},[],{"trials":143,"activeCount":98},[],{"trials":145,"activeCount":98},[],{"trials":147,"activeCount":98},[],{"trials":149,"activeCount":94,"soonestReadout":155},[150],{"nctId":151,"briefTitle":152,"status":153,"phases":154,"primaryCompletion":155,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":164},"NCT05746143","The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion","RECRUITING",[90],"2029-01-31","2030-12-31","2022-02-01",140,[160,161,162,163],"Spine Fusion","Lumbar Spine Degeneration","Pain, Postoperative","Lumbar Spine Spondylosis",[138],{"trials":166,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":187},{"trials":170,"activeCount":98},[],{"trials":172,"activeCount":98},[],{"trials":174,"activeCount":98},[],{"trials":176,"activeCount":98},[],{"trials":178,"activeCount":94,"soonestReadout":78},[179],{"nctId":76,"briefTitle":77,"status":153,"phases":180,"primaryCompletion":78,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},[90],"2027-12","2025-06-01",120,[185],"Infertility, Female",[79],{"trials":188,"activeCount":98},[],{"intervention":190,"totalTrials":94,"cells":191},"Cefixime 400mg",{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":213,"NA":215},{"trials":193,"activeCount":98},[],{"trials":195,"activeCount":98},[],{"trials":197,"activeCount":98},[],{"trials":199,"activeCount":94,"soonestReadout":204},[200],{"nctId":201,"briefTitle":202,"status":153,"phases":203,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":211},"NCT04958122","Cefixime Clinical Trial",[89],"2027-01-01","2027-06-30","2021-06-20",400,[209,210],"Syphilis","Human Immunodeficiency Virus",[190,212],"benzathine penicillin",{"trials":214,"activeCount":98},[],{"trials":216,"activeCount":98},[],{"intervention":212,"totalTrials":94,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":231,"NA":233},{"trials":220,"activeCount":98},[],{"trials":222,"activeCount":98},[],{"trials":224,"activeCount":98},[],{"trials":226,"activeCount":94,"soonestReadout":204},[227],{"nctId":201,"briefTitle":202,"status":153,"phases":228,"primaryCompletion":204,"completion":205,"start":206,"enrollment":207,"conditions":229,"interventions":230},[89],[209,210],[190,212],{"trials":232,"activeCount":98},[],{"trials":234,"activeCount":98},[],{"intervention":55,"totalTrials":236,"cells":237},6,{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":290,"PHASE3":349,"PHASE4":351,"NA":353},{"trials":239,"activeCount":98},[],{"trials":241,"activeCount":289,"soonestReadout":274},[242,270],{"nctId":243,"briefTitle":244,"status":245,"phases":246,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":251,"interventions":265},"NCT04616248","In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w\u002F Unresectable and Metastatic Solid Tumors","ACTIVE_NOT_RECRUITING",[87],"2027-01-09","2028-01-09","2023-01-09",14,[252,253,254,255,256,257,258,259,260,261,262,263,264],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Breast Carcinoma","Prognostic Stage IV Breast Cancer AJCC v8","Unresectable Breast Carcinoma","Metastatic Melanoma","Unresectable Melanoma","Cutaneous Squamous Cell Carcinoma","Merkel Cell Carcinoma","Soft Tissue Sarcoma","Bone Sarcoma","Sarcoma,Soft Tissue","Sarcoma of Bone","Basal Cell Carcinoma",[266,267,268,55,269],"Anti-CD40 Agonist Monoclonal Antibody CDX-1140","Poly ICLC","Recombinant Flt3 Ligand","Tocilizumab",{"nctId":271,"briefTitle":272,"status":245,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":277,"interventions":280},"NCT04387084","Short-term Fasting Prior to PD-1\u002FPD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy",[87],"2026-08-12","2027-08-12","2020-08-12",[278,279],"Advanced Malignant Skin Neoplasm","Metastatic Malignant Skin Neoplasm",[281,282,283,50,284,55,285,286,287,288],"Atezolizumab","Avelumab","Cemiplimab","Nivolumab","Dostarlimab","Retifanlimab","Toripalimab","Tislelizumab",2,{"trials":291,"activeCount":348,"soonestReadout":54},[292,301,324,334],{"nctId":52,"briefTitle":53,"status":245,"phases":293,"primaryCompletion":54,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":299},[87,88],"2026-06-21","2019-06-21",75,[24,298],"Colorectal Cancer Metastatic",[55,300],"Regorafenib",{"nctId":302,"briefTitle":303,"status":304,"phases":305,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":322},"NCT03049618","Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475","COMPLETED",[88],"2024-09-04","2017-03-10",42,[310,311,312,313,314,315,316,317,318,319,320,321],"ALK Gene Mutation","BRAF Gene Mutation","EGFR Gene Mutation","Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Carcinoma","Recurrent Head and Neck Carcinoma","Recurrent Non-Small Cell Lung Carcinoma","ROS1 Gene Mutation","Stage III Non-Small Cell Lung Cancer","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer",[55,323],"Recombinant EphB4-HSA Fusion Protein",{"nctId":67,"briefTitle":68,"status":245,"phases":325,"primaryCompletion":69,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":333},[88],"2026-11-21","2016-11-21",103,[330,331,332],"Stage IV Bladder Urothelial Carcinoma","Prostate Cancer","Urothelial Carcinoma",[55,323],{"nctId":335,"briefTitle":336,"status":245,"phases":337,"primaryCompletion":338,"completion":339,"start":340,"enrollment":32,"conditions":341,"interventions":344},"NCT05514990","Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial",[87,88],"2026-12-31","2027-08-22","2022-10-07",[342,343],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[345,346,347,55],"Bortezomib","Dexamethasone","Pelareorep",3,{"trials":350,"activeCount":98},[],{"trials":352,"activeCount":98},[],{"trials":354,"activeCount":98},[],{"intervention":323,"totalTrials":356,"cells":357},7,{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":435,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":359,"activeCount":98},[],{"trials":361,"activeCount":94,"soonestReadout":44},[362,382,395,417],{"nctId":42,"briefTitle":43,"status":245,"phases":363,"primaryCompletion":44,"completion":338,"start":364,"enrollment":365,"conditions":366,"interventions":378},[87],"2015-09-03",61,[313,367,368,369,370,316,371,372,319,373,320,374,321,375,376,377],"Metastatic Pancreatic Adenocarcinoma","Non-Resectable Cholangiocarcinoma","Pancreatic Adenocarcinoma","Recurrent Gallbladder Carcinoma","Stage III Pancreatic Cancer","Stage IIIA Gallbladder Cancer","Stage IIIB Gallbladder Cancer","Stage IV Gallbladder Cancer","Stage IV Pancreatic Cancer","Unresectable Gallbladder Carcinoma","Unresectable Pancreatic Cancer",[45,379,380,381,323],"Docetaxel","Gemcitabine Hydrochloride","Paclitaxel Albumin-Stabilized Nanoparticle Formulation",{"nctId":383,"briefTitle":384,"status":385,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":98,"conditions":390,"interventions":394},"NCT03552796","sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer","WITHDRAWN",[87],"2024-08-01","2025-08-01","2023-08-01",[391,392,393],"Recurrent Bladder Carcinoma","Bladder Cancer Stage 0","Bladder Cancer Stage I",[323],{"nctId":396,"briefTitle":397,"status":398,"phases":399,"primaryCompletion":400,"completion":400,"start":401,"enrollment":348,"conditions":402,"interventions":414},"NCT03519984","EphB4-HSA Fusion Protein and Cytarabine \u002For Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia","TERMINATED",[87],"2020-11-24","2018-05-09",[403,404,405,406,407,408,409,410,411,412,413],"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Blasts 5 Percent or More of Bone Marrow Nucleated Cells","Myelodysplastic\u002FMyeloproliferative Neoplasm","Philadelphia Chromosome Positive","Recurrent Acute Lymphoblastic Leukemia","Recurrent Adult Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia","Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Secondary Acute Myeloid Leukemia","T Acute Lymphoblastic Leukemia",[415,323,416],"Cytarabine","Vincristine Liposomal",{"nctId":418,"briefTitle":419,"status":398,"phases":420,"primaryCompletion":421,"completion":422,"start":423,"enrollment":289,"conditions":424,"interventions":434},"NCT02767921","sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer",[87],"2020-01-28","2021-11-15","2016-08-02",[425,391,426,427,428,429,430,431,432,433],"Infiltrating Bladder Urothelial Carcinoma","Stage I Prostate Cancer","Stage I Renal Cell Cancer","Stage II Bladder Urothelial Carcinoma","Stage II Renal Cell Cancer","Stage IIA Prostate Cancer","Stage IIB Prostate Cancer","Stage III Prostate Cancer","Stage III Renal Cell Cancer",[323],{"trials":436,"activeCount":94,"soonestReadout":69},[437,451,455],{"nctId":438,"briefTitle":439,"status":398,"phases":440,"primaryCompletion":441,"completion":442,"start":443,"enrollment":356,"conditions":444,"interventions":448},"NCT03146871","Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent",[88],"2019-03-19","2019-03-27","2017-04-20",[403,445,446,447,408],"Chronic Myelomonocytic Leukemia","Previously Treated Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes",[449,450,323],"Azacitidine","Decitabine",{"nctId":302,"briefTitle":303,"status":304,"phases":452,"primaryCompletion":306,"completion":306,"start":307,"enrollment":308,"conditions":453,"interventions":454},[88],[310,311,312,313,314,315,316,317,318,319,320,321],[55,323],{"nctId":67,"briefTitle":68,"status":245,"phases":456,"primaryCompletion":69,"completion":326,"start":327,"enrollment":328,"conditions":457,"interventions":458},[88],[330,331,332],[55,323],{"trials":460,"activeCount":98},[],{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"intervention":466,"totalTrials":348,"cells":467},"Guadecitabine",{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":503,"PHASE3":532,"PHASE4":534,"NA":536},{"trials":469,"activeCount":98},[],{"trials":471,"activeCount":94,"soonestReadout":49},[472],{"nctId":47,"briefTitle":48,"status":245,"phases":473,"primaryCompletion":49,"completion":338,"start":474,"enrollment":475,"conditions":476,"interventions":502},[87],"2018-02-07",55,[477,478,367,479,370,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,376,501],"Extrahepatic Bile Duct Adenocarcinoma, Biliary Type","Gallbladder Adenocarcinoma, Biliary Type","Recurrent Cholangiocarcinoma","Recurrent Hepatocellular Carcinoma","Recurrent Intrahepatic Cholangiocarcinoma","Recurrent Pancreatic Carcinoma","Stage III Gallbladder Cancer AJCC V7","Stage III Hepatocellular Carcinoma AJCC v7","Stage III Intrahepatic Cholangiocarcinoma AJCC v7","Stage III Pancreatic Cancer AJCC v6 and v7","Stage IIIA Gallbladder Cancer AJCC v7","Stage IIIA Hepatocellular Carcinoma AJCC v7","Stage IIIB Gallbladder Cancer AJCC v7","Stage IIIB Hepatocellular Carcinoma AJCC v7","Stage IIIC Hepatocellular Carcinoma AJCC v7","Stage IV Gallbladder Cancer AJCC v7","Stage IV Hepatocellular Carcinoma AJCC v7","Stage IV Pancreatic Cancer AJCC v6 and v7","Stage IVA Gallbladder Cancer AJCC v7","Stage IVA Hepatocellular Carcinoma AJCC v7","Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7","Stage IVB Gallbladder Cancer AJCC v7","Stage IVB Hepatocellular Carcinoma AJCC v7","Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7","Unresectable Pancreatic Carcinoma",[50,466],{"trials":504,"activeCount":94,"soonestReadout":338},[505,515],{"nctId":506,"briefTitle":507,"status":245,"phases":508,"primaryCompletion":338,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":514},"NCT02935361","Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed",[87,88],"2027-12-31","2016-11-02",33,[445,513,447],"Myelodysplastic Syndrome",[281,466],{"nctId":516,"briefTitle":517,"status":385,"phases":518,"primaryCompletion":519,"completion":520,"start":521,"enrollment":98,"conditions":522,"interventions":531},"NCT03576963","Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer",[87,88],"2022-01-30","2023-01-30","2020-01-30",[523,524,525,526,527,528,529,530],"Colorectal Adenocarcinoma","CpG Island Methylator Phenotype","Metastatic Microsatellite Stable Colorectal Carcinoma","Refractory Colorectal Carcinoma","Stage IV Colorectal Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8",[466,284],{"trials":533,"activeCount":98},[],{"trials":535,"activeCount":98},[],{"trials":537,"activeCount":98},[],{"intervention":539,"totalTrials":289,"cells":540},"Tirzepatide",{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":570,"PHASE4":572,"NA":574},{"trials":542,"activeCount":98},[],{"trials":544,"activeCount":98},[],{"trials":546,"activeCount":289,"soonestReadout":551},[547,558],{"nctId":548,"briefTitle":549,"status":153,"phases":550,"primaryCompletion":551,"completion":551,"start":552,"enrollment":308,"conditions":553,"interventions":557},"NCT06994338","Tirzepatide for Alcohol Use Disorder",[88],"2026-08-31","2025-10-06",[554,555,556],"Alcohol Use Disorder","Obesity and Overweight","Alcohol",[539],{"nctId":559,"briefTitle":560,"status":153,"phases":561,"primaryCompletion":562,"completion":563,"start":564,"enrollment":565,"conditions":566,"interventions":569},"NCT07602699","Multi-Site Trial of Tirzepatide for Smoking Cessation",[88],"2028-03","2028-09","2026-05-31",300,[567,568],"Smoking Cessation","Smoking Behaviors",[539],{"trials":571,"activeCount":98},[],{"trials":573,"activeCount":98},[],{"trials":575,"activeCount":98},[],{"intervention":283,"totalTrials":289,"cells":577},{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":586,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":579,"activeCount":98},[],{"trials":581,"activeCount":94,"soonestReadout":274},[582],{"nctId":271,"briefTitle":272,"status":245,"phases":583,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":584,"interventions":585},[87],[278,279],[281,282,283,50,284,55,285,286,287,288],{"trials":587,"activeCount":94,"soonestReadout":338},[588],{"nctId":589,"briefTitle":590,"status":245,"phases":591,"primaryCompletion":338,"completion":509,"start":592,"enrollment":593,"conditions":594,"interventions":600},"NCT04315701","A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer",[88],"2020-06-17",35,[595,596,597,598,599],"Recurrent Skin Squamous Cell Carcinoma","Resectable Skin Squamous Cell Carcinoma","Stage I Skin Cancer","Stage II Skin Cancer","Stage III Skin Cancer",[283],{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":98},[],{"intervention":281,"totalTrials":289,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":617,"PHASE3":623,"PHASE4":625,"NA":627},{"trials":610,"activeCount":98},[],{"trials":612,"activeCount":94,"soonestReadout":274},[613],{"nctId":271,"briefTitle":272,"status":245,"phases":614,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":615,"interventions":616},[87],[278,279],[281,282,283,50,284,55,285,286,287,288],{"trials":618,"activeCount":94,"soonestReadout":338},[619],{"nctId":506,"briefTitle":507,"status":245,"phases":620,"primaryCompletion":338,"completion":509,"start":510,"enrollment":511,"conditions":621,"interventions":622},[87,88],[445,513,447],[281,466],{"trials":624,"activeCount":98},[],{"trials":626,"activeCount":98},[],{"trials":628,"activeCount":98},[],{"intervention":630,"totalTrials":631,"cells":632},"Capecitabine",4,{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":682,"PHASE4":703,"NA":705},{"trials":634,"activeCount":98},[],{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":94,"soonestReadout":643},[639,655,670],{"nctId":640,"briefTitle":641,"status":153,"phases":642,"primaryCompletion":643,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":652},"NCT04333706","A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2\u002FNeu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)",[87,88],"2026-11-03","2027-05-03","2020-09-26",65,[648,649,650,31,651],"Breast","Metastatic","Triple Negative","Disseminated Tumor Cell",[630,653,654],"Sarilumab 150mg or 200 mg plus Capecitabine","Sarilumab 150mg plus Capecitabine",{"nctId":656,"briefTitle":657,"status":398,"phases":658,"primaryCompletion":659,"completion":659,"start":660,"enrollment":32,"conditions":661,"interventions":665},"NCT01873833","Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",[88],"2021-03-02","2013-07-29",[662,663,664],"HER2-positive Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer",[666,667,668,669],"capecitabine","cyclophosphamide","lapatinib ditosylate","trastuzumab",{"nctId":671,"briefTitle":672,"status":304,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT00159432","Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer",[88],"2009-06","2013-03","2005-02",63,[24],[680,681,630],"Oxaliplatin","Bevacizumab",{"trials":683,"activeCount":98},[684],{"nctId":685,"briefTitle":686,"status":398,"phases":687,"primaryCompletion":688,"completion":688,"start":689,"enrollment":631,"conditions":690,"interventions":699},"NCT03300609","5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab",[89],"2019-10-03","2018-02-27",[523,691,692,693,694,695,696,697,698],"RAS Wild Type","Stage III Colorectal Cancer AJCC v7","Stage IIIA Colorectal Cancer AJCC v7","Stage IIIB Colorectal Cancer AJCC v7","Stage IIIC Colorectal Cancer AJCC v7","Stage IV Colorectal Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7",[700,680,701,702,630],"Panitumumab","Leucovorin Calcium","Fluorouracil",{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[],{"intervention":415,"totalTrials":631,"cells":708},{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":753,"PHASE3":778,"PHASE4":780,"NA":782},{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[713,717],{"nctId":396,"briefTitle":397,"status":398,"phases":714,"primaryCompletion":400,"completion":400,"start":401,"enrollment":348,"conditions":715,"interventions":716},[87],[403,404,405,406,407,408,409,410,411,412,413],[415,323,416],{"nctId":718,"briefTitle":719,"status":398,"phases":720,"primaryCompletion":721,"completion":722,"start":723,"enrollment":32,"conditions":724,"interventions":750},"NCT01801046","Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia",[87],"2017-07-27","2017-08-20","2013-03-06",[725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744,745,746,408,747,412,748,749],"Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Childhood Acute Erythroleukemia (M6)","Childhood Acute Megakaryocytic Leukemia (M7)","Childhood Acute Monoblastic Leukemia (M5a)","Childhood Acute Monocytic Leukemia (M5b)","Childhood Acute Myeloblastic Leukemia With Maturation (M2)","Childhood Acute Myeloblastic Leukemia Without Maturation (M1)","Childhood Acute Myeloid Leukemia in Remission","Childhood Acute Myelomonocytic Leukemia (M4)","Recurrent Childhood Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia","Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies",[751,752],"mitoxantrone hydrochloride","cytarabine",{"trials":754,"activeCount":94,"soonestReadout":338},[755,766],{"nctId":756,"briefTitle":757,"status":385,"phases":758,"primaryCompletion":759,"completion":760,"start":761,"enrollment":98,"conditions":762,"interventions":763},"NCT02587871","Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission",[88],"2020-11-12","2022-11-12","2018-12-12",[730,745],[415,764,765],"Therapeutic Allogeneic Lymphocytes","G-CSF mobilized peripheral blood cells",{"nctId":767,"briefTitle":768,"status":245,"phases":769,"primaryCompletion":338,"completion":509,"start":770,"enrollment":771,"conditions":772,"interventions":775},"NCT03330821","Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia",[87,88],"2018-04-18",53,[403,773,774],"Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Therapy-Related Acute Myeloid Leukemia",[415,776,777],"Idarubicin","Pevonedistat",{"trials":779,"activeCount":98},[],{"trials":781,"activeCount":98},[],{"trials":783,"activeCount":98},[],{"intervention":40,"totalTrials":289,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":809,"PHASE4":811,"NA":813},{"trials":787,"activeCount":98},[],{"trials":789,"activeCount":98},[],{"trials":791,"activeCount":94,"soonestReadout":39},[792,802],{"nctId":793,"briefTitle":794,"status":304,"phases":795,"primaryCompletion":796,"completion":797,"start":798,"enrollment":236,"conditions":799,"interventions":801},"NCT03012191","Gentamicin for RDEB",[87,88],"2018-05-05","2018-08-31","2017-02-02",[800],"Recessive Dystrophic Epidermolysis Bullosa",[40],{"nctId":37,"briefTitle":38,"status":153,"phases":803,"primaryCompletion":39,"completion":804,"start":805,"enrollment":236,"conditions":806,"interventions":808},[87,88],"2020-08-31","2018-06-01",[807],"Junctional Epidermolysis Bullosa",[40],{"trials":810,"activeCount":98},[],{"trials":812,"activeCount":98},[],{"trials":814,"activeCount":98},[],{"intervention":300,"totalTrials":289,"cells":816},{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":818,"activeCount":98},[],{"trials":820,"activeCount":98},[],{"trials":822,"activeCount":94,"soonestReadout":54},[823,827],{"nctId":52,"briefTitle":53,"status":245,"phases":824,"primaryCompletion":54,"completion":294,"start":295,"enrollment":296,"conditions":825,"interventions":826},[87,88],[24,298],[55,300],{"nctId":828,"briefTitle":829,"status":304,"phases":830,"primaryCompletion":831,"completion":831,"start":832,"enrollment":348,"conditions":833,"interventions":843},"NCT02259725","Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors",[88],"2020-08-20","2016-08-16",[834,835,836,837,838,839,840,841,842],"Gastrinoma","Glucagonoma","Insulinoma","Metastatic Gastrointestinal Carcinoid Tumor","Pancreatic Polypeptide Tumor","Pulmonary Carcinoid Tumor","Recurrent Gastrointestinal Carcinoid Tumor","Recurrent Islet Cell Carcinoma","Somatostatinoma",[844],"regorafenib",{"trials":846,"activeCount":98},[],{"trials":848,"activeCount":98},[],{"trials":850,"activeCount":98},[],{"intervention":345,"totalTrials":289,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":866,"PHASE3":872,"PHASE4":874,"NA":876},{"trials":854,"activeCount":98},[],{"trials":856,"activeCount":98},[857],{"nctId":858,"briefTitle":859,"status":304,"phases":860,"primaryCompletion":861,"completion":861,"start":862,"enrollment":250,"conditions":863,"interventions":864},"NCT02514382","Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",[87],"2022-04-19","2015-08-21",[342,343],[345,346,865],"Wild-type Reovirus",{"trials":867,"activeCount":94,"soonestReadout":338},[868],{"nctId":335,"briefTitle":336,"status":245,"phases":869,"primaryCompletion":338,"completion":339,"start":340,"enrollment":32,"conditions":870,"interventions":871},[87,88],[342,343],[345,346,347,55],{"trials":873,"activeCount":98},[],{"trials":875,"activeCount":98},[],{"trials":877,"activeCount":98},[],{"intervention":653,"totalTrials":94,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":890,"PHASE4":892,"NA":894},{"trials":881,"activeCount":98},[],{"trials":883,"activeCount":98},[],{"trials":885,"activeCount":94,"soonestReadout":643},[886],{"nctId":640,"briefTitle":641,"status":153,"phases":887,"primaryCompletion":643,"completion":644,"start":645,"enrollment":646,"conditions":888,"interventions":889},[87,88],[648,649,650,31,651],[630,653,654],{"trials":891,"activeCount":98},[],{"trials":893,"activeCount":98},[],{"trials":895,"activeCount":98},[],{"intervention":654,"totalTrials":94,"cells":897},{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":902,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":899,"activeCount":98},[],{"trials":901,"activeCount":98},[],{"trials":903,"activeCount":94,"soonestReadout":643},[904],{"nctId":640,"briefTitle":641,"status":153,"phases":905,"primaryCompletion":643,"completion":644,"start":645,"enrollment":646,"conditions":906,"interventions":907},[87,88],[648,649,650,31,651],[630,653,654],{"trials":909,"activeCount":98},[],{"trials":911,"activeCount":98},[],{"trials":913,"activeCount":98},[],{"intervention":915,"totalTrials":94,"cells":916},"Group B, Linezolid 10d",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":918,"activeCount":98},[],{"trials":920,"activeCount":98},[],{"trials":922,"activeCount":94,"soonestReadout":927},[923],{"nctId":924,"briefTitle":925,"status":245,"phases":926,"primaryCompletion":927,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":931},"NCT05548426","Linezolid for Syphilis Pilot Study",[88],"2026-08","2023-09-28",24,[209],[915,932],"Group A, Penicillin",{"trials":934,"activeCount":98},[],{"trials":936,"activeCount":98},[],{"trials":938,"activeCount":98},[],{"intervention":932,"totalTrials":94,"cells":940},{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":942,"activeCount":98},[],{"trials":944,"activeCount":98},[],{"trials":946,"activeCount":94,"soonestReadout":927},[947],{"nctId":924,"briefTitle":925,"status":245,"phases":948,"primaryCompletion":927,"completion":927,"start":928,"enrollment":929,"conditions":949,"interventions":950},[88],[209],[915,932],{"trials":952,"activeCount":98},[],{"trials":954,"activeCount":98},[],{"trials":956,"activeCount":98},[],{"intervention":958,"totalTrials":94,"cells":959},"Enzalutamide",{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":978,"PHASE4":980,"NA":982},{"trials":961,"activeCount":98},[],{"trials":963,"activeCount":98},[],{"trials":965,"activeCount":94,"soonestReadout":326},[966],{"nctId":967,"briefTitle":968,"status":245,"phases":969,"primaryCompletion":326,"completion":970,"start":971,"enrollment":972,"conditions":973,"interventions":977},"NCT03344211","Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer",[88],"2027-11-21","2018-11-21",30,[974,975,976],"Castration-Resistant Prostate Carcinoma","Prostate Carcinoma Metastatic in the Bone","Stage IV Prostate Cancer",[958],{"trials":979,"activeCount":98},[],{"trials":981,"activeCount":98},[],{"trials":983,"activeCount":98},[],{"intervention":985,"totalTrials":94,"cells":986},"Anti-OX40 Antibody PF-04518600",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":1007,"PHASE4":1009,"NA":1011},{"trials":988,"activeCount":98},[],{"trials":990,"activeCount":98},[],{"trials":992,"activeCount":94,"soonestReadout":997},[993],{"nctId":994,"briefTitle":995,"status":245,"phases":996,"primaryCompletion":997,"completion":338,"start":998,"enrollment":999,"conditions":1000,"interventions":1005},"NCT03092856","Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer",[88],"2026-06-30","2017-07-19",62,[1001,1002,1003,1004],"Clear Cell Renal Cell Carcinoma","Metastatic Renal Cell Cancer","Recurrent Renal Cell Carcinoma","Stage IV Renal Cell Cancer",[985,1006],"Axitinib",{"trials":1008,"activeCount":98},[],{"trials":1010,"activeCount":98},[],{"trials":1012,"activeCount":98},[],{"intervention":1006,"totalTrials":94,"cells":1014},{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1025,"PHASE4":1027,"NA":1029},{"trials":1016,"activeCount":98},[],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":94,"soonestReadout":997},[1021],{"nctId":994,"briefTitle":995,"status":245,"phases":1022,"primaryCompletion":997,"completion":338,"start":998,"enrollment":999,"conditions":1023,"interventions":1024},[88],[1001,1002,1003,1004],[985,1006],{"trials":1026,"activeCount":98},[],{"trials":1028,"activeCount":98},[],{"trials":1030,"activeCount":98},[],{"intervention":1032,"totalTrials":94,"cells":1033},"Minocyclin",{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1053,"PHASE4":1055,"NA":1057},{"trials":1035,"activeCount":98},[],{"trials":1037,"activeCount":98},[],{"trials":1039,"activeCount":94,"soonestReadout":509},[1040],{"nctId":1041,"briefTitle":1042,"status":245,"phases":1043,"primaryCompletion":509,"completion":1044,"start":1045,"enrollment":1046,"conditions":1047,"interventions":1052},"NCT04876638","Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)",[88],"2028-12-30","2019-07-01",20,[1048,1049,1050,1051],"Aneurysm, Ruptured","Vasospasm, Intracranial","Delayed Cerebral Ischemia","Blood Brain Barrier Defect",[1032],{"trials":1054,"activeCount":98},[],{"trials":1056,"activeCount":98},[],{"trials":1058,"activeCount":98},[],{"intervention":776,"totalTrials":94,"cells":1060},{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1071,"PHASE4":1073,"NA":1075},{"trials":1062,"activeCount":98},[],{"trials":1064,"activeCount":98},[],{"trials":1066,"activeCount":94,"soonestReadout":338},[1067],{"nctId":767,"briefTitle":768,"status":245,"phases":1068,"primaryCompletion":338,"completion":509,"start":770,"enrollment":771,"conditions":1069,"interventions":1070},[87,88],[403,773,774],[415,776,777],{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":98},[],{"trials":1076,"activeCount":98},[],{"intervention":777,"totalTrials":94,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1080,"activeCount":98},[],{"trials":1082,"activeCount":98},[],{"trials":1084,"activeCount":94,"soonestReadout":338},[1085],{"nctId":767,"briefTitle":768,"status":245,"phases":1086,"primaryCompletion":338,"completion":509,"start":770,"enrollment":771,"conditions":1087,"interventions":1088},[87,88],[403,773,774],[415,776,777],{"trials":1090,"activeCount":98},[],{"trials":1092,"activeCount":98},[],{"trials":1094,"activeCount":98},[],{"intervention":1096,"totalTrials":94,"cells":1097},"Oral bazedoxifene 20 mg \u002F conjugated estrogens 0.45 mg",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1099,"activeCount":98},[],{"trials":1101,"activeCount":98},[],{"trials":1103,"activeCount":94,"soonestReadout":1108},[1104],{"nctId":1105,"briefTitle":1106,"status":245,"phases":1107,"primaryCompletion":1108,"completion":338,"start":1109,"enrollment":1110,"conditions":1111,"interventions":1114},"NCT04103476","Advancing Postmenopausal Preventive Therapy",[88],"2026-10-31","2021-04-13",385,[1112,1113],"Atherosclerosis","Cognitive Decline",[1096],{"trials":1116,"activeCount":98},[],{"trials":1118,"activeCount":98},[],{"trials":1120,"activeCount":98},[],{"intervention":1122,"totalTrials":94,"cells":1123},"Metformin Extended Release Oral",{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1141,"PHASE4":1143,"NA":1145},{"trials":1125,"activeCount":98},[],{"trials":1127,"activeCount":98},[],{"trials":1129,"activeCount":94,"soonestReadout":1134},[1130],{"nctId":1131,"briefTitle":1132,"status":108,"phases":1133,"primaryCompletion":1134,"completion":1135,"start":1136,"enrollment":1137,"conditions":1138,"interventions":1140},"NCT07129473","Hyperemesis Gravidarum Risk Reduction With Metformin",[88],"2030-01","2031-01","2026-01",224,[1139],"Hyperemesis Gravidarum",[1122],{"trials":1142,"activeCount":98},[],{"trials":1144,"activeCount":98},[],{"trials":1146,"activeCount":98},[],{"intervention":1148,"totalTrials":94,"cells":1149},"Angiotensin Receptor Blockers",{"EARLY_PHASE1":1150,"PHASE1":1152,"PHASE2":1154,"PHASE3":1169,"PHASE4":1171,"NA":1173},{"trials":1151,"activeCount":98},[],{"trials":1153,"activeCount":98},[],{"trials":1155,"activeCount":94,"soonestReadout":1160},[1156],{"nctId":1157,"briefTitle":1158,"status":108,"phases":1159,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":32,"conditions":1163,"interventions":1167},"NCT07447206","Vascular Intervention Strategies Trial for Alzheimer's",[88],"2027-06","2028-06","2026-05",[1164,1165,1166],"Hypertension","Hypercholesterolemia","Dementia Risk Factors",[1148,1168],"Hydrophilic Statins or Non-Statin Alternative",{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[],{"trials":1174,"activeCount":98},[],{"intervention":1168,"totalTrials":94,"cells":1176},{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1187,"PHASE4":1189,"NA":1191},{"trials":1178,"activeCount":98},[],{"trials":1180,"activeCount":98},[],{"trials":1182,"activeCount":94,"soonestReadout":1160},[1183],{"nctId":1157,"briefTitle":1158,"status":108,"phases":1184,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":32,"conditions":1185,"interventions":1186},[88],[1164,1165,1166],[1148,1168],{"trials":1188,"activeCount":98},[],{"trials":1190,"activeCount":98},[],{"trials":1192,"activeCount":98},[],{"intervention":1194,"totalTrials":94,"cells":1195},"80mg\u002Fday Ketamine HCl Prolonged Release",{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1197,"activeCount":98},[],{"trials":1199,"activeCount":98},[],{"trials":1201,"activeCount":94,"soonestReadout":1206},[1202],{"nctId":1203,"briefTitle":1204,"status":108,"phases":1205,"primaryCompletion":1206,"completion":1207,"start":1208,"enrollment":646,"conditions":1209,"interventions":1211},"NCT06419985","Ketamine HCl Prolonged Release Oral Tablets for CRPS",[88],"2028-01","2028-07","2026-07",[1210],"Complex Regional Pain Syndromes",[1194,1212],"160mg\u002Fday Ketamine HCl Prolonged Release",{"trials":1214,"activeCount":98},[],{"trials":1216,"activeCount":98},[],{"trials":1218,"activeCount":98},[],{"intervention":1212,"totalTrials":94,"cells":1220},{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1231,"PHASE4":1233,"NA":1235},{"trials":1222,"activeCount":98},[],{"trials":1224,"activeCount":98},[],{"trials":1226,"activeCount":94,"soonestReadout":1206},[1227],{"nctId":1203,"briefTitle":1204,"status":108,"phases":1228,"primaryCompletion":1206,"completion":1207,"start":1208,"enrollment":646,"conditions":1229,"interventions":1230},[88],[1210],[1194,1212],{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[],{"intervention":1238,"totalTrials":94,"cells":1239},"Atezolizumab and Recombinant Human Hyaluronidase",{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":94,"soonestReadout":338},[1246],{"nctId":1247,"briefTitle":1248,"status":245,"phases":1249,"primaryCompletion":338,"completion":509,"start":1250,"enrollment":1251,"conditions":1252,"interventions":1264},"NCT05340309","Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer",[88],"2022-12-07",5,[1253,1254,1255,1256,1257,1258,1259,1260,1261,1262,1263],"Lung Non-Small Cell Carcinoma","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8",[1238],{"trials":1266,"activeCount":98},[],{"trials":1268,"activeCount":98},[],{"trials":1270,"activeCount":98},[],{"intervention":1272,"totalTrials":94,"cells":1273},"Psilocybin plus mindfulness training",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1291,"PHASE4":1293,"NA":1295},{"trials":1275,"activeCount":98},[],{"trials":1277,"activeCount":98},[],{"trials":1279,"activeCount":94,"soonestReadout":927},[1280],{"nctId":1281,"briefTitle":1282,"status":153,"phases":1283,"primaryCompletion":927,"completion":1284,"start":1285,"enrollment":1286,"conditions":1287,"interventions":1289},"NCT06233344","Mindfulness-assisted Psychedelic Therapy",[88],"2027-08","2025-07-30",40,[1288],"Mental Health",[1272,1290],"Psilocybin",{"trials":1292,"activeCount":98},[],{"trials":1294,"activeCount":98},[],{"trials":1296,"activeCount":98},[],{"intervention":1290,"totalTrials":94,"cells":1298},{"EARLY_PHASE1":1299,"PHASE1":1301,"PHASE2":1303,"PHASE3":1309,"PHASE4":1311,"NA":1313},{"trials":1300,"activeCount":98},[],{"trials":1302,"activeCount":98},[],{"trials":1304,"activeCount":94,"soonestReadout":927},[1305],{"nctId":1281,"briefTitle":1282,"status":153,"phases":1306,"primaryCompletion":927,"completion":1284,"start":1285,"enrollment":1286,"conditions":1307,"interventions":1308},[88],[1288],[1272,1290],{"trials":1310,"activeCount":98},[],{"trials":1312,"activeCount":98},[],{"trials":1314,"activeCount":98},[],{"intervention":347,"totalTrials":94,"cells":1316},{"EARLY_PHASE1":1317,"PHASE1":1319,"PHASE2":1321,"PHASE3":1327,"PHASE4":1329,"NA":1331},{"trials":1318,"activeCount":98},[],{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":94,"soonestReadout":338},[1323],{"nctId":335,"briefTitle":336,"status":245,"phases":1324,"primaryCompletion":338,"completion":339,"start":340,"enrollment":32,"conditions":1325,"interventions":1326},[87,88],[342,343],[345,346,347,55],{"trials":1328,"activeCount":98},[],{"trials":1330,"activeCount":98},[],{"trials":1332,"activeCount":98},[],{"intervention":1334,"totalTrials":94,"cells":1335},"T2:C100",{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1352,"PHASE4":1354,"NA":1356},{"trials":1337,"activeCount":98},[],{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":94,"soonestReadout":83},[1342],{"nctId":1343,"briefTitle":1344,"status":245,"phases":1345,"primaryCompletion":83,"completion":1346,"start":1347,"enrollment":183,"conditions":1348,"interventions":1351},"NCT05644262","Life's End Benefits of cannaBidiol and tetrahYdrocannabinol",[88],"2026-08-01","2023-12-18",[1349,1350],"Agitation","Dementia",[1334],{"trials":1353,"activeCount":98},[],{"trials":1355,"activeCount":98},[],{"trials":1357,"activeCount":98},[],{"intervention":1359,"totalTrials":94,"cells":1360},"Imiquimod",{"EARLY_PHASE1":1361,"PHASE1":1363,"PHASE2":1365,"PHASE3":1378,"PHASE4":1380,"NA":1382},{"trials":1362,"activeCount":98},[],{"trials":1364,"activeCount":98},[],{"trials":1366,"activeCount":94,"soonestReadout":1371},[1367],{"nctId":1368,"briefTitle":1369,"status":153,"phases":1370,"primaryCompletion":1371,"completion":1371,"start":1372,"enrollment":1046,"conditions":1373,"interventions":1377},"NCT07210775","Topical Imiquimod Treatment of Oral Dysplasia",[87,88],"2027-10-01","2025-10-01",[1374,1375,1376],"Oral Dysplasia","Leukoplakia Oral","Leukoplakia",[1359],{"trials":1379,"activeCount":98},[],{"trials":1381,"activeCount":98},[],{"trials":1383,"activeCount":98},[],{"intervention":1385,"totalTrials":94,"cells":1386},"Danazol Pill",{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1402,"PHASE4":1404,"NA":1406},{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":94,"soonestReadout":1397},[1393],{"nctId":1394,"briefTitle":1395,"status":153,"phases":1396,"primaryCompletion":1397,"completion":1397,"start":387,"enrollment":32,"conditions":1398,"interventions":1401},"NCT04873102","Danazol for Treatment of Cytopenias in Patients With Cirrhosis",[88],"2027-08-01",[1399,1400],"Cirrhosis, Liver","Cytopenia",[1385],{"trials":1403,"activeCount":98},[],{"trials":1405,"activeCount":98},[],{"trials":1407,"activeCount":98},[],{"intervention":346,"totalTrials":1251,"cells":1409},{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1418,"PHASE3":1451,"PHASE4":1453,"NA":1455},{"trials":1411,"activeCount":98},[],{"trials":1413,"activeCount":98},[1414],{"nctId":858,"briefTitle":859,"status":304,"phases":1415,"primaryCompletion":861,"completion":861,"start":862,"enrollment":250,"conditions":1416,"interventions":1417},[87],[342,343],[345,346,865],{"trials":1419,"activeCount":94,"soonestReadout":338},[1420,1433,1447],{"nctId":1421,"briefTitle":1422,"status":304,"phases":1423,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":593,"conditions":1427,"interventions":1429},"NCT00003449","Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer",[88],"2002-06","2004-02","1998-05",[1428],"Ovarian Cancer",[1430,1431,1432],"dexamethasone","gemcitabine hydrochloride","paclitaxel",{"nctId":1434,"briefTitle":1435,"status":398,"phases":1436,"primaryCompletion":1437,"completion":1438,"start":1439,"enrollment":22,"conditions":1440,"interventions":1444},"NCT01518465","Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma",[88],"2016-12-31","2017-10-31","2012-01-09",[1441,1442,1443],"Stage I Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma",[1445,1446,1430],"dalteparin","lenalidomide",{"nctId":335,"briefTitle":336,"status":245,"phases":1448,"primaryCompletion":338,"completion":339,"start":340,"enrollment":32,"conditions":1449,"interventions":1450},[87,88],[342,343],[345,346,347,55],{"trials":1452,"activeCount":98},[],{"trials":1454,"activeCount":98},[],{"trials":1456,"activeCount":98},[1457],{"nctId":1458,"briefTitle":1459,"status":398,"phases":1460,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1467},"NCT02550119","Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy",[91],"2010-04-01","2006-04-19",19,[1465,1466],"Malignant Digestive System Neoplasm","Nausea and Vomiting",[1468,346,1469],"Aprepitant","Dolasetron Mesylate",{"intervention":50,"totalTrials":289,"cells":1471},{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1484,"PHASE3":1486,"PHASE4":1488,"NA":1490},{"trials":1473,"activeCount":98},[],{"trials":1475,"activeCount":289,"soonestReadout":49},[1476,1480],{"nctId":47,"briefTitle":48,"status":245,"phases":1477,"primaryCompletion":49,"completion":338,"start":474,"enrollment":475,"conditions":1478,"interventions":1479},[87],[477,478,367,479,370,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,376,501],[50,466],{"nctId":271,"briefTitle":272,"status":245,"phases":1481,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":1482,"interventions":1483},[87],[278,279],[281,282,283,50,284,55,285,286,287,288],{"trials":1485,"activeCount":98},[],{"trials":1487,"activeCount":98},[],{"trials":1489,"activeCount":98},[],{"trials":1491,"activeCount":98},[],{"intervention":379,"totalTrials":631,"cells":1493},{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1502,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":94,"soonestReadout":44},[1498],{"nctId":42,"briefTitle":43,"status":245,"phases":1499,"primaryCompletion":44,"completion":338,"start":364,"enrollment":365,"conditions":1500,"interventions":1501},[87],[313,367,368,369,370,316,371,372,319,373,320,374,321,375,376,377],[45,379,380,381,323],{"trials":1503,"activeCount":98},[1504,1516,1527],{"nctId":1505,"briefTitle":1506,"status":304,"phases":1507,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":1046,"conditions":1511,"interventions":1513},"NCT00183924","Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.",[88],"2006-07","2008-12","2001-03",[1512],"Prostate Adenocarcinoma",[1514,379,1515],"Estramustine","Carboplatin",{"nctId":1517,"briefTitle":1518,"status":398,"phases":1519,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":1524,"interventions":1525},"NCT00183937","Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer",[88],"2010-10-23","2012-06-11","2005-04-30",15,[331],[1526,379],"PS 341",{"nctId":1528,"briefTitle":1529,"status":398,"phases":1530,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":1523,"conditions":1534,"interventions":1539},"NCT01382706","Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder",[88],"2013-07-15","2017-12-15","2011-06-13",[1535,1536,1537,1538],"Recurrent Bladder Cancer","Stage III Bladder Cancer","Stage IV Bladder Cancer","Transitional Cell Carcinoma of the Bladder",[1540,668,1541],"docetaxel","fluorescence in situ hybridization",{"trials":1543,"activeCount":98},[],{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":98},[],{"intervention":1549,"totalTrials":631,"cells":1550},"Cyclophosphamide",{"EARLY_PHASE1":1551,"PHASE1":1553,"PHASE2":1567,"PHASE3":1598,"PHASE4":1600,"NA":1602},{"trials":1552,"activeCount":98},[],{"trials":1554,"activeCount":94,"soonestReadout":509},[1555],{"nctId":1556,"briefTitle":1557,"status":153,"phases":1558,"primaryCompletion":509,"completion":1559,"start":1560,"enrollment":1046,"conditions":1561,"interventions":1563},"NCT05989828","A2-ESO-1 TCR-Engineered T Cells for Relapsed\u002FRefractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer",[87],"2028-12-31","2024-12-17",[1562],"Triple Negative Breast Cancer",[1564,1565,1549,1566],"Aldesleukin","Anti-HLA-A2\u002FNY-ESO-1 TCR-transduced Autologous T Lymphocytes","Fludarabine",{"trials":1568,"activeCount":98},[1569,1583,1587],{"nctId":1570,"briefTitle":1571,"status":398,"phases":1572,"primaryCompletion":1573,"completion":1574,"start":1575,"enrollment":32,"conditions":1576,"interventions":1579},"NCT03267680","IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3",[88],"2023-08-04","2024-03-13","2017-11-08",[1577,1578],"Cervical Squamous Cell Carcinoma In Situ","Vulvar High Grade Squamous Intraepithelial Lesion",[1549,1580,1581,1582],"Indomethacin","IRX-2","Omeprazole",{"nctId":656,"briefTitle":657,"status":398,"phases":1584,"primaryCompletion":659,"completion":659,"start":660,"enrollment":32,"conditions":1585,"interventions":1586},[88],[662,663,664],[666,667,668,669],{"nctId":1588,"briefTitle":1589,"status":304,"phases":1590,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":112,"conditions":1593,"interventions":1595},"NCT00003050","Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer",[88],"2000-03","1997-04",[1594],"Breast Cancer",[667,1596,1432,1597],"doxorubicin hydrochloride","tamoxifen citrate",{"trials":1599,"activeCount":98},[],{"trials":1601,"activeCount":98},[],{"trials":1603,"activeCount":98},[],{"intervention":1431,"totalTrials":348,"cells":1605},{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1614,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":94,"soonestReadout":44},[1610],{"nctId":42,"briefTitle":43,"status":245,"phases":1611,"primaryCompletion":44,"completion":338,"start":364,"enrollment":365,"conditions":1612,"interventions":1613},[87],[313,367,368,369,370,316,371,372,319,373,320,374,321,375,376,377],[45,379,380,381,323],{"trials":1615,"activeCount":98},[1616,1620],{"nctId":1421,"briefTitle":1422,"status":304,"phases":1617,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":593,"conditions":1618,"interventions":1619},[88],[1428],[1430,1431,1432],{"nctId":1621,"briefTitle":1622,"status":385,"phases":1623,"primaryCompletion":1624,"completion":1624,"start":1624,"enrollment":98,"conditions":1625,"interventions":1633},"NCT01639521","Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer",[88],"2013-05",[1626,1627,1628,1535,1629,1630,1536,1538,1631,1632],"Anterior Urethral Cancer","Localized Transitional Cell Cancer of the Renal Pelvis and Ureter","Posterior Urethral Cancer","Recurrent Urethral Cancer","Regional Transitional Cell Cancer of the Renal Pelvis and Ureter","Ureter Cancer","Urethral Cancer Associated With Invasive Bladder Cancer",[1634,1431,1635,1636,1596,1637],"cisplatin","methotrexate","vinblastine","pegfilgrastim",{"trials":1639,"activeCount":98},[],{"trials":1641,"activeCount":98},[],{"trials":1643,"activeCount":98},[],{"intervention":1645,"totalTrials":348,"cells":1646},"aldesleukin",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1664,"PHASE3":1686,"PHASE4":1688,"NA":1690},{"trials":1648,"activeCount":98},[],{"trials":1650,"activeCount":94,"soonestReadout":509},[1651,1660],{"nctId":1652,"briefTitle":1653,"status":398,"phases":1654,"primaryCompletion":1655,"completion":1655,"start":1656,"enrollment":19,"conditions":1657,"interventions":1659},"NCT00003009","Inhaled Interleukin-2 in Treating Patients With Metastatic or Unresectable Cancer",[87],"2000-08","1996-02",[1658],"Unspecified Adult Solid Tumor, Protocol Specific",[1645],{"nctId":1556,"briefTitle":1557,"status":153,"phases":1661,"primaryCompletion":509,"completion":1559,"start":1560,"enrollment":1046,"conditions":1662,"interventions":1663},[87],[1562],[1564,1565,1549,1566],{"trials":1665,"activeCount":98},[1666],{"nctId":1667,"briefTitle":1668,"status":398,"phases":1669,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1676},"NCT00006113","Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma",[88],"2003-05","2006-04","1999-06",25,[1675],"Melanoma (Skin)",[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],"MART-1 antigen","gp100 antigen","recombinant CD40-ligand","recombinant interferon gamma","recombinant interleukin-4","sargramostim","therapeutic autologous dendritic cells","therapeutic tumor infiltrating lymphocytes","tyrosinase peptide",{"trials":1687,"activeCount":98},[],{"trials":1689,"activeCount":98},[],{"trials":1691,"activeCount":98},[],{"intervention":45,"totalTrials":289,"cells":1693},{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1702,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1695,"activeCount":98},[],{"trials":1697,"activeCount":94,"soonestReadout":44},[1698],{"nctId":42,"briefTitle":43,"status":245,"phases":1699,"primaryCompletion":44,"completion":338,"start":364,"enrollment":365,"conditions":1700,"interventions":1701},[87],[313,367,368,369,370,316,371,372,319,373,320,374,321,375,376,377],[45,379,380,381,323],{"trials":1703,"activeCount":98},[1704],{"nctId":1621,"briefTitle":1622,"status":385,"phases":1705,"primaryCompletion":1624,"completion":1624,"start":1624,"enrollment":98,"conditions":1706,"interventions":1707},[88],[1626,1627,1628,1535,1629,1630,1536,1538,1631,1632],[1634,1431,1635,1636,1596,1637],{"trials":1709,"activeCount":98},[],{"trials":1711,"activeCount":98},[],{"trials":1713,"activeCount":98},[],{"intervention":284,"totalTrials":289,"cells":1715},{"EARLY_PHASE1":1716,"PHASE1":1718,"PHASE2":1724,"PHASE3":1730,"PHASE4":1732,"NA":1734},{"trials":1717,"activeCount":98},[],{"trials":1719,"activeCount":94,"soonestReadout":274},[1720],{"nctId":271,"briefTitle":272,"status":245,"phases":1721,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":1722,"interventions":1723},[87],[278,279],[281,282,283,50,284,55,285,286,287,288],{"trials":1725,"activeCount":98},[1726],{"nctId":516,"briefTitle":517,"status":385,"phases":1727,"primaryCompletion":519,"completion":520,"start":521,"enrollment":98,"conditions":1728,"interventions":1729},[87,88],[523,524,525,526,527,528,529,530],[466,284],{"trials":1731,"activeCount":98},[],{"trials":1733,"activeCount":98},[],{"trials":1735,"activeCount":98},[],{"intervention":1737,"totalTrials":289,"cells":1738},"PEOX-based Polymer Encapsulated Paclitaxel FID-007",{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1763,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1740,"activeCount":98},[],{"trials":1742,"activeCount":94,"soonestReadout":338},[1743,1752],{"nctId":1744,"briefTitle":1745,"status":398,"phases":1746,"primaryCompletion":1747,"completion":1748,"start":1749,"enrollment":94,"conditions":1750,"interventions":1751},"NCT06338657","FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer",[87],"2025-09-03","2025-09-09","2024-04-01",[313],[1737],{"nctId":1753,"briefTitle":1754,"status":245,"phases":1755,"primaryCompletion":338,"completion":1756,"start":1757,"enrollment":1758,"conditions":1759,"interventions":1762},"NCT03537690","FID-007 in Treating Participants With Advanced Solid Tumors",[87],"2027-05-25","2018-05-25",50,[1760,1761],"Advanced Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm",[1737],{"trials":1764,"activeCount":98},[],{"trials":1766,"activeCount":98},[],{"trials":1768,"activeCount":98},[],{"trials":1770,"activeCount":98},[],{"intervention":381,"totalTrials":94,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1781,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":94,"soonestReadout":44},[1777],{"nctId":42,"briefTitle":43,"status":245,"phases":1778,"primaryCompletion":44,"completion":338,"start":364,"enrollment":365,"conditions":1779,"interventions":1780},[87],[313,367,368,369,370,316,371,372,319,373,320,374,321,375,376,377],[45,379,380,381,323],{"trials":1782,"activeCount":98},[],{"trials":1784,"activeCount":98},[],{"trials":1786,"activeCount":98},[],{"trials":1788,"activeCount":98},[],{"intervention":1790,"totalTrials":94,"cells":1791},"RNA Transcription Modulator AU-409",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1811,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1793,"activeCount":98},[],{"trials":1795,"activeCount":94,"soonestReadout":1800},[1796],{"nctId":1797,"briefTitle":1798,"status":153,"phases":1799,"primaryCompletion":1800,"completion":1801,"start":1802,"enrollment":1803,"conditions":1804,"interventions":1810},"NCT05791448","AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease",[87],"2027-03-29","2028-03-29","2023-03-29",36,[1805,1806,1760,1807,1761,1808,1809],"Advanced Cholangiocarcinoma","Advanced Hepatocellular Carcinoma","Metastatic Malignant Neoplasm in the Liver","Stage III Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8",[1790],{"trials":1812,"activeCount":98},[],{"trials":1814,"activeCount":98},[],{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"intervention":74,"totalTrials":94,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1832,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1822,"activeCount":98},[],{"trials":1824,"activeCount":94,"soonestReadout":73},[1825],{"nctId":71,"briefTitle":72,"status":108,"phases":1826,"primaryCompletion":73,"completion":73,"start":1827,"enrollment":1828,"conditions":1829,"interventions":1831},[87],"2024-09-15",12,[1830],"Alcohol-Related Disorders",[74],{"trials":1833,"activeCount":98},[],{"trials":1835,"activeCount":98},[],{"trials":1837,"activeCount":98},[],{"trials":1839,"activeCount":98},[],{"intervention":1841,"totalTrials":94,"cells":1842},"Balstilimab",{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1858,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1844,"activeCount":98},[],{"trials":1846,"activeCount":94,"soonestReadout":1851},[1847],{"nctId":1848,"briefTitle":1849,"status":153,"phases":1850,"primaryCompletion":1851,"completion":1852,"start":1853,"enrollment":1523,"conditions":1854,"interventions":1856},"NCT06336902","Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer",[87],"2027-01-15","2028-01-15","2025-01-15",[1855,527],"Metastatic Colorectal Adenocarcinoma",[1841,1857],"Botensilimab",{"trials":1859,"activeCount":98},[],{"trials":1861,"activeCount":98},[],{"trials":1863,"activeCount":98},[],{"trials":1865,"activeCount":98},[],{"intervention":1857,"totalTrials":94,"cells":1867},{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1876,"PHASE3":1878,"PHASE4":1880,"NA":1882},{"trials":1869,"activeCount":98},[],{"trials":1871,"activeCount":94,"soonestReadout":1851},[1872],{"nctId":1848,"briefTitle":1849,"status":153,"phases":1873,"primaryCompletion":1851,"completion":1852,"start":1853,"enrollment":1523,"conditions":1874,"interventions":1875},[87],[1855,527],[1841,1857],{"trials":1877,"activeCount":98},[],{"trials":1879,"activeCount":98},[],{"trials":1881,"activeCount":98},[],{"trials":1883,"activeCount":98},[],{"intervention":1885,"totalTrials":94,"cells":1886},"d-beta-hydroxybutrate",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1901,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":94,"soonestReadout":1895},[1891],{"nctId":1892,"briefTitle":1893,"status":108,"phases":1894,"primaryCompletion":1895,"completion":1895,"start":1896,"enrollment":1758,"conditions":1897,"interventions":1900},"NCT07218497","Investigating the Evolutionary Impact of Metabolic Flexibility on Physical Activity-Dependent BDNF and Cognition: Insights From the Val66Met Polymorphism",[87],"2027-05-01","2025-11-01",[1898,1899],"Cognition","BDNF",[1885],{"trials":1902,"activeCount":98},[],{"trials":1904,"activeCount":98},[],{"trials":1906,"activeCount":98},[],{"trials":1908,"activeCount":98},[],{"intervention":1910,"totalTrials":94,"cells":1911},"Ultradent Ultra Seal XT Plus",{"EARLY_PHASE1":1912,"PHASE1":1914,"PHASE2":1926,"PHASE3":1928,"PHASE4":1930,"NA":1932},{"trials":1913,"activeCount":98},[],{"trials":1915,"activeCount":94,"soonestReadout":997},[1916],{"nctId":1917,"briefTitle":1918,"status":153,"phases":1919,"primaryCompletion":997,"completion":997,"start":1920,"enrollment":1921,"conditions":1922,"interventions":1925},"NCT06342258","COES: Curing Order Effects on Sealants",[87],"2024-02-23",217,[1923,1924],"Dental Sealant","Sealant Retention",[1910],{"trials":1927,"activeCount":98},[],{"trials":1929,"activeCount":98},[],{"trials":1931,"activeCount":98},[],{"trials":1933,"activeCount":98},[],{"intervention":60,"totalTrials":94,"cells":1935},{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1948,"PHASE3":1950,"PHASE4":1952,"NA":1954},{"trials":1937,"activeCount":98},[],{"trials":1939,"activeCount":94,"soonestReadout":59},[1940],{"nctId":57,"briefTitle":58,"status":153,"phases":1941,"primaryCompletion":59,"completion":551,"start":1942,"enrollment":1943,"conditions":1944,"interventions":1947},[87],"2023-09-13",800,[1945,1946],"Nicotine Dependence","Tobacco Dependence",[60],{"trials":1949,"activeCount":98},[],{"trials":1951,"activeCount":98},[],{"trials":1953,"activeCount":98},[],{"trials":1955,"activeCount":98},[],{"intervention":266,"totalTrials":94,"cells":1957},{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1966,"PHASE3":1968,"PHASE4":1970,"NA":1972},{"trials":1959,"activeCount":98},[],{"trials":1961,"activeCount":94,"soonestReadout":247},[1962],{"nctId":243,"briefTitle":244,"status":245,"phases":1963,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":1964,"interventions":1965},[87],[252,253,254,255,256,257,258,259,260,261,262,263,264],[266,267,268,55,269],{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[],{"trials":1971,"activeCount":98},[],{"trials":1973,"activeCount":98},[],{"intervention":267,"totalTrials":94,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1984,"PHASE3":1986,"PHASE4":1988,"NA":1990},{"trials":1977,"activeCount":98},[],{"trials":1979,"activeCount":94,"soonestReadout":247},[1980],{"nctId":243,"briefTitle":244,"status":245,"phases":1981,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":1982,"interventions":1983},[87],[252,253,254,255,256,257,258,259,260,261,262,263,264],[266,267,268,55,269],{"trials":1985,"activeCount":98},[],{"trials":1987,"activeCount":98},[],{"trials":1989,"activeCount":98},[],{"trials":1991,"activeCount":98},[],{"intervention":268,"totalTrials":94,"cells":1993},{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":2002,"PHASE3":2004,"PHASE4":2006,"NA":2008},{"trials":1995,"activeCount":98},[],{"trials":1997,"activeCount":94,"soonestReadout":247},[1998],{"nctId":243,"briefTitle":244,"status":245,"phases":1999,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":2000,"interventions":2001},[87],[252,253,254,255,256,257,258,259,260,261,262,263,264],[266,267,268,55,269],{"trials":2003,"activeCount":98},[],{"trials":2005,"activeCount":98},[],{"trials":2007,"activeCount":98},[],{"trials":2009,"activeCount":98},[],{"intervention":269,"totalTrials":94,"cells":2011},{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2020,"PHASE3":2022,"PHASE4":2024,"NA":2026},{"trials":2013,"activeCount":98},[],{"trials":2015,"activeCount":94,"soonestReadout":247},[2016],{"nctId":243,"briefTitle":244,"status":245,"phases":2017,"primaryCompletion":247,"completion":248,"start":249,"enrollment":250,"conditions":2018,"interventions":2019},[87],[252,253,254,255,256,257,258,259,260,261,262,263,264],[266,267,268,55,269],{"trials":2021,"activeCount":98},[],{"trials":2023,"activeCount":98},[],{"trials":2025,"activeCount":98},[],{"trials":2027,"activeCount":98},[],{"intervention":1565,"totalTrials":94,"cells":2029},{"EARLY_PHASE1":2030,"PHASE1":2032,"PHASE2":2038,"PHASE3":2040,"PHASE4":2042,"NA":2044},{"trials":2031,"activeCount":98},[],{"trials":2033,"activeCount":94,"soonestReadout":509},[2034],{"nctId":1556,"briefTitle":1557,"status":153,"phases":2035,"primaryCompletion":509,"completion":1559,"start":1560,"enrollment":1046,"conditions":2036,"interventions":2037},[87],[1562],[1564,1565,1549,1566],{"trials":2039,"activeCount":98},[],{"trials":2041,"activeCount":98},[],{"trials":2043,"activeCount":98},[],{"trials":2045,"activeCount":98},[],{"intervention":1566,"totalTrials":94,"cells":2047},{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2056,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2049,"activeCount":98},[],{"trials":2051,"activeCount":94,"soonestReadout":509},[2052],{"nctId":1556,"briefTitle":1557,"status":153,"phases":2053,"primaryCompletion":509,"completion":1559,"start":1560,"enrollment":1046,"conditions":2054,"interventions":2055},[87],[1562],[1564,1565,1549,1566],{"trials":2057,"activeCount":98},[],{"trials":2059,"activeCount":98},[],{"trials":2061,"activeCount":98},[],{"trials":2063,"activeCount":98},[],{"intervention":282,"totalTrials":94,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2074,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":2067,"activeCount":98},[],{"trials":2069,"activeCount":94,"soonestReadout":274},[2070],{"nctId":271,"briefTitle":272,"status":245,"phases":2071,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":2072,"interventions":2073},[87],[278,279],[281,282,283,50,284,55,285,286,287,288],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[],{"trials":2079,"activeCount":98},[],{"trials":2081,"activeCount":98},[],{"intervention":285,"totalTrials":94,"cells":2083},{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2092,"PHASE3":2094,"PHASE4":2096,"NA":2098},{"trials":2085,"activeCount":98},[],{"trials":2087,"activeCount":94,"soonestReadout":274},[2088],{"nctId":271,"briefTitle":272,"status":245,"phases":2089,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":2090,"interventions":2091},[87],[278,279],[281,282,283,50,284,55,285,286,287,288],{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[],{"trials":2097,"activeCount":98},[],{"trials":2099,"activeCount":98},[],{"intervention":286,"totalTrials":94,"cells":2101},{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2110,"PHASE3":2112,"PHASE4":2114,"NA":2116},{"trials":2103,"activeCount":98},[],{"trials":2105,"activeCount":94,"soonestReadout":274},[2106],{"nctId":271,"briefTitle":272,"status":245,"phases":2107,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":2108,"interventions":2109},[87],[278,279],[281,282,283,50,284,55,285,286,287,288],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"trials":2115,"activeCount":98},[],{"trials":2117,"activeCount":98},[],{"intervention":287,"totalTrials":94,"cells":2119},{"EARLY_PHASE1":2120,"PHASE1":2122,"PHASE2":2128,"PHASE3":2130,"PHASE4":2132,"NA":2134},{"trials":2121,"activeCount":98},[],{"trials":2123,"activeCount":94,"soonestReadout":274},[2124],{"nctId":271,"briefTitle":272,"status":245,"phases":2125,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":2126,"interventions":2127},[87],[278,279],[281,282,283,50,284,55,285,286,287,288],{"trials":2129,"activeCount":98},[],{"trials":2131,"activeCount":98},[],{"trials":2133,"activeCount":98},[],{"trials":2135,"activeCount":98},[],{"intervention":288,"totalTrials":94,"cells":2137},{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2146,"PHASE3":2148,"PHASE4":2150,"NA":2152},{"trials":2139,"activeCount":98},[],{"trials":2141,"activeCount":94,"soonestReadout":274},[2142],{"nctId":271,"briefTitle":272,"status":245,"phases":2143,"primaryCompletion":274,"completion":275,"start":276,"enrollment":32,"conditions":2144,"interventions":2145},[87],[278,279],[281,282,283,50,284,55,285,286,287,288],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"trials":2151,"activeCount":98},[],{"trials":2153,"activeCount":98},[],{"intervention":2155,"totalTrials":289,"cells":2156},"Perflutren Lipid Microspheres",{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2173,"PHASE3":2175,"PHASE4":2177,"NA":2179},{"trials":2158,"activeCount":98},[],{"trials":2160,"activeCount":94,"soonestReadout":2165},[2161],{"nctId":2162,"briefTitle":2163,"status":153,"phases":2164,"primaryCompletion":2165,"completion":2166,"start":2167,"enrollment":2168,"conditions":2169,"interventions":2171},"NCT06171607","Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses",[87],"2026-11-05","2027-11-05","2020-11-05",100,[2170],"Breast Carcinoma",[2155,2172],"Sulfur Hexafluoride Lipid Microspheres",{"trials":2174,"activeCount":98},[],{"trials":2176,"activeCount":98},[],{"trials":2178,"activeCount":98},[],{"trials":2180,"activeCount":98},[2181],{"nctId":2182,"briefTitle":2183,"status":385,"phases":2184,"primaryCompletion":2185,"completion":2186,"start":2187,"enrollment":98,"conditions":2188,"interventions":2190},"NCT03300401","Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization",[91],"2019-11-07","2020-11-07","2017-11-07",[2189],"Hepatocellular Carcinoma",[2155,2172,2191],"Yttrium-90",{"intervention":2172,"totalTrials":289,"cells":2193},{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2202,"PHASE3":2204,"PHASE4":2206,"NA":2208},{"trials":2195,"activeCount":98},[],{"trials":2197,"activeCount":94,"soonestReadout":2165},[2198],{"nctId":2162,"briefTitle":2163,"status":153,"phases":2199,"primaryCompletion":2165,"completion":2166,"start":2167,"enrollment":2168,"conditions":2200,"interventions":2201},[87],[2170],[2155,2172],{"trials":2203,"activeCount":98},[],{"trials":2205,"activeCount":98},[],{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[2210],{"nctId":2182,"briefTitle":2183,"status":385,"phases":2211,"primaryCompletion":2185,"completion":2186,"start":2187,"enrollment":98,"conditions":2212,"interventions":2213},[91],[2189],[2155,2172,2191],{"intervention":84,"totalTrials":94,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2226,"PHASE2":2228,"PHASE3":2230,"PHASE4":2232,"NA":2234},{"trials":2217,"activeCount":94,"soonestReadout":83},[2218],{"nctId":81,"briefTitle":82,"status":2219,"phases":2220,"primaryCompletion":83,"completion":997,"start":49,"enrollment":1758,"conditions":2221,"interventions":2224},"ENROLLING_BY_INVITATION",[86],[2222,2223],"DRESS Syndrome","Drug-Induced Hypersensitivity Syndrome",[84,2225],"Methylprednisolone and Prednisone",{"trials":2227,"activeCount":98},[],{"trials":2229,"activeCount":98},[],{"trials":2231,"activeCount":98},[],{"trials":2233,"activeCount":98},[],{"trials":2235,"activeCount":98},[],{"intervention":2225,"totalTrials":94,"cells":2237},{"EARLY_PHASE1":2238,"PHASE1":2244,"PHASE2":2246,"PHASE3":2248,"PHASE4":2250,"NA":2252},{"trials":2239,"activeCount":94,"soonestReadout":83},[2240],{"nctId":81,"briefTitle":82,"status":2219,"phases":2241,"primaryCompletion":83,"completion":997,"start":49,"enrollment":1758,"conditions":2242,"interventions":2243},[86],[2222,2223],[84,2225],{"trials":2245,"activeCount":98},[],{"trials":2247,"activeCount":98},[],{"trials":2249,"activeCount":98},[],{"trials":2251,"activeCount":98},[],{"trials":2253,"activeCount":98},[],{"intervention":556,"totalTrials":94,"cells":2255},{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2260,"PHASE3":2262,"PHASE4":2264,"NA":2266},{"trials":2257,"activeCount":98},[],{"trials":2259,"activeCount":98},[],{"trials":2261,"activeCount":98},[],{"trials":2263,"activeCount":98},[],{"trials":2265,"activeCount":98},[],{"trials":2267,"activeCount":94,"soonestReadout":2272},[2268],{"nctId":2269,"briefTitle":2270,"status":153,"phases":2271,"primaryCompletion":2272,"completion":2272,"start":2273,"enrollment":2274,"conditions":2275,"interventions":2278},"NCT06627803","Social Facilitation of Alcohol Effects and Alcohol Misuse in Young Adults",[91],"2029-08-31","2025-02-20",200,[2276,2277],"Alcohol Consumption","Alcohol Abuse\u002FDependence",[556],{"intervention":2280,"totalTrials":94,"cells":2281},"Blood sample",{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2288,"PHASE4":2290,"NA":2292},{"trials":2283,"activeCount":98},[],{"trials":2285,"activeCount":98},[],{"trials":2287,"activeCount":98},[],{"trials":2289,"activeCount":98},[],{"trials":2291,"activeCount":98},[],{"trials":2293,"activeCount":94,"soonestReadout":2298},[2294],{"nctId":2295,"briefTitle":2296,"status":2219,"phases":2297,"primaryCompletion":2298,"completion":2299,"start":2300,"enrollment":2168,"conditions":2301,"interventions":2303},"NCT03275610","Genetic Markers of Patients With History of Pulmonary Embolism Post Total Joint Arthroplasty",[],"2030-04-23","2035-04-23","2017-04-24",[2302],"Pulmonary Embolism",[2280],{"intervention":2305,"totalTrials":289,"cells":2306},"Celecoxib",{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2324,"PHASE4":2326,"NA":2344},{"trials":2308,"activeCount":98},[],{"trials":2310,"activeCount":98},[],{"trials":2312,"activeCount":98},[2313],{"nctId":2314,"briefTitle":2315,"status":304,"phases":2316,"primaryCompletion":2317,"completion":2318,"start":2319,"enrollment":296,"conditions":2320,"interventions":2322},"NCT00159484","Phase I\u002FII Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer",[87,88],"2015-01-13","2023-03-23","2004-10-12",[2321,24],"Colon Cancer",[2323,2305],"EPO906",{"trials":2325,"activeCount":98},[],{"trials":2327,"activeCount":98},[2328],{"nctId":2329,"briefTitle":2330,"status":398,"phases":2331,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2335,"interventions":2336},"NCT02987920","Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty",[90],"2018-01","2017-01",23,[162],[2337,2338,2339,2305,2340,2341,2342,2343],"Dextromethorphan","Acetaminophen","Oxycodone","Pantoprazole","Ketorolac","Gabapentin","Hydromorphone",{"trials":2345,"activeCount":98},[],{"intervention":2343,"totalTrials":289,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2356,"NA":2374},{"trials":2349,"activeCount":98},[],{"trials":2351,"activeCount":98},[],{"trials":2353,"activeCount":98},[],{"trials":2355,"activeCount":98},[],{"trials":2357,"activeCount":98},[2358,2362],{"nctId":2329,"briefTitle":2330,"status":398,"phases":2359,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2360,"interventions":2361},[90],[162],[2337,2338,2339,2305,2340,2341,2342,2343],{"nctId":2363,"briefTitle":2364,"status":398,"phases":2365,"primaryCompletion":2366,"completion":2367,"start":2368,"enrollment":2369,"conditions":2370,"interventions":2372},"NCT03104816","The Effectiveness of IV\u002FPO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion",[90],"2017-10","2017-12","2016-10",28,[2371],"Fusion of Spine, Lumbar Region",[2373,2338,2343],"Acetaminophen IV Soln 10 MG\u002FML",{"trials":2375,"activeCount":98},[],{"intervention":2377,"totalTrials":94,"cells":2378},"Tedizolid PO",{"EARLY_PHASE1":2379,"PHASE1":2381,"PHASE2":2383,"PHASE3":2385,"PHASE4":2387,"NA":2399},{"trials":2380,"activeCount":98},[],{"trials":2382,"activeCount":98},[],{"trials":2384,"activeCount":98},[],{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[2389],{"nctId":2390,"briefTitle":2391,"status":304,"phases":2392,"primaryCompletion":2393,"completion":2393,"start":2394,"enrollment":25,"conditions":2395,"interventions":2397},"NCT02444234","Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis",[90],"2017-12-31","2015-07",[2396],"Cystic Fibrosis",[2377,2398],"Tedizolid IV",{"trials":2400,"activeCount":98},[],{"intervention":2398,"totalTrials":94,"cells":2402},{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2407,"PHASE3":2409,"PHASE4":2411,"NA":2417},{"trials":2404,"activeCount":98},[],{"trials":2406,"activeCount":98},[],{"trials":2408,"activeCount":98},[],{"trials":2410,"activeCount":98},[],{"trials":2412,"activeCount":98},[2413],{"nctId":2390,"briefTitle":2391,"status":304,"phases":2414,"primaryCompletion":2393,"completion":2393,"start":2394,"enrollment":25,"conditions":2415,"interventions":2416},[90],[2396],[2377,2398],{"trials":2418,"activeCount":98},[],{"intervention":2420,"totalTrials":94,"cells":2421},"Elagolix 200 MG Oral Tablet [Orilissa]",{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2428,"PHASE4":2430,"NA":2443},{"trials":2423,"activeCount":98},[],{"trials":2425,"activeCount":98},[],{"trials":2427,"activeCount":98},[],{"trials":2429,"activeCount":98},[],{"trials":2431,"activeCount":98},[2432],{"nctId":2433,"briefTitle":2434,"status":2435,"phases":2436,"primaryCompletion":2437,"completion":2438,"start":2439,"enrollment":1828,"conditions":2440,"interventions":2442},"NCT04060992","Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle","UNKNOWN",[90],"2020-10-30","2021-07-01","2019-10-01",[2441],"Ovulation; Failure or Lack of",[2420],{"trials":2444,"activeCount":98},[],{"intervention":2446,"totalTrials":94,"cells":2447},"Kuvan",{"EARLY_PHASE1":2448,"PHASE1":2450,"PHASE2":2452,"PHASE3":2454,"PHASE4":2456,"NA":2467},{"trials":2449,"activeCount":98},[],{"trials":2451,"activeCount":98},[],{"trials":2453,"activeCount":98},[],{"trials":2455,"activeCount":98},[],{"trials":2457,"activeCount":98},[2458],{"nctId":2459,"briefTitle":2460,"status":304,"phases":2461,"primaryCompletion":2462,"completion":2462,"start":2463,"enrollment":32,"conditions":2464,"interventions":2466},"NCT01617070","Effects of Kuvan on Melatonin Secretion",[90],"2014-12","2012-05",[2465],"Phenylketonuria (PKU)",[2446],{"trials":2468,"activeCount":98},[],{"intervention":2470,"totalTrials":94,"cells":2471},"Haloperidol",{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2480,"NA":2495},{"trials":2473,"activeCount":98},[],{"trials":2475,"activeCount":98},[],{"trials":2477,"activeCount":98},[],{"trials":2479,"activeCount":98},[],{"trials":2481,"activeCount":98},[2482],{"nctId":2483,"briefTitle":2484,"status":304,"phases":2485,"primaryCompletion":2486,"completion":2487,"start":2488,"enrollment":2489,"conditions":2490,"interventions":2491},"NCT00457366","A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room",[90],"2008-08","2009-05","2006-05",72,[1349],[2492,2470,2493,2494],"Quetiapine","Lorazepam","Cogentin",{"trials":2496,"activeCount":98},[],{"intervention":2493,"totalTrials":94,"cells":2498},{"EARLY_PHASE1":2499,"PHASE1":2501,"PHASE2":2503,"PHASE3":2505,"PHASE4":2507,"NA":2513},{"trials":2500,"activeCount":98},[],{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[],{"trials":2506,"activeCount":98},[],{"trials":2508,"activeCount":98},[2509],{"nctId":2483,"briefTitle":2484,"status":304,"phases":2510,"primaryCompletion":2486,"completion":2487,"start":2488,"enrollment":2489,"conditions":2511,"interventions":2512},[90],[1349],[2492,2470,2493,2494],{"trials":2514,"activeCount":98},[],{"intervention":2494,"totalTrials":94,"cells":2516},{"EARLY_PHASE1":2517,"PHASE1":2519,"PHASE2":2521,"PHASE3":2523,"PHASE4":2525,"NA":2531},{"trials":2518,"activeCount":98},[],{"trials":2520,"activeCount":98},[],{"trials":2522,"activeCount":98},[],{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[2527],{"nctId":2483,"briefTitle":2484,"status":304,"phases":2528,"primaryCompletion":2486,"completion":2487,"start":2488,"enrollment":2489,"conditions":2529,"interventions":2530},[90],[1349],[2492,2470,2493,2494],{"trials":2532,"activeCount":98},[],{"intervention":2534,"totalTrials":94,"cells":2535},"Doxycycline",{"EARLY_PHASE1":2536,"PHASE1":2538,"PHASE2":2540,"PHASE3":2542,"PHASE4":2544,"NA":2555},{"trials":2537,"activeCount":98},[],{"trials":2539,"activeCount":98},[],{"trials":2541,"activeCount":98},[],{"trials":2543,"activeCount":98},[],{"trials":2545,"activeCount":98},[2546],{"nctId":2547,"briefTitle":2548,"status":304,"phases":2549,"primaryCompletion":2550,"completion":2550,"start":2551,"enrollment":2552,"conditions":2553,"interventions":2554},"NCT01323101","Doxycycline Effects on Inflammation in Cystic Fibrosis",[90],"2010-12","2008-04",21,[2396],[2534],{"trials":2556,"activeCount":98},[],{"intervention":2558,"totalTrials":94,"cells":2559},"Tolvaptan",{"EARLY_PHASE1":2560,"PHASE1":2562,"PHASE2":2564,"PHASE3":2566,"PHASE4":2568,"NA":2580},{"trials":2561,"activeCount":98},[],{"trials":2563,"activeCount":98},[],{"trials":2565,"activeCount":98},[],{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[2570],{"nctId":2571,"briefTitle":2572,"status":304,"phases":2573,"primaryCompletion":2574,"completion":2575,"start":2462,"enrollment":511,"conditions":2576,"interventions":2578},"NCT02183792","Aquaresis Utility for Hyponatremic Acute Heart Failure Study",[90],"2018-02","2018-03",[2577],"Heart Failure",[2558,2579],"Furosemide",{"trials":2581,"activeCount":98},[],{"intervention":2579,"totalTrials":94,"cells":2583},{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2590,"PHASE4":2592,"NA":2598},{"trials":2585,"activeCount":98},[],{"trials":2587,"activeCount":98},[],{"trials":2589,"activeCount":98},[],{"trials":2591,"activeCount":98},[],{"trials":2593,"activeCount":98},[2594],{"nctId":2571,"briefTitle":2572,"status":304,"phases":2595,"primaryCompletion":2574,"completion":2575,"start":2462,"enrollment":511,"conditions":2596,"interventions":2597},[90],[2577],[2558,2579],{"trials":2599,"activeCount":98},[],{"intervention":2601,"totalTrials":94,"cells":2602},"Bupivacaine liposome",{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2611,"NA":2625},{"trials":2604,"activeCount":98},[],{"trials":2606,"activeCount":98},[],{"trials":2608,"activeCount":98},[],{"trials":2610,"activeCount":98},[],{"trials":2612,"activeCount":98},[2613],{"nctId":2614,"briefTitle":2615,"status":304,"phases":2616,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":1286,"conditions":2620,"interventions":2623},"NCT03638960","Interscalene Single Shot With Plain Bupivacaine Versus Liposomal Bupivacaine for Arthroscopic Shoulder Surgery",[90],"2023-01-11","2023-06-06","2019-02-21",[2621,2622],"Shoulder Pain","Postoperative Pain",[2601,2624],"Bupivacaine Hydrochloride",{"trials":2626,"activeCount":98},[],{"intervention":2624,"totalTrials":94,"cells":2628},{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2635,"PHASE4":2637,"NA":2643},{"trials":2630,"activeCount":98},[],{"trials":2632,"activeCount":98},[],{"trials":2634,"activeCount":98},[],{"trials":2636,"activeCount":98},[],{"trials":2638,"activeCount":98},[2639],{"nctId":2614,"briefTitle":2615,"status":304,"phases":2640,"primaryCompletion":2617,"completion":2618,"start":2619,"enrollment":1286,"conditions":2641,"interventions":2642},[90],[2621,2622],[2601,2624],{"trials":2644,"activeCount":98},[],{"intervention":2646,"totalTrials":94,"cells":2647},"Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg",{"EARLY_PHASE1":2648,"PHASE1":2650,"PHASE2":2652,"PHASE3":2654,"PHASE4":2656,"NA":2667},{"trials":2649,"activeCount":98},[],{"trials":2651,"activeCount":98},[],{"trials":2653,"activeCount":98},[],{"trials":2655,"activeCount":98},[],{"trials":2657,"activeCount":98},[2658],{"nctId":2659,"briefTitle":2660,"status":2435,"phases":2661,"primaryCompletion":2662,"completion":2662,"start":2663,"enrollment":1286,"conditions":2664,"interventions":2666},"NCT03711253","Empiric Treatment for Acute HIV in the ED",[90],"2023-06-01","2019-10-14",[2665],"Acute HIV Infection",[2646],{"trials":2668,"activeCount":98},[],{"intervention":2670,"totalTrials":94,"cells":2671},"Ceftazidime\u002Favibactam",{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2676,"PHASE3":2678,"PHASE4":2680,"NA":2689},{"trials":2673,"activeCount":98},[],{"trials":2675,"activeCount":98},[],{"trials":2677,"activeCount":98},[],{"trials":2679,"activeCount":98},[],{"trials":2681,"activeCount":98},[2682],{"nctId":2683,"briefTitle":2684,"status":304,"phases":2685,"primaryCompletion":2368,"completion":2368,"start":2686,"enrollment":1828,"conditions":2687,"interventions":2688},"NCT02504827","Steady-state Pharmacokinetics of Ceftazidime\u002FAvibactam in Cystic Fibrosis",[90],"2015-09",[2396],[2670],{"trials":2690,"activeCount":98},[],{"intervention":2692,"totalTrials":94,"cells":2693},"Docusate Sodium",{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2698,"PHASE3":2700,"PHASE4":2702,"NA":2715},{"trials":2695,"activeCount":98},[],{"trials":2697,"activeCount":98},[],{"trials":2699,"activeCount":98},[],{"trials":2701,"activeCount":98},[],{"trials":2703,"activeCount":98},[2704],{"nctId":2705,"briefTitle":2706,"status":398,"phases":2707,"primaryCompletion":2708,"completion":2709,"start":2710,"enrollment":2711,"conditions":2712,"interventions":2714},"NCT03523715","Prunes for Gastrointestinal Function After Gynecologic Surgery",[90],"2020-06-30","2020-07-31","2017-11-30",77,[2713],"Constipation",[2692],{"trials":2716,"activeCount":98},[],{"intervention":2718,"totalTrials":94,"cells":2719},"Neostigmine",{"EARLY_PHASE1":2720,"PHASE1":2722,"PHASE2":2724,"PHASE3":2726,"PHASE4":2728,"NA":2739},{"trials":2721,"activeCount":98},[],{"trials":2723,"activeCount":98},[],{"trials":2725,"activeCount":98},[],{"trials":2727,"activeCount":98},[],{"trials":2729,"activeCount":98},[2730],{"nctId":2731,"briefTitle":2732,"status":2435,"phases":2733,"primaryCompletion":388,"completion":388,"start":2734,"enrollment":2735,"conditions":2736,"interventions":2738},"NCT04951726","Neostigmine Route for Acute Colonic Pseudo Obstruction",[90],"2022-02-04",90,[2737],"Ogilvie Syndrome",[2718],{"trials":2740,"activeCount":98},[],{"intervention":2337,"totalTrials":94,"cells":2742},{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2749,"PHASE4":2751,"NA":2757},{"trials":2744,"activeCount":98},[],{"trials":2746,"activeCount":98},[],{"trials":2748,"activeCount":98},[],{"trials":2750,"activeCount":98},[],{"trials":2752,"activeCount":98},[2753],{"nctId":2329,"briefTitle":2330,"status":398,"phases":2754,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2755,"interventions":2756},[90],[162],[2337,2338,2339,2305,2340,2341,2342,2343],{"trials":2758,"activeCount":98},[],{"intervention":2339,"totalTrials":94,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2769,"NA":2775},{"trials":2762,"activeCount":98},[],{"trials":2764,"activeCount":98},[],{"trials":2766,"activeCount":98},[],{"trials":2768,"activeCount":98},[],{"trials":2770,"activeCount":98},[2771],{"nctId":2329,"briefTitle":2330,"status":398,"phases":2772,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2773,"interventions":2774},[90],[162],[2337,2338,2339,2305,2340,2341,2342,2343],{"trials":2776,"activeCount":98},[],{"intervention":2340,"totalTrials":94,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2785,"PHASE4":2787,"NA":2793},{"trials":2780,"activeCount":98},[],{"trials":2782,"activeCount":98},[],{"trials":2784,"activeCount":98},[],{"trials":2786,"activeCount":98},[],{"trials":2788,"activeCount":98},[2789],{"nctId":2329,"briefTitle":2330,"status":398,"phases":2790,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2791,"interventions":2792},[90],[162],[2337,2338,2339,2305,2340,2341,2342,2343],{"trials":2794,"activeCount":98},[],{"intervention":2341,"totalTrials":94,"cells":2796},{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2803,"PHASE4":2805,"NA":2811},{"trials":2798,"activeCount":98},[],{"trials":2800,"activeCount":98},[],{"trials":2802,"activeCount":98},[],{"trials":2804,"activeCount":98},[],{"trials":2806,"activeCount":98},[2807],{"nctId":2329,"briefTitle":2330,"status":398,"phases":2808,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2809,"interventions":2810},[90],[162],[2337,2338,2339,2305,2340,2341,2342,2343],{"trials":2812,"activeCount":98},[],{"intervention":2342,"totalTrials":94,"cells":2814},{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2821,"PHASE4":2823,"NA":2829},{"trials":2816,"activeCount":98},[],{"trials":2818,"activeCount":98},[],{"trials":2820,"activeCount":98},[],{"trials":2822,"activeCount":98},[],{"trials":2824,"activeCount":98},[2825],{"nctId":2329,"briefTitle":2330,"status":398,"phases":2826,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":2827,"interventions":2828},[90],[162],[2337,2338,2339,2305,2340,2341,2342,2343],{"trials":2830,"activeCount":98},[],{"intervention":2832,"totalTrials":94,"cells":2833},"nutrition education plus active supplement",{"EARLY_PHASE1":2834,"PHASE1":2836,"PHASE2":2838,"PHASE3":2840,"PHASE4":2842,"NA":2854},{"trials":2835,"activeCount":98},[],{"trials":2837,"activeCount":98},[],{"trials":2839,"activeCount":98},[],{"trials":2841,"activeCount":98},[],{"trials":2843,"activeCount":98},[2844],{"nctId":2845,"briefTitle":2846,"status":398,"phases":2847,"primaryCompletion":2486,"completion":2486,"start":2848,"enrollment":2849,"conditions":2850,"interventions":2852},"NCT00699413","Supplements for Controlling Resistance to Insulin",[90],"2008-02",8,[15,2851],"Diabetes Mellitus, Type 2",[2832,2853],"nutrition education plus inactive supplement",{"trials":2855,"activeCount":98},[],{"intervention":2853,"totalTrials":94,"cells":2857},{"EARLY_PHASE1":2858,"PHASE1":2860,"PHASE2":2862,"PHASE3":2864,"PHASE4":2866,"NA":2872},{"trials":2859,"activeCount":98},[],{"trials":2861,"activeCount":98},[],{"trials":2863,"activeCount":98},[],{"trials":2865,"activeCount":98},[],{"trials":2867,"activeCount":98},[2868],{"nctId":2845,"briefTitle":2846,"status":398,"phases":2869,"primaryCompletion":2486,"completion":2486,"start":2848,"enrollment":2849,"conditions":2870,"interventions":2871},[90],[15,2851],[2832,2853],{"trials":2873,"activeCount":98},[],{"intervention":2373,"totalTrials":94,"cells":2875},{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2882,"PHASE4":2884,"NA":2890},{"trials":2877,"activeCount":98},[],{"trials":2879,"activeCount":98},[],{"trials":2881,"activeCount":98},[],{"trials":2883,"activeCount":98},[],{"trials":2885,"activeCount":98},[2886],{"nctId":2363,"briefTitle":2364,"status":398,"phases":2887,"primaryCompletion":2366,"completion":2367,"start":2368,"enrollment":2369,"conditions":2888,"interventions":2889},[90],[2371],[2373,2338,2343],{"trials":2891,"activeCount":98},[],{"intervention":2893,"totalTrials":94,"cells":2894},"Ceftriaxone",{"EARLY_PHASE1":2895,"PHASE1":2897,"PHASE2":2899,"PHASE3":2901,"PHASE4":2903,"NA":2914},{"trials":2896,"activeCount":98},[],{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":98},[],{"trials":2902,"activeCount":98},[],{"trials":2904,"activeCount":98},[2905],{"nctId":2906,"briefTitle":2907,"status":2435,"phases":2908,"primaryCompletion":1920,"completion":1920,"start":2909,"enrollment":2274,"conditions":2910,"interventions":2912},"NCT03087656","Antibiotics to Decrease Post ERCP Cholangitis",[90],"2017-03-29",[2911],"Cholangitis",[2893,2913],"Levofloxacin",{"trials":2915,"activeCount":98},[],{"intervention":2913,"totalTrials":94,"cells":2917},{"EARLY_PHASE1":2918,"PHASE1":2920,"PHASE2":2922,"PHASE3":2924,"PHASE4":2926,"NA":2932},{"trials":2919,"activeCount":98},[],{"trials":2921,"activeCount":98},[],{"trials":2923,"activeCount":98},[],{"trials":2925,"activeCount":98},[],{"trials":2927,"activeCount":98},[2928],{"nctId":2906,"briefTitle":2907,"status":2435,"phases":2929,"primaryCompletion":1920,"completion":1920,"start":2909,"enrollment":2274,"conditions":2930,"interventions":2931},[90],[2911],[2893,2913],{"trials":2933,"activeCount":98},[],{"intervention":2935,"totalTrials":94,"cells":2936},"Trikafta [orange tablet containing ELX 100mg, TEZ 50mg, and IVA 75mg]",{"EARLY_PHASE1":2937,"PHASE1":2939,"PHASE2":2941,"PHASE3":2943,"PHASE4":2945,"NA":2957},{"trials":2938,"activeCount":98},[],{"trials":2940,"activeCount":98},[],{"trials":2942,"activeCount":98},[],{"trials":2944,"activeCount":98},[],{"trials":2946,"activeCount":98},[2947],{"nctId":2948,"briefTitle":2949,"status":304,"phases":2950,"primaryCompletion":2951,"completion":2951,"start":2952,"enrollment":236,"conditions":2953,"interventions":2955},"NCT04840862","Impact of Rifabutin on the Pharmacokinetics of Elexacaftor\u002FTezacaftor\u002FIvacaftor",[90],"2024-05-30","2022-05-09",[2954],"Drug Drug Interaction",[2935,2956],"Rifabutin 300mg",{"trials":2958,"activeCount":98},[],{"intervention":2956,"totalTrials":94,"cells":2960},{"EARLY_PHASE1":2961,"PHASE1":2963,"PHASE2":2965,"PHASE3":2967,"PHASE4":2969,"NA":2975},{"trials":2962,"activeCount":98},[],{"trials":2964,"activeCount":98},[],{"trials":2966,"activeCount":98},[],{"trials":2968,"activeCount":98},[],{"trials":2970,"activeCount":98},[2971],{"nctId":2948,"briefTitle":2949,"status":304,"phases":2972,"primaryCompletion":2951,"completion":2951,"start":2952,"enrollment":236,"conditions":2973,"interventions":2974},[90],[2954],[2935,2956],{"trials":2976,"activeCount":98},[],{"intervention":2978,"totalTrials":94,"cells":2979},"Levonorgestrel and Ethinyl Estradiol",{"EARLY_PHASE1":2980,"PHASE1":2982,"PHASE2":2984,"PHASE3":2986,"PHASE4":2988,"NA":3001},{"trials":2981,"activeCount":98},[],{"trials":2983,"activeCount":98},[],{"trials":2985,"activeCount":98},[],{"trials":2987,"activeCount":98},[],{"trials":2989,"activeCount":98},[2990],{"nctId":2991,"briefTitle":2992,"status":398,"phases":2993,"primaryCompletion":2994,"completion":2995,"start":2996,"enrollment":9,"conditions":2997,"interventions":3000},"NCT02531321","Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics",[90],"2016-11","2016-11-01","2015-08",[2998,2999],"Contraception","HIV",[2978],{"trials":3002,"activeCount":98},[],{"intervention":3004,"totalTrials":94,"cells":3005},"Liposomal bupivacaine",{"EARLY_PHASE1":3006,"PHASE1":3008,"PHASE2":3010,"PHASE3":3012,"PHASE4":3014,"NA":3028},{"trials":3007,"activeCount":98},[],{"trials":3009,"activeCount":98},[],{"trials":3011,"activeCount":98},[],{"trials":3013,"activeCount":98},[],{"trials":3015,"activeCount":98},[3016],{"nctId":3017,"briefTitle":3018,"status":304,"phases":3019,"primaryCompletion":3020,"completion":3021,"start":3022,"enrollment":3023,"conditions":3024,"interventions":3026},"NCT05374499","Double-Blinded Randomized Controlled Study Investigating the Efficacy of Exparel (Liposomal Bupivacaine) for Postoperative Pain Relief in Mandibular Third Molar Extractions",[90],"2023-12-01","2024-05-01","2022-09-01",73,[3025],"Post Operative Pain",[3004,3027],"0.5% bupivacaine with 1:100,000 epinephrine",{"trials":3029,"activeCount":98},[],{"intervention":3027,"totalTrials":94,"cells":3031},{"EARLY_PHASE1":3032,"PHASE1":3034,"PHASE2":3036,"PHASE3":3038,"PHASE4":3040,"NA":3046},{"trials":3033,"activeCount":98},[],{"trials":3035,"activeCount":98},[],{"trials":3037,"activeCount":98},[],{"trials":3039,"activeCount":98},[],{"trials":3041,"activeCount":98},[3042],{"nctId":3017,"briefTitle":3018,"status":304,"phases":3043,"primaryCompletion":3020,"completion":3021,"start":3022,"enrollment":3023,"conditions":3044,"interventions":3045},[90],[3025],[3004,3027],{"trials":3047,"activeCount":98},[],{"intervention":3049,"totalTrials":94,"cells":3050},"Betamethasone Sodium Phosphate",{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3055,"PHASE3":3057,"PHASE4":3059,"NA":3073},{"trials":3052,"activeCount":98},[],{"trials":3054,"activeCount":98},[],{"trials":3056,"activeCount":98},[],{"trials":3058,"activeCount":98},[],{"trials":3060,"activeCount":98},[3061],{"nctId":3062,"briefTitle":3063,"status":2435,"phases":3064,"primaryCompletion":3065,"completion":3066,"start":3067,"enrollment":3068,"conditions":3069,"interventions":3072},"NCT04869709","Late Preterm Corticosteroids and Neonatal Hypoglycemia",[90],"2023-07","2024-07","2021-07",210,[3070,3071],"Neonatal Hypoglycemia","Prematurity",[3049],{"trials":3074,"activeCount":98},[],{"intervention":3076,"totalTrials":94,"cells":3077},"CYP2C19 genotyping",{"EARLY_PHASE1":3078,"PHASE1":3080,"PHASE2":3082,"PHASE3":3084,"PHASE4":3086,"NA":3101},{"trials":3079,"activeCount":98},[],{"trials":3081,"activeCount":98},[],{"trials":3083,"activeCount":98},[],{"trials":3085,"activeCount":98},[],{"trials":3087,"activeCount":98},[3088],{"nctId":3089,"briefTitle":3090,"status":2435,"phases":3091,"primaryCompletion":3092,"completion":3093,"start":3094,"enrollment":2274,"conditions":3095,"interventions":3100},"NCT04090281","Implementing Precision Medicine Approaches to Guide Anti-platelet Selection",[90],"2023-05-31","2023-11-30","2020-03-13",[3096,3097,3098,3099],"Acute Coronary Syndrome (ACS)","STEMI - ST Elevation Myocardial Infarction (MI)","NSTEMI - Non-ST Segment Elevation MI","Unstable Angina (UA)",[3076],{"trials":3102,"activeCount":98},[],{"intervention":3104,"totalTrials":94,"cells":3105},"Ibuprofen 600 mg",{"EARLY_PHASE1":3106,"PHASE1":3108,"PHASE2":3110,"PHASE3":3112,"PHASE4":3114,"NA":3128},{"trials":3107,"activeCount":98},[],{"trials":3109,"activeCount":98},[],{"trials":3111,"activeCount":98},[],{"trials":3113,"activeCount":98},[],{"trials":3115,"activeCount":98},[3116],{"nctId":3117,"briefTitle":3118,"status":2435,"phases":3119,"primaryCompletion":3120,"completion":3120,"start":3121,"enrollment":2274,"conditions":3122,"interventions":3127},"NCT03824119","Postpartum NSAIDS and Maternal Hypertension",[90],"2022-12-11","2018-12-11",[3123,3124,3125,3126],"Preeclampsia","Gestational Hypertension","Superimposed Preeclampsia","Chronic Hypertension in Obstetric Context",[3104],{"trials":3129,"activeCount":98},[],{"intervention":3131,"totalTrials":94,"cells":3132},"Twice-daily Tacrolimus",{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3139,"PHASE4":3141,"NA":3157},{"trials":3134,"activeCount":98},[],{"trials":3136,"activeCount":98},[],{"trials":3138,"activeCount":98},[],{"trials":3140,"activeCount":98},[],{"trials":3142,"activeCount":98},[3143],{"nctId":3144,"briefTitle":3145,"status":398,"phases":3146,"primaryCompletion":1920,"completion":1920,"start":3147,"enrollment":1046,"conditions":3148,"interventions":3151},"NCT04773392","Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR",[90],"2021-11-23",[3149,3150],"Kidney Transplantation","Kidney Transplant Rejection",[3131,3152,3153,3154,3155,3156],"Once-daily envarsus XR","Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin","Methylprednisolone, prednisone","Mycophenolate mofetil","Azathioprine",{"trials":3158,"activeCount":98},[],{"intervention":3152,"totalTrials":94,"cells":3160},{"EARLY_PHASE1":3161,"PHASE1":3163,"PHASE2":3165,"PHASE3":3167,"PHASE4":3169,"NA":3175},{"trials":3162,"activeCount":98},[],{"trials":3164,"activeCount":98},[],{"trials":3166,"activeCount":98},[],{"trials":3168,"activeCount":98},[],{"trials":3170,"activeCount":98},[3171],{"nctId":3144,"briefTitle":3145,"status":398,"phases":3172,"primaryCompletion":1920,"completion":1920,"start":3147,"enrollment":1046,"conditions":3173,"interventions":3174},[90],[3149,3150],[3131,3152,3153,3154,3155,3156],{"trials":3176,"activeCount":98},[],{"intervention":3153,"totalTrials":94,"cells":3178},{"EARLY_PHASE1":3179,"PHASE1":3181,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3193},{"trials":3180,"activeCount":98},[],{"trials":3182,"activeCount":98},[],{"trials":3184,"activeCount":98},[],{"trials":3186,"activeCount":98},[],{"trials":3188,"activeCount":98},[3189],{"nctId":3144,"briefTitle":3145,"status":398,"phases":3190,"primaryCompletion":1920,"completion":1920,"start":3147,"enrollment":1046,"conditions":3191,"interventions":3192},[90],[3149,3150],[3131,3152,3153,3154,3155,3156],{"trials":3194,"activeCount":98},[],{"intervention":3154,"totalTrials":94,"cells":3196},{"EARLY_PHASE1":3197,"PHASE1":3199,"PHASE2":3201,"PHASE3":3203,"PHASE4":3205,"NA":3211},{"trials":3198,"activeCount":98},[],{"trials":3200,"activeCount":98},[],{"trials":3202,"activeCount":98},[],{"trials":3204,"activeCount":98},[],{"trials":3206,"activeCount":98},[3207],{"nctId":3144,"briefTitle":3145,"status":398,"phases":3208,"primaryCompletion":1920,"completion":1920,"start":3147,"enrollment":1046,"conditions":3209,"interventions":3210},[90],[3149,3150],[3131,3152,3153,3154,3155,3156],{"trials":3212,"activeCount":98},[],{"intervention":3155,"totalTrials":94,"cells":3214},{"EARLY_PHASE1":3215,"PHASE1":3217,"PHASE2":3219,"PHASE3":3221,"PHASE4":3223,"NA":3229},{"trials":3216,"activeCount":98},[],{"trials":3218,"activeCount":98},[],{"trials":3220,"activeCount":98},[],{"trials":3222,"activeCount":98},[],{"trials":3224,"activeCount":98},[3225],{"nctId":3144,"briefTitle":3145,"status":398,"phases":3226,"primaryCompletion":1920,"completion":1920,"start":3147,"enrollment":1046,"conditions":3227,"interventions":3228},[90],[3149,3150],[3131,3152,3153,3154,3155,3156],{"trials":3230,"activeCount":98},[],{"intervention":3156,"totalTrials":94,"cells":3232},{"EARLY_PHASE1":3233,"PHASE1":3235,"PHASE2":3237,"PHASE3":3239,"PHASE4":3241,"NA":3247},{"trials":3234,"activeCount":98},[],{"trials":3236,"activeCount":98},[],{"trials":3238,"activeCount":98},[],{"trials":3240,"activeCount":98},[],{"trials":3242,"activeCount":98},[3243],{"nctId":3144,"briefTitle":3145,"status":398,"phases":3244,"primaryCompletion":1920,"completion":1920,"start":3147,"enrollment":1046,"conditions":3245,"interventions":3246},[90],[3149,3150],[3131,3152,3153,3154,3155,3156],{"trials":3248,"activeCount":98},[],{"intervention":3250,"totalTrials":94,"cells":3251},"Biotene oral spray",{"EARLY_PHASE1":3252,"PHASE1":3254,"PHASE2":3256,"PHASE3":3258,"PHASE4":3260,"NA":3274},{"trials":3253,"activeCount":98},[],{"trials":3255,"activeCount":98},[],{"trials":3257,"activeCount":98},[],{"trials":3259,"activeCount":98},[],{"trials":3261,"activeCount":98},[3262],{"nctId":3263,"briefTitle":3264,"status":385,"phases":3265,"primaryCompletion":3266,"completion":3267,"start":3268,"enrollment":98,"conditions":3269,"interventions":3273},"NCT02522936","Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use",[90],"2019-07-31","2019-12-30","2018-08-01",[3270,3271,3272],"Overactive Bladder","Xerostomia","Compliance",[3250],{"trials":3275,"activeCount":98},[],{"intervention":3277,"totalTrials":94,"cells":3278},"Etonogestrel\u002Fethinyl estradiol contraceptive vaginal ring",{"EARLY_PHASE1":3279,"PHASE1":3281,"PHASE2":3283,"PHASE3":3285,"PHASE4":3287,"NA":3300},{"trials":3280,"activeCount":98},[],{"trials":3282,"activeCount":98},[],{"trials":3284,"activeCount":98},[],{"trials":3286,"activeCount":98},[],{"trials":3288,"activeCount":98},[3289],{"nctId":3290,"briefTitle":3291,"status":2435,"phases":3292,"primaryCompletion":3293,"completion":3294,"start":3295,"enrollment":1803,"conditions":3296,"interventions":3299},"NCT03120728","Application for the Etonogestrel\u002FEthinyl Estradiol Ring",[90],"2018-06-30","2018-07-01","2017-07-10",[3297,3298],"Emergency Contraception","Healthy, Reproductive Age Women",[3277],{"trials":3301,"activeCount":98},[],{"intervention":3303,"totalTrials":356,"cells":3304},"fluorouracil",{"EARLY_PHASE1":3305,"PHASE1":3307,"PHASE2":3328,"PHASE3":3398,"PHASE4":3404,"NA":3406},{"trials":3306,"activeCount":98},[],{"trials":3308,"activeCount":98},[3309],{"nctId":3310,"briefTitle":3311,"status":398,"phases":3312,"primaryCompletion":2462,"completion":3313,"start":3314,"enrollment":356,"conditions":3315,"interventions":3320},"NCT01238965","Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy",[87],"2015-04","2010-10",[3316,3317,3318,3319],"Recurrent Colon Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer","Stage IV Rectal Cancer",[3321,3303,3322,3323,3324,3325,3326,3327],"panobinostat","leucovorin calcium","reverse transcriptase-polymerase chain reaction","western blotting","gene expression analysis","RNA analysis","polymorphism analysis",{"trials":3329,"activeCount":98},[3330,3341,3360,3371,3386],{"nctId":3331,"briefTitle":3332,"status":398,"phases":3333,"primaryCompletion":3334,"completion":3334,"start":3335,"enrollment":3336,"conditions":3337,"interventions":3338},"NCT00006037","Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer",[88],"2001-11","1999-11",18,[24],[3303,3339,3340],"irinotecan hydrochloride","oglufanide disodium",{"nctId":3342,"briefTitle":3343,"status":2435,"phases":3344,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":9,"conditions":3348,"interventions":3357},"NCT01871571","Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer",[88],"2022-06-24","2023-06-24","2013-08-02",[3349,3350,3351,3352,3353,3354,3355,3356],"Mucinous Adenocarcinoma of the Rectum","Signet Ring Adenocarcinoma of the Rectum","Stage IIA Rectal Cancer","Stage IIB Rectal Cancer","Stage IIC Rectal Cancer","Stage IIIA Rectal Cancer","Stage IIIB Rectal Cancer","Stage IIIC Rectal Cancer",[3358,3359,3322,3303],"bevacizumab","oxaliplatin",{"nctId":3361,"briefTitle":3362,"status":304,"phases":3363,"primaryCompletion":3364,"completion":3365,"start":3366,"enrollment":2552,"conditions":3367,"interventions":3369},"NCT00002955","Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas",[88],"2000-05","2006-06","1995-08",[3368],"Pancreatic Cancer",[3303,3322,3370],"trimetrexate glucuronate",{"nctId":3372,"briefTitle":3373,"status":385,"phases":3374,"primaryCompletion":3375,"completion":2575,"start":3376,"enrollment":98,"conditions":3377,"interventions":3384},"NCT02235324","Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",[88],"2017-03","2015-03",[3378,3349,3316,3317,3379,3350,3380,3381,3382,3383],"Mucinous Adenocarcinoma of the Colon","Signet Ring Adenocarcinoma of the Colon","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Rectal Cancer",[3385,3322,3303],"ziv-aflibercept",{"nctId":3387,"briefTitle":3388,"status":385,"phases":3389,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":98,"conditions":3393,"interventions":3396},"NCT02413853","Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer",[88],"2017-11","2018-11","2015-11",[523,3394,3395],"Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer",[3397,681,701,680,702],"CBP\u002Fbeta-catenin Antagonist PRI-724",{"trials":3399,"activeCount":98},[3400],{"nctId":685,"briefTitle":686,"status":398,"phases":3401,"primaryCompletion":688,"completion":688,"start":689,"enrollment":631,"conditions":3402,"interventions":3403},[89],[523,691,692,693,694,695,696,697,698],[700,680,701,702,630],{"trials":3405,"activeCount":98},[],{"trials":3407,"activeCount":98},[],{"intervention":680,"totalTrials":236,"cells":3409},{"EARLY_PHASE1":3410,"PHASE1":3412,"PHASE2":3414,"PHASE3":3451,"PHASE4":3457,"NA":3459},{"trials":3411,"activeCount":98},[],{"trials":3413,"activeCount":98},[],{"trials":3415,"activeCount":98},[3416,3427,3439,3443,3447],{"nctId":3417,"briefTitle":3418,"status":398,"phases":3419,"primaryCompletion":3420,"completion":3421,"start":3422,"enrollment":1828,"conditions":3423,"interventions":3425},"NCT00184028","Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck",[88],"2009-07","2010-07","2004-09",[3424],"Carcinoma of the Head and Neck",[3426,680],"Taxotere",{"nctId":3428,"briefTitle":3429,"status":304,"phases":3430,"primaryCompletion":3431,"completion":3432,"start":3365,"enrollment":3433,"conditions":3434,"interventions":3437},"NCT01338792","Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer",[88],"2011-12","2012-12",47,[3435,3436],"Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer",[3359,3438,3323,3327],"pemetrexed disodium",{"nctId":3342,"briefTitle":3343,"status":2435,"phases":3440,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":9,"conditions":3441,"interventions":3442},[88],[3349,3350,3351,3352,3353,3354,3355,3356],[3358,3359,3322,3303],{"nctId":671,"briefTitle":672,"status":304,"phases":3444,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":3445,"interventions":3446},[88],[24],[680,681,630],{"nctId":3387,"briefTitle":3388,"status":385,"phases":3448,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":98,"conditions":3449,"interventions":3450},[88],[523,3394,3395],[3397,681,701,680,702],{"trials":3452,"activeCount":98},[3453],{"nctId":685,"briefTitle":686,"status":398,"phases":3454,"primaryCompletion":688,"completion":688,"start":689,"enrollment":631,"conditions":3455,"interventions":3456},[89],[523,691,692,693,694,695,696,697,698],[700,680,701,702,630],{"trials":3458,"activeCount":98},[],{"trials":3460,"activeCount":98},[],{"intervention":3322,"totalTrials":236,"cells":3462},{"EARLY_PHASE1":3463,"PHASE1":3465,"PHASE2":3471,"PHASE3":3489,"PHASE4":3495,"NA":3497},{"trials":3464,"activeCount":98},[],{"trials":3466,"activeCount":98},[3467],{"nctId":3310,"briefTitle":3311,"status":398,"phases":3468,"primaryCompletion":2462,"completion":3313,"start":3314,"enrollment":356,"conditions":3469,"interventions":3470},[87],[3316,3317,3318,3319],[3321,3303,3322,3323,3324,3325,3326,3327],{"trials":3472,"activeCount":98},[3473,3477,3481,3485],{"nctId":3342,"briefTitle":3343,"status":2435,"phases":3474,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":9,"conditions":3475,"interventions":3476},[88],[3349,3350,3351,3352,3353,3354,3355,3356],[3358,3359,3322,3303],{"nctId":3361,"briefTitle":3362,"status":304,"phases":3478,"primaryCompletion":3364,"completion":3365,"start":3366,"enrollment":2552,"conditions":3479,"interventions":3480},[88],[3368],[3303,3322,3370],{"nctId":3372,"briefTitle":3373,"status":385,"phases":3482,"primaryCompletion":3375,"completion":2575,"start":3376,"enrollment":98,"conditions":3483,"interventions":3484},[88],[3378,3349,3316,3317,3379,3350,3380,3381,3382,3383],[3385,3322,3303],{"nctId":3387,"briefTitle":3388,"status":385,"phases":3486,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":98,"conditions":3487,"interventions":3488},[88],[523,3394,3395],[3397,681,701,680,702],{"trials":3490,"activeCount":98},[3491],{"nctId":685,"briefTitle":686,"status":398,"phases":3492,"primaryCompletion":688,"completion":688,"start":689,"enrollment":631,"conditions":3493,"interventions":3494},[89],[523,691,692,693,694,695,696,697,698],[700,680,701,702,630],{"trials":3496,"activeCount":98},[],{"trials":3498,"activeCount":98},[],{"intervention":3500,"totalTrials":94,"cells":3501},"Renuva Allograft Adipose Matrix",{"EARLY_PHASE1":3502,"PHASE1":3504,"PHASE2":3506,"PHASE3":3508,"PHASE4":3520,"NA":3522},{"trials":3503,"activeCount":98},[],{"trials":3505,"activeCount":98},[],{"trials":3507,"activeCount":98},[],{"trials":3509,"activeCount":98},[3510],{"nctId":3511,"briefTitle":3512,"status":2435,"phases":3513,"primaryCompletion":3514,"completion":3515,"start":3516,"enrollment":1758,"conditions":3517,"interventions":3519},"NCT04700566","Allograft Adipose Injectable for Vocal Fold Paralysis",[89],"2024-12-31","2025-07-01","2022-05-16",[3518],"Vocal Fold Palsy",[3500],{"trials":3521,"activeCount":98},[],{"trials":3523,"activeCount":98},[],{"intervention":3525,"totalTrials":94,"cells":3526},"Testosterone",{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3531,"PHASE3":3533,"PHASE4":3547,"NA":3549},{"trials":3528,"activeCount":98},[],{"trials":3530,"activeCount":98},[],{"trials":3532,"activeCount":98},[],{"trials":3534,"activeCount":98},[3535],{"nctId":3536,"briefTitle":3537,"status":304,"phases":3538,"primaryCompletion":3539,"completion":3539,"start":3540,"enrollment":250,"conditions":3541,"interventions":3546},"NCT01595581","Testosterone Administration and ACL Reconstruction in Men",[89],"2015-05","2012-04",[3542,3543,3544,3545],"Muscle Atrophy","ACL Reconstruction","Trauma","Osteoarthritis",[3525],{"trials":3548,"activeCount":98},[],{"trials":3550,"activeCount":98},[],{"intervention":3552,"totalTrials":94,"cells":3553},"Chlorhexidine",{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3558,"PHASE3":3560,"PHASE4":3572,"NA":3574},{"trials":3555,"activeCount":98},[],{"trials":3557,"activeCount":98},[],{"trials":3559,"activeCount":98},[],{"trials":3561,"activeCount":98},[3562],{"nctId":3563,"briefTitle":3564,"status":2435,"phases":3565,"primaryCompletion":3566,"completion":59,"start":3567,"enrollment":1286,"conditions":3568,"interventions":3570},"NCT03700788","2% Chlorhexidine (CHX) vs CaOH2 (CH) Calcium Hydroxide Paste as an Intracanal Medicament",[89],"2025-06-30","2023-05-30",[3569],"Apical Periodontitis",[3552,3571],"Calcium Hydroxide",{"trials":3573,"activeCount":98},[],{"trials":3575,"activeCount":98},[],{"intervention":3571,"totalTrials":94,"cells":3577},{"EARLY_PHASE1":3578,"PHASE1":3580,"PHASE2":3582,"PHASE3":3584,"PHASE4":3590,"NA":3592},{"trials":3579,"activeCount":98},[],{"trials":3581,"activeCount":98},[],{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[3586],{"nctId":3563,"briefTitle":3564,"status":2435,"phases":3587,"primaryCompletion":3566,"completion":59,"start":3567,"enrollment":1286,"conditions":3588,"interventions":3589},[89],[3569],[3552,3571],{"trials":3591,"activeCount":98},[],{"trials":3593,"activeCount":98},[],{"intervention":3595,"totalTrials":94,"cells":3596},"Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate",{"EARLY_PHASE1":3597,"PHASE1":3599,"PHASE2":3601,"PHASE3":3603,"PHASE4":3617,"NA":3619},{"trials":3598,"activeCount":98},[],{"trials":3600,"activeCount":98},[],{"trials":3602,"activeCount":98},[],{"trials":3604,"activeCount":98},[3605],{"nctId":3606,"briefTitle":3607,"status":304,"phases":3608,"primaryCompletion":3609,"completion":3610,"start":3611,"enrollment":3612,"conditions":3613,"interventions":3615},"NCT03106454","Ovulation Incidence in Oral Contraceptive Users",[89],"2024-01","2024-01-01","2014-08",58,[2998,3614],"Ovulation",[3595,3616],"Norethindrone",{"trials":3618,"activeCount":98},[],{"trials":3620,"activeCount":98},[],{"intervention":3616,"totalTrials":94,"cells":3622},{"EARLY_PHASE1":3623,"PHASE1":3625,"PHASE2":3627,"PHASE3":3629,"PHASE4":3635,"NA":3637},{"trials":3624,"activeCount":98},[],{"trials":3626,"activeCount":98},[],{"trials":3628,"activeCount":98},[],{"trials":3630,"activeCount":98},[3631],{"nctId":3606,"briefTitle":3607,"status":304,"phases":3632,"primaryCompletion":3609,"completion":3610,"start":3611,"enrollment":3612,"conditions":3633,"interventions":3634},[89],[2998,3614],[3595,3616],{"trials":3636,"activeCount":98},[],{"trials":3638,"activeCount":98},[],{"intervention":3640,"totalTrials":94,"cells":3641},"Saline Solution",{"EARLY_PHASE1":3642,"PHASE1":3644,"PHASE2":3646,"PHASE3":3648,"PHASE4":3660,"NA":3662},{"trials":3643,"activeCount":98},[],{"trials":3645,"activeCount":98},[],{"trials":3647,"activeCount":98},[],{"trials":3649,"activeCount":98},[3650],{"nctId":3651,"briefTitle":3652,"status":398,"phases":3653,"primaryCompletion":3654,"completion":3654,"start":3655,"enrollment":1046,"conditions":3656,"interventions":3658},"NCT03819231","Mindfulness Training Plus Oxytocin Effects on Smoking Behavior",[88,89],"2023-12-31","2018-10-10",[3657,567],"Smoking",[3659,3640],"Oxytocin",{"trials":3661,"activeCount":98},[],{"trials":3663,"activeCount":98},[],{"intervention":700,"totalTrials":94,"cells":3665},{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3670,"PHASE3":3672,"PHASE4":3678,"NA":3680},{"trials":3667,"activeCount":98},[],{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[3674],{"nctId":685,"briefTitle":686,"status":398,"phases":3675,"primaryCompletion":688,"completion":688,"start":689,"enrollment":631,"conditions":3676,"interventions":3677},[89],[523,691,692,693,694,695,696,697,698],[700,680,701,702,630],{"trials":3679,"activeCount":98},[],{"trials":3681,"activeCount":98},[],{"intervention":3683,"totalTrials":94,"cells":3684},"MDMA",{"EARLY_PHASE1":3685,"PHASE1":3687,"PHASE2":3689,"PHASE3":3691,"PHASE4":3703,"NA":3705},{"trials":3686,"activeCount":98},[],{"trials":3688,"activeCount":98},[],{"trials":3690,"activeCount":98},[],{"trials":3692,"activeCount":98},[3693],{"nctId":3694,"briefTitle":3695,"status":304,"phases":3696,"primaryCompletion":3697,"completion":3514,"start":3698,"enrollment":3699,"conditions":3700,"interventions":3702},"NCT06189027","Epigenetics and MDMA-Assisted Psychotherapy for PTSD",[89],"2023-11-01","2018-11-20",45,[3701],"PTSD",[3683],{"trials":3704,"activeCount":98},[],{"trials":3706,"activeCount":98},[],{"intervention":3708,"totalTrials":94,"cells":3709},"Insulin",{"EARLY_PHASE1":3710,"PHASE1":3712,"PHASE2":3714,"PHASE3":3716,"PHASE4":3728,"NA":3730},{"trials":3711,"activeCount":98},[],{"trials":3713,"activeCount":98},[],{"trials":3715,"activeCount":98},[],{"trials":3717,"activeCount":98},[3718],{"nctId":3719,"briefTitle":3720,"status":304,"phases":3721,"primaryCompletion":3121,"completion":3121,"start":3722,"enrollment":3723,"conditions":3724,"interventions":3727},"NCT01767909","The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)",[88,89],"2014-01-08",240,[3725,3726],"Amnestic Mild Cognitive Impairment","Alzheimer's Disease",[3708],{"trials":3729,"activeCount":98},[],{"trials":3731,"activeCount":98},[],{"intervention":3733,"totalTrials":94,"cells":3734},"Ropivacaine Hydrochloride",{"EARLY_PHASE1":3735,"PHASE1":3737,"PHASE2":3739,"PHASE3":3741,"PHASE4":3754,"NA":3756},{"trials":3736,"activeCount":98},[],{"trials":3738,"activeCount":98},[],{"trials":3740,"activeCount":98},[],{"trials":3742,"activeCount":98},[3743],{"nctId":3744,"briefTitle":3745,"status":385,"phases":3746,"primaryCompletion":3747,"completion":3748,"start":3749,"enrollment":98,"conditions":3750,"interventions":3753},"NCT02438852","Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer",[89],"2021-02-25","2022-02-25","2019-02-25",[3751,3752],"Bladder Carcinoma","Post-operative Pain",[3733],{"trials":3755,"activeCount":98},[],{"trials":3757,"activeCount":98},[],{"intervention":1685,"totalTrials":2849,"cells":3759},{"EARLY_PHASE1":3760,"PHASE1":3762,"PHASE2":3786,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3761,"activeCount":98},[],{"trials":3763,"activeCount":98},[3764,3776],{"nctId":3765,"briefTitle":3766,"status":304,"phases":3767,"primaryCompletion":3768,"completion":3769,"start":3770,"enrollment":1463,"conditions":3771,"interventions":3773},"NCT00025181","Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery",[87],"2003-01","2005-06","2001-10",[3772,1675],"Intraocular Melanoma",[1677,1678,3774,3775,1685],"incomplete Freund's adjuvant","ipilimumab",{"nctId":3777,"briefTitle":3778,"status":398,"phases":3779,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":1523,"conditions":3783,"interventions":3784},"NCT00005841","Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma",[87],"2000-12","2002-10","2000-06",[3772,1675],[1677,1678,3774,3785,1685],"progenipoietin",{"trials":3787,"activeCount":98},[3788,3797,3801,3809,3838,3847],{"nctId":3789,"briefTitle":3790,"status":304,"phases":3791,"primaryCompletion":3335,"completion":3422,"start":3792,"enrollment":3793,"conditions":3794,"interventions":3795},"NCT00003339","Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma",[88],"1998-11",48,[3772,1675],[1678,3774,3796,1685],"recombinant interleukin-12",{"nctId":1667,"briefTitle":1668,"status":398,"phases":3798,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":3799,"interventions":3800},[88],[1675],[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],{"nctId":3802,"briefTitle":3803,"status":304,"phases":3804,"primaryCompletion":3769,"completion":3769,"start":3805,"enrollment":236,"conditions":3806,"interventions":3807},"NCT00334776","Vaccine Therapy in Treating Patients With Metastatic Melanoma",[88],"2003-10",[3772,1675],[1677,3808,1683,1685],"gp100:209-217(210M) peptide vaccine",{"nctId":3810,"briefTitle":3811,"status":304,"phases":3812,"primaryCompletion":3813,"completion":3813,"start":3814,"enrollment":308,"conditions":3815,"interventions":3833},"NCT00085189","Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma",[88],"2007-09","2004-05",[3816,3817,3818,3819,3820,3821,3822,3823,3824,3825,3826,3827,3828,3829,3830,3831,3832],"Ciliary Body and Choroid Melanoma, Medium\u002FLarge Size","Ciliary Body and Choroid Melanoma, Small Size","Extraocular Extension Melanoma","Iris Melanoma","Metastatic Intraocular Melanoma","Mucosal Melanoma","Recurrent Intraocular Melanoma","Recurrent Melanoma","Stage IIC Melanoma","Stage IIIA Intraocular Melanoma","Stage IIIA Melanoma","Stage IIIB Intraocular Melanoma","Stage IIIB Melanoma","Stage IIIC Intraocular Melanoma","Stage IIIC Melanoma","Stage IV Intraocular Melanoma","Stage IV Melanoma",[1678,1685,3834,3835,3774,3836,3837],"recombinant MAGE-3.1 antigen","multi-epitope melanoma peptide vaccine","Montanide ISA 51 VG","agatolimod sodium",{"nctId":3839,"briefTitle":3840,"status":304,"phases":3841,"primaryCompletion":3842,"completion":3843,"start":3844,"enrollment":3793,"conditions":3845,"interventions":3846},"NCT00003274","Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery",[88],"2001-09","2002-11","1998-03",[1675],[1678,3774,1682,1685],{"nctId":3848,"briefTitle":3849,"status":304,"phases":3850,"primaryCompletion":3851,"completion":3852,"start":3853,"enrollment":3854,"conditions":3855,"interventions":3856},"NCT00031733","Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma",[88],"2004-12","2007-11","2002-02",60,[3772,1675],[1677,1678,3774,3796,1682,1685,3857],"alum adjuvant",{"trials":3859,"activeCount":98},[],{"trials":3861,"activeCount":98},[],{"trials":3863,"activeCount":98},[],{"intervention":1678,"totalTrials":356,"cells":3865},{"EARLY_PHASE1":3866,"PHASE1":3868,"PHASE2":3878,"PHASE3":3900,"PHASE4":3902,"NA":3904},{"trials":3867,"activeCount":98},[],{"trials":3869,"activeCount":98},[3870,3874],{"nctId":3765,"briefTitle":3766,"status":304,"phases":3871,"primaryCompletion":3768,"completion":3769,"start":3770,"enrollment":1463,"conditions":3872,"interventions":3873},[87],[3772,1675],[1677,1678,3774,3775,1685],{"nctId":3777,"briefTitle":3778,"status":398,"phases":3875,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":1523,"conditions":3876,"interventions":3877},[87],[3772,1675],[1677,1678,3774,3785,1685],{"trials":3879,"activeCount":98},[3880,3884,3888,3892,3896],{"nctId":3789,"briefTitle":3790,"status":304,"phases":3881,"primaryCompletion":3335,"completion":3422,"start":3792,"enrollment":3793,"conditions":3882,"interventions":3883},[88],[3772,1675],[1678,3774,3796,1685],{"nctId":1667,"briefTitle":1668,"status":398,"phases":3885,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":3886,"interventions":3887},[88],[1675],[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],{"nctId":3810,"briefTitle":3811,"status":304,"phases":3889,"primaryCompletion":3813,"completion":3813,"start":3814,"enrollment":308,"conditions":3890,"interventions":3891},[88],[3816,3817,3818,3819,3820,3821,3822,3823,3824,3825,3826,3827,3828,3829,3830,3831,3832],[1678,1685,3834,3835,3774,3836,3837],{"nctId":3839,"briefTitle":3840,"status":304,"phases":3893,"primaryCompletion":3842,"completion":3843,"start":3844,"enrollment":3793,"conditions":3894,"interventions":3895},[88],[1675],[1678,3774,1682,1685],{"nctId":3848,"briefTitle":3849,"status":304,"phases":3897,"primaryCompletion":3851,"completion":3852,"start":3853,"enrollment":3854,"conditions":3898,"interventions":3899},[88],[3772,1675],[1677,1678,3774,3796,1682,1685,3857],{"trials":3901,"activeCount":98},[],{"trials":3903,"activeCount":98},[],{"trials":3905,"activeCount":98},[],{"intervention":3774,"totalTrials":236,"cells":3907},{"EARLY_PHASE1":3908,"PHASE1":3910,"PHASE2":3920,"PHASE3":3938,"PHASE4":3940,"NA":3942},{"trials":3909,"activeCount":98},[],{"trials":3911,"activeCount":98},[3912,3916],{"nctId":3765,"briefTitle":3766,"status":304,"phases":3913,"primaryCompletion":3768,"completion":3769,"start":3770,"enrollment":1463,"conditions":3914,"interventions":3915},[87],[3772,1675],[1677,1678,3774,3775,1685],{"nctId":3777,"briefTitle":3778,"status":398,"phases":3917,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":1523,"conditions":3918,"interventions":3919},[87],[3772,1675],[1677,1678,3774,3785,1685],{"trials":3921,"activeCount":98},[3922,3926,3930,3934],{"nctId":3789,"briefTitle":3790,"status":304,"phases":3923,"primaryCompletion":3335,"completion":3422,"start":3792,"enrollment":3793,"conditions":3924,"interventions":3925},[88],[3772,1675],[1678,3774,3796,1685],{"nctId":3810,"briefTitle":3811,"status":304,"phases":3927,"primaryCompletion":3813,"completion":3813,"start":3814,"enrollment":308,"conditions":3928,"interventions":3929},[88],[3816,3817,3818,3819,3820,3821,3822,3823,3824,3825,3826,3827,3828,3829,3830,3831,3832],[1678,1685,3834,3835,3774,3836,3837],{"nctId":3839,"briefTitle":3840,"status":304,"phases":3931,"primaryCompletion":3842,"completion":3843,"start":3844,"enrollment":3793,"conditions":3932,"interventions":3933},[88],[1675],[1678,3774,1682,1685],{"nctId":3848,"briefTitle":3849,"status":304,"phases":3935,"primaryCompletion":3851,"completion":3852,"start":3853,"enrollment":3854,"conditions":3936,"interventions":3937},[88],[3772,1675],[1677,1678,3774,3796,1682,1685,3857],{"trials":3939,"activeCount":98},[],{"trials":3941,"activeCount":98},[],{"trials":3943,"activeCount":98},[],{"intervention":1677,"totalTrials":1251,"cells":3945},{"EARLY_PHASE1":3946,"PHASE1":3948,"PHASE2":3958,"PHASE3":3972,"PHASE4":3974,"NA":3976},{"trials":3947,"activeCount":98},[],{"trials":3949,"activeCount":98},[3950,3954],{"nctId":3765,"briefTitle":3766,"status":304,"phases":3951,"primaryCompletion":3768,"completion":3769,"start":3770,"enrollment":1463,"conditions":3952,"interventions":3953},[87],[3772,1675],[1677,1678,3774,3775,1685],{"nctId":3777,"briefTitle":3778,"status":398,"phases":3955,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":1523,"conditions":3956,"interventions":3957},[87],[3772,1675],[1677,1678,3774,3785,1685],{"trials":3959,"activeCount":98},[3960,3964,3968],{"nctId":1667,"briefTitle":1668,"status":398,"phases":3961,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":3962,"interventions":3963},[88],[1675],[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],{"nctId":3802,"briefTitle":3803,"status":304,"phases":3965,"primaryCompletion":3769,"completion":3769,"start":3805,"enrollment":236,"conditions":3966,"interventions":3967},[88],[3772,1675],[1677,3808,1683,1685],{"nctId":3848,"briefTitle":3849,"status":304,"phases":3969,"primaryCompletion":3851,"completion":3852,"start":3853,"enrollment":3854,"conditions":3970,"interventions":3971},[88],[3772,1675],[1677,1678,3774,3796,1682,1685,3857],{"trials":3973,"activeCount":98},[],{"trials":3975,"activeCount":98},[],{"trials":3977,"activeCount":98},[],{"intervention":1682,"totalTrials":348,"cells":3979},{"EARLY_PHASE1":3980,"PHASE1":3982,"PHASE2":3984,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3981,"activeCount":98},[],{"trials":3983,"activeCount":98},[],{"trials":3985,"activeCount":98},[3986,3990,3994],{"nctId":1667,"briefTitle":1668,"status":398,"phases":3987,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":3988,"interventions":3989},[88],[1675],[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],{"nctId":3839,"briefTitle":3840,"status":304,"phases":3991,"primaryCompletion":3842,"completion":3843,"start":3844,"enrollment":3793,"conditions":3992,"interventions":3993},[88],[1675],[1678,3774,1682,1685],{"nctId":3848,"briefTitle":3849,"status":304,"phases":3995,"primaryCompletion":3851,"completion":3852,"start":3853,"enrollment":3854,"conditions":3996,"interventions":3997},[88],[3772,1675],[1677,1678,3774,3796,1682,1685,3857],{"trials":3999,"activeCount":98},[],{"trials":4001,"activeCount":98},[],{"trials":4003,"activeCount":98},[],{"intervention":681,"totalTrials":348,"cells":4005},{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4010,"PHASE3":4024,"PHASE4":4026,"NA":4028},{"trials":4007,"activeCount":98},[],{"trials":4009,"activeCount":98},[],{"trials":4011,"activeCount":98},[4012,4016,4020],{"nctId":3342,"briefTitle":3343,"status":2435,"phases":4013,"primaryCompletion":3345,"completion":3346,"start":3347,"enrollment":9,"conditions":4014,"interventions":4015},[88],[3349,3350,3351,3352,3353,3354,3355,3356],[3358,3359,3322,3303],{"nctId":671,"briefTitle":672,"status":304,"phases":4017,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":4018,"interventions":4019},[88],[24],[680,681,630],{"nctId":3387,"briefTitle":3388,"status":385,"phases":4021,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":98,"conditions":4022,"interventions":4023},[88],[523,3394,3395],[3397,681,701,680,702],{"trials":4025,"activeCount":98},[],{"trials":4027,"activeCount":98},[],{"trials":4029,"activeCount":98},[],{"intervention":1432,"totalTrials":289,"cells":4031},{"EARLY_PHASE1":4032,"PHASE1":4034,"PHASE2":4036,"PHASE3":4046,"PHASE4":4048,"NA":4050},{"trials":4033,"activeCount":98},[],{"trials":4035,"activeCount":98},[],{"trials":4037,"activeCount":98},[4038,4042],{"nctId":1421,"briefTitle":1422,"status":304,"phases":4039,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":593,"conditions":4040,"interventions":4041},[88],[1428],[1430,1431,1432],{"nctId":1588,"briefTitle":1589,"status":304,"phases":4043,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":112,"conditions":4044,"interventions":4045},[88],[1594],[667,1596,1432,1597],{"trials":4047,"activeCount":98},[],{"trials":4049,"activeCount":98},[],{"trials":4051,"activeCount":98},[],{"intervention":4053,"totalTrials":289,"cells":4054},"Gentamicin",{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4059,"PHASE3":4078,"PHASE4":4080,"NA":4082},{"trials":4056,"activeCount":98},[],{"trials":4058,"activeCount":98},[],{"trials":4060,"activeCount":98},[4061,4070],{"nctId":4062,"briefTitle":4063,"status":304,"phases":4064,"primaryCompletion":4065,"completion":4066,"start":4067,"enrollment":1251,"conditions":4068,"interventions":4069},"NCT02698735","Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients",[87,88],"2017-03-31","2017-06-30","2016-02-25",[800],[4053],{"nctId":4071,"briefTitle":4072,"status":2435,"phases":4073,"primaryCompletion":3020,"completion":3020,"start":4074,"enrollment":4075,"conditions":4076,"interventions":4077},"NCT03392909","Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)",[87,88],"2018-07-05",9,[800],[4053],{"trials":4079,"activeCount":98},[],{"trials":4081,"activeCount":98},[],{"trials":4083,"activeCount":98},[],{"intervention":4085,"totalTrials":289,"cells":4086},"Arsenic Trioxide",{"EARLY_PHASE1":4087,"PHASE1":4089,"PHASE2":4091,"PHASE3":4113,"PHASE4":4115,"NA":4117},{"trials":4088,"activeCount":98},[],{"trials":4090,"activeCount":98},[],{"trials":4092,"activeCount":98},[4093,4103],{"nctId":4094,"briefTitle":4095,"status":385,"phases":4096,"primaryCompletion":4097,"completion":4097,"start":4098,"enrollment":98,"conditions":4099,"interventions":4101},"NCT00670150","New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia",[88],"2010-08","2010-05",[4100],"Acute Promyelocytic Leukemia",[4102,4085],"NRX 195183",{"nctId":4104,"briefTitle":4105,"status":398,"phases":4106,"primaryCompletion":674,"completion":4107,"start":4108,"enrollment":25,"conditions":4109,"interventions":4111},"NCT00184054","Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia",[88],"2011-08","2002-04",[4110],"Acute Myelogenous Leukemia",[4085,4112],"Ascorbic Acid",{"trials":4114,"activeCount":98},[],{"trials":4116,"activeCount":98},[],{"trials":4118,"activeCount":98},[],{"intervention":3323,"totalTrials":289,"cells":4120},{"EARLY_PHASE1":4121,"PHASE1":4123,"PHASE2":4129,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4122,"activeCount":98},[],{"trials":4124,"activeCount":98},[4125],{"nctId":3310,"briefTitle":3311,"status":398,"phases":4126,"primaryCompletion":2462,"completion":3313,"start":3314,"enrollment":356,"conditions":4127,"interventions":4128},[87],[3316,3317,3318,3319],[3321,3303,3322,3323,3324,3325,3326,3327],{"trials":4130,"activeCount":98},[4131],{"nctId":3428,"briefTitle":3429,"status":304,"phases":4132,"primaryCompletion":3431,"completion":3432,"start":3365,"enrollment":3433,"conditions":4133,"interventions":4134},[88],[3435,3436],[3359,3438,3323,3327],{"trials":4136,"activeCount":98},[],{"trials":4138,"activeCount":98},[],{"trials":4140,"activeCount":98},[],{"intervention":3327,"totalTrials":289,"cells":4142},{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4151,"PHASE3":4157,"PHASE4":4159,"NA":4161},{"trials":4144,"activeCount":98},[],{"trials":4146,"activeCount":98},[4147],{"nctId":3310,"briefTitle":3311,"status":398,"phases":4148,"primaryCompletion":2462,"completion":3313,"start":3314,"enrollment":356,"conditions":4149,"interventions":4150},[87],[3316,3317,3318,3319],[3321,3303,3322,3323,3324,3325,3326,3327],{"trials":4152,"activeCount":98},[4153],{"nctId":3428,"briefTitle":3429,"status":304,"phases":4154,"primaryCompletion":3431,"completion":3432,"start":3365,"enrollment":3433,"conditions":4155,"interventions":4156},[88],[3435,3436],[3359,3438,3323,3327],{"trials":4158,"activeCount":98},[],{"trials":4160,"activeCount":98},[],{"trials":4162,"activeCount":98},[],{"intervention":3340,"totalTrials":289,"cells":4164},{"EARLY_PHASE1":4165,"PHASE1":4167,"PHASE2":4179,"PHASE3":4185,"PHASE4":4187,"NA":4189},{"trials":4166,"activeCount":98},[],{"trials":4168,"activeCount":98},[4169],{"nctId":4170,"briefTitle":4171,"status":304,"phases":4172,"primaryCompletion":4173,"completion":4174,"start":4175,"enrollment":4176,"conditions":4177,"interventions":4178},"NCT00003773","IM-862 in Treating Patients With Recurrent Ovarian Cancer",[87],"2000-07","2001-08","1999-02",43,[1428],[3340],{"trials":4180,"activeCount":98},[4181],{"nctId":3331,"briefTitle":3332,"status":398,"phases":4182,"primaryCompletion":3334,"completion":3334,"start":3335,"enrollment":3336,"conditions":4183,"interventions":4184},[88],[24],[3303,3339,3340],{"trials":4186,"activeCount":98},[],{"trials":4188,"activeCount":98},[],{"trials":4190,"activeCount":98},[],{"intervention":3796,"totalTrials":289,"cells":4192},{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4197,"PHASE3":4207,"PHASE4":4209,"NA":4211},{"trials":4194,"activeCount":98},[],{"trials":4196,"activeCount":98},[],{"trials":4198,"activeCount":98},[4199,4203],{"nctId":3789,"briefTitle":3790,"status":304,"phases":4200,"primaryCompletion":3335,"completion":3422,"start":3792,"enrollment":3793,"conditions":4201,"interventions":4202},[88],[3772,1675],[1678,3774,3796,1685],{"nctId":3848,"briefTitle":3849,"status":304,"phases":4204,"primaryCompletion":3851,"completion":3852,"start":3853,"enrollment":3854,"conditions":4205,"interventions":4206},[88],[3772,1675],[1677,1678,3774,3796,1682,1685,3857],{"trials":4208,"activeCount":98},[],{"trials":4210,"activeCount":98},[],{"trials":4212,"activeCount":98},[],{"intervention":1596,"totalTrials":289,"cells":4214},{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4219,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4216,"activeCount":98},[],{"trials":4218,"activeCount":98},[],{"trials":4220,"activeCount":98},[4221,4225],{"nctId":1621,"briefTitle":1622,"status":385,"phases":4222,"primaryCompletion":1624,"completion":1624,"start":1624,"enrollment":98,"conditions":4223,"interventions":4224},[88],[1626,1627,1628,1535,1629,1630,1536,1538,1631,1632],[1634,1431,1635,1636,1596,1637],{"nctId":1588,"briefTitle":1589,"status":304,"phases":4226,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":112,"conditions":4227,"interventions":4228},[88],[1594],[667,1596,1432,1597],{"trials":4230,"activeCount":98},[],{"trials":4232,"activeCount":98},[],{"trials":4234,"activeCount":98},[],{"intervention":4236,"totalTrials":289,"cells":4237},"prednisone",{"EARLY_PHASE1":4238,"PHASE1":4240,"PHASE2":4242,"PHASE3":4268,"PHASE4":4270,"NA":4272},{"trials":4239,"activeCount":98},[],{"trials":4241,"activeCount":98},[],{"trials":4243,"activeCount":98},[4244,4255],{"nctId":4245,"briefTitle":4246,"status":2435,"phases":4247,"primaryCompletion":4248,"completion":2575,"start":4249,"enrollment":4250,"conditions":4251,"interventions":4252},"NCT01685125","Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",[88],"2016-03","2012-09",96,[3435,3436,976],[4253,4254,4236],"abiraterone acetate","dasatinib",{"nctId":4256,"briefTitle":4257,"status":398,"phases":4258,"primaryCompletion":4259,"completion":4260,"start":4261,"enrollment":4075,"conditions":4262,"interventions":4264},"NCT01469338","Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel",[88],"2014-10","2014-11","2012-07",[4263,3435,3436,426,430,431,432,976],"Diarrhea",[4265,4236,4266,4267],"cabazitaxel","octreotide pamoate","octreotide acetate",{"trials":4269,"activeCount":98},[],{"trials":4271,"activeCount":98},[],{"trials":4273,"activeCount":98},[],{"intervention":1683,"totalTrials":289,"cells":4275},{"EARLY_PHASE1":4276,"PHASE1":4278,"PHASE2":4280,"PHASE3":4290,"PHASE4":4292,"NA":4294},{"trials":4277,"activeCount":98},[],{"trials":4279,"activeCount":98},[],{"trials":4281,"activeCount":98},[4282,4286],{"nctId":1667,"briefTitle":1668,"status":398,"phases":4283,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":4284,"interventions":4285},[88],[1675],[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],{"nctId":3802,"briefTitle":3803,"status":304,"phases":4287,"primaryCompletion":3769,"completion":3769,"start":3805,"enrollment":236,"conditions":4288,"interventions":4289},[88],[3772,1675],[1677,3808,1683,1685],{"trials":4291,"activeCount":98},[],{"trials":4293,"activeCount":98},[],{"trials":4295,"activeCount":98},[],{"intervention":668,"totalTrials":289,"cells":4297},{"EARLY_PHASE1":4298,"PHASE1":4300,"PHASE2":4302,"PHASE3":4312,"PHASE4":4314,"NA":4316},{"trials":4299,"activeCount":98},[],{"trials":4301,"activeCount":98},[],{"trials":4303,"activeCount":98},[4304,4308],{"nctId":656,"briefTitle":657,"status":398,"phases":4305,"primaryCompletion":659,"completion":659,"start":660,"enrollment":32,"conditions":4306,"interventions":4307},[88],[662,663,664],[666,667,668,669],{"nctId":1528,"briefTitle":1529,"status":398,"phases":4309,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":1523,"conditions":4310,"interventions":4311},[88],[1535,1536,1537,1538],[1540,668,1541],{"trials":4313,"activeCount":98},[],{"trials":4315,"activeCount":98},[],{"trials":4317,"activeCount":98},[],{"intervention":3426,"totalTrials":94,"cells":4319},{"EARLY_PHASE1":4320,"PHASE1":4322,"PHASE2":4324,"PHASE3":4330,"PHASE4":4332,"NA":4334},{"trials":4321,"activeCount":98},[],{"trials":4323,"activeCount":98},[],{"trials":4325,"activeCount":98},[4326],{"nctId":3417,"briefTitle":3418,"status":398,"phases":4327,"primaryCompletion":3420,"completion":3421,"start":3422,"enrollment":1828,"conditions":4328,"interventions":4329},[88],[3424],[3426,680],{"trials":4331,"activeCount":98},[],{"trials":4333,"activeCount":98},[],{"trials":4335,"activeCount":98},[],{"intervention":4337,"totalTrials":94,"cells":4338},"candesartan",{"EARLY_PHASE1":4339,"PHASE1":4341,"PHASE2":4343,"PHASE3":4358,"PHASE4":4360,"NA":4362},{"trials":4340,"activeCount":98},[],{"trials":4342,"activeCount":98},[],{"trials":4344,"activeCount":98},[4345],{"nctId":4346,"briefTitle":4347,"status":304,"phases":4348,"primaryCompletion":3431,"completion":3432,"start":4349,"enrollment":771,"conditions":4350,"interventions":4353},"NCT00605072","The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial",[88],"2008-01",[4351,1164,4352],"Cognitive Impairment","Aging",[4337,4354,4355,4356,4357],"lisinopril","hydrochlorothiazide","nifedipine, long acting","metoprolol, long-acting",{"trials":4359,"activeCount":98},[],{"trials":4361,"activeCount":98},[],{"trials":4363,"activeCount":98},[],{"intervention":4354,"totalTrials":94,"cells":4365},{"EARLY_PHASE1":4366,"PHASE1":4368,"PHASE2":4370,"PHASE3":4376,"PHASE4":4378,"NA":4380},{"trials":4367,"activeCount":98},[],{"trials":4369,"activeCount":98},[],{"trials":4371,"activeCount":98},[4372],{"nctId":4346,"briefTitle":4347,"status":304,"phases":4373,"primaryCompletion":3431,"completion":3432,"start":4349,"enrollment":771,"conditions":4374,"interventions":4375},[88],[4351,1164,4352],[4337,4354,4355,4356,4357],{"trials":4377,"activeCount":98},[],{"trials":4379,"activeCount":98},[],{"trials":4381,"activeCount":98},[],{"intervention":4355,"totalTrials":94,"cells":4383},{"EARLY_PHASE1":4384,"PHASE1":4386,"PHASE2":4388,"PHASE3":4394,"PHASE4":4396,"NA":4398},{"trials":4385,"activeCount":98},[],{"trials":4387,"activeCount":98},[],{"trials":4389,"activeCount":98},[4390],{"nctId":4346,"briefTitle":4347,"status":304,"phases":4391,"primaryCompletion":3431,"completion":3432,"start":4349,"enrollment":771,"conditions":4392,"interventions":4393},[88],[4351,1164,4352],[4337,4354,4355,4356,4357],{"trials":4395,"activeCount":98},[],{"trials":4397,"activeCount":98},[],{"trials":4399,"activeCount":98},[],{"intervention":4356,"totalTrials":94,"cells":4401},{"EARLY_PHASE1":4402,"PHASE1":4404,"PHASE2":4406,"PHASE3":4412,"PHASE4":4414,"NA":4416},{"trials":4403,"activeCount":98},[],{"trials":4405,"activeCount":98},[],{"trials":4407,"activeCount":98},[4408],{"nctId":4346,"briefTitle":4347,"status":304,"phases":4409,"primaryCompletion":3431,"completion":3432,"start":4349,"enrollment":771,"conditions":4410,"interventions":4411},[88],[4351,1164,4352],[4337,4354,4355,4356,4357],{"trials":4413,"activeCount":98},[],{"trials":4415,"activeCount":98},[],{"trials":4417,"activeCount":98},[],{"intervention":4357,"totalTrials":94,"cells":4419},{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4424,"PHASE3":4430,"PHASE4":4432,"NA":4434},{"trials":4421,"activeCount":98},[],{"trials":4423,"activeCount":98},[],{"trials":4425,"activeCount":98},[4426],{"nctId":4346,"briefTitle":4347,"status":304,"phases":4427,"primaryCompletion":3431,"completion":3432,"start":4349,"enrollment":771,"conditions":4428,"interventions":4429},[88],[4351,1164,4352],[4337,4354,4355,4356,4357],{"trials":4431,"activeCount":98},[],{"trials":4433,"activeCount":98},[],{"trials":4435,"activeCount":98},[],{"intervention":4437,"totalTrials":94,"cells":4438},"Nicotine Transdermal Patch",{"EARLY_PHASE1":4439,"PHASE1":4441,"PHASE2":4443,"PHASE3":4456,"PHASE4":4458,"NA":4460},{"trials":4440,"activeCount":98},[],{"trials":4442,"activeCount":98},[],{"trials":4444,"activeCount":98},[4445],{"nctId":4446,"briefTitle":4447,"status":304,"phases":4448,"primaryCompletion":4449,"completion":4450,"start":4451,"enrollment":4452,"conditions":4453,"interventions":4455},"NCT02720445","Memory Improvement Through Nicotine Dosing (MIND) Study",[88],"2025-08-25","2025-09-16","2017-01-13",348,[4454],"Mild Cognitive Impairment",[4437],{"trials":4457,"activeCount":98},[],{"trials":4459,"activeCount":98},[],{"trials":4461,"activeCount":98},[],{"intervention":4463,"totalTrials":94,"cells":4464},"17B-estradiol",{"EARLY_PHASE1":4465,"PHASE1":4467,"PHASE2":4469,"PHASE3":4481,"PHASE4":4483,"NA":4485},{"trials":4466,"activeCount":98},[],{"trials":4468,"activeCount":98},[],{"trials":4470,"activeCount":98},[4471],{"nctId":4472,"briefTitle":4473,"status":304,"phases":4474,"primaryCompletion":4475,"completion":4476,"start":4477,"enrollment":4478,"conditions":4479,"interventions":4480},"NCT00114517","ELITE: Early Versus Late Intervention Trial With Estradiol",[88],"2013-02-12","2013-03-05","2004-07",643,[1112],[4463],{"trials":4482,"activeCount":98},[],{"trials":4484,"activeCount":98},[],{"trials":4486,"activeCount":98},[],{"intervention":4488,"totalTrials":94,"cells":4489},"gemcitabine, capecitabine",{"EARLY_PHASE1":4490,"PHASE1":4492,"PHASE2":4494,"PHASE3":4504,"PHASE4":4506,"NA":4508},{"trials":4491,"activeCount":98},[],{"trials":4493,"activeCount":98},[],{"trials":4495,"activeCount":98},[4496],{"nctId":4497,"briefTitle":4498,"status":304,"phases":4499,"primaryCompletion":4500,"completion":3852,"start":4501,"enrollment":771,"conditions":4502,"interventions":4503},"NCT00159445","Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer",[88],"2007-03","2004-03",[24,2321],[4488],{"trials":4505,"activeCount":98},[],{"trials":4507,"activeCount":98},[],{"trials":4509,"activeCount":98},[],{"intervention":4511,"totalTrials":94,"cells":4512},"paclitaxel, gemcitabine, and oxaliplatin",{"EARLY_PHASE1":4513,"PHASE1":4515,"PHASE2":4517,"PHASE3":4530,"PHASE4":4532,"NA":4534},{"trials":4514,"activeCount":98},[],{"trials":4516,"activeCount":98},[],{"trials":4518,"activeCount":98},[4519],{"nctId":4520,"briefTitle":4521,"status":304,"phases":4522,"primaryCompletion":4523,"completion":4524,"start":4525,"enrollment":972,"conditions":4526,"interventions":4529},"NCT00183820","Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma",[88],"2015-12","2016-08","2004-11",[4527,4528],"Testicular Cancer","Germ Cell Neoplasm",[4511],{"trials":4531,"activeCount":98},[],{"trials":4533,"activeCount":98},[],{"trials":4535,"activeCount":98},[],{"intervention":4537,"totalTrials":94,"cells":4538},"baclofen",{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4543,"PHASE3":4553,"PHASE4":4555,"NA":4557},{"trials":4540,"activeCount":98},[],{"trials":4542,"activeCount":98},[],{"trials":4544,"activeCount":98},[4545],{"nctId":4546,"briefTitle":4547,"status":304,"phases":4548,"completion":1671,"start":4549,"enrollment":32,"conditions":4550,"interventions":4552},"NCT00255073","Does Reducing Spasticity Permit an Increase in Strength?",[88],"2005-01",[4551],"Spastic Diplegic Cerebral Palsy",[4537],{"trials":4554,"activeCount":98},[],{"trials":4556,"activeCount":98},[],{"trials":4558,"activeCount":98},[],{"intervention":4102,"totalTrials":94,"cells":4560},{"EARLY_PHASE1":4561,"PHASE1":4563,"PHASE2":4565,"PHASE3":4571,"PHASE4":4573,"NA":4575},{"trials":4562,"activeCount":98},[],{"trials":4564,"activeCount":98},[],{"trials":4566,"activeCount":98},[4567],{"nctId":4094,"briefTitle":4095,"status":385,"phases":4568,"primaryCompletion":4097,"completion":4097,"start":4098,"enrollment":98,"conditions":4569,"interventions":4570},[88],[4100],[4102,4085],{"trials":4572,"activeCount":98},[],{"trials":4574,"activeCount":98},[],{"trials":4576,"activeCount":98},[],{"intervention":3438,"totalTrials":94,"cells":4578},{"EARLY_PHASE1":4579,"PHASE1":4581,"PHASE2":4583,"PHASE3":4589,"PHASE4":4591,"NA":4593},{"trials":4580,"activeCount":98},[],{"trials":4582,"activeCount":98},[],{"trials":4584,"activeCount":98},[4585],{"nctId":3428,"briefTitle":3429,"status":304,"phases":4586,"primaryCompletion":3431,"completion":3432,"start":3365,"enrollment":3433,"conditions":4587,"interventions":4588},[88],[3435,3436],[3359,3438,3323,3327],{"trials":4590,"activeCount":98},[],{"trials":4592,"activeCount":98},[],{"trials":4594,"activeCount":98},[],{"intervention":4596,"totalTrials":94,"cells":4597},"Magnesium Sulfate",{"EARLY_PHASE1":4598,"PHASE1":4600,"PHASE2":4602,"PHASE3":4613,"PHASE4":4615,"NA":4617},{"trials":4599,"activeCount":98},[],{"trials":4601,"activeCount":98},[],{"trials":4603,"activeCount":98},[4604],{"nctId":4605,"briefTitle":4606,"status":398,"phases":4607,"primaryCompletion":4608,"completion":4608,"start":4609,"enrollment":631,"conditions":4610,"interventions":4612},"NCT01502761","Intra-arterial Magnesium Administration for Acute Stroke",[87,88],"2016-05","2012-03",[4611],"Acute Stroke",[4596],{"trials":4614,"activeCount":98},[],{"trials":4616,"activeCount":98},[],{"trials":4618,"activeCount":98},[],{"intervention":4620,"totalTrials":94,"cells":4621},"irinotecan, cisplatin, celecoxib",{"EARLY_PHASE1":4622,"PHASE1":4624,"PHASE2":4626,"PHASE3":4637,"PHASE4":4639,"NA":4641},{"trials":4623,"activeCount":98},[],{"trials":4625,"activeCount":98},[],{"trials":4627,"activeCount":98},[4628],{"nctId":4629,"briefTitle":4630,"status":398,"phases":4631,"primaryCompletion":4632,"completion":4633,"start":3805,"enrollment":236,"conditions":4634,"interventions":4636},"NCT00183807","A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer",[88],"2006-02","2008-03",[4635],"Esophageal Cancer",[4620],{"trials":4638,"activeCount":98},[],{"trials":4640,"activeCount":98},[],{"trials":4642,"activeCount":98},[],{"intervention":4644,"totalTrials":94,"cells":4645},"Montanide ISA 51",{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4650,"PHASE3":4661,"PHASE4":4663,"NA":4665},{"trials":4647,"activeCount":98},[],{"trials":4649,"activeCount":98},[],{"trials":4651,"activeCount":98},[4652],{"nctId":4653,"briefTitle":4654,"status":398,"phases":4655,"primaryCompletion":4656,"completion":4657,"start":3814,"enrollment":2334,"conditions":4658,"interventions":4660},"NCT00184067","Continuation Booster Trial After a Vaccine Combining Tyrosinase\u002FGP100\u002FMART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma",[88],"2007-04","2009-09",[4659],"Melanoma",[4644],{"trials":4662,"activeCount":98},[],{"trials":4664,"activeCount":98},[],{"trials":4666,"activeCount":98},[],{"intervention":4668,"totalTrials":94,"cells":4669},"methylene blue",{"EARLY_PHASE1":4670,"PHASE1":4672,"PHASE2":4674,"PHASE3":4687,"PHASE4":4689,"NA":4691},{"trials":4671,"activeCount":98},[],{"trials":4673,"activeCount":98},[],{"trials":4675,"activeCount":98},[4676],{"nctId":4677,"briefTitle":4678,"status":398,"phases":4679,"primaryCompletion":4680,"completion":4680,"start":2550,"enrollment":631,"conditions":4681,"interventions":4685},"NCT01276054","Sentinel and\u002For Axillary Lymph Node Biopsy With or Without Axillary Reverse Mapping in Reducing Incidence and Severity of Arm Lymphedema in Stage 0-2 Patients.",[88],"2011-10",[4682,663,4683,4684,27],"Lymphedema","Stage IA Breast Cancer","Stage IB Breast Cancer",[4668,4686],"indocyanine green solution",{"trials":4688,"activeCount":98},[],{"trials":4690,"activeCount":98},[],{"trials":4692,"activeCount":98},[],{"intervention":4686,"totalTrials":94,"cells":4694},{"EARLY_PHASE1":4695,"PHASE1":4697,"PHASE2":4699,"PHASE3":4705,"PHASE4":4707,"NA":4709},{"trials":4696,"activeCount":98},[],{"trials":4698,"activeCount":98},[],{"trials":4700,"activeCount":98},[4701],{"nctId":4677,"briefTitle":4678,"status":398,"phases":4702,"primaryCompletion":4680,"completion":4680,"start":2550,"enrollment":631,"conditions":4703,"interventions":4704},[88],[4682,663,4683,4684,27],[4668,4686],{"trials":4706,"activeCount":98},[],{"trials":4708,"activeCount":98},[],{"trials":4710,"activeCount":98},[],{"intervention":4712,"totalTrials":94,"cells":4713},"Rituximab",{"EARLY_PHASE1":4714,"PHASE1":4716,"PHASE2":4718,"PHASE3":4731,"PHASE4":4733,"NA":4735},{"trials":4715,"activeCount":98},[],{"trials":4717,"activeCount":98},[],{"trials":4719,"activeCount":98},[4720],{"nctId":4721,"briefTitle":4722,"status":304,"phases":4723,"primaryCompletion":4724,"completion":4725,"start":4726,"enrollment":4727,"conditions":4728,"interventions":4730},"NCT00599170","Rituximab Plus CHOP With Sargramostim in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma",[88],"2020-01-10","2021-01-10","2008-01-10",52,[4729],"Diffuse, Large B-Cell, Lymphoma",[4712],{"trials":4732,"activeCount":98},[],{"trials":4734,"activeCount":98},[],{"trials":4736,"activeCount":98},[],{"intervention":450,"totalTrials":94,"cells":4738},{"EARLY_PHASE1":4739,"PHASE1":4741,"PHASE2":4743,"PHASE3":4749,"PHASE4":4751,"NA":4753},{"trials":4740,"activeCount":98},[],{"trials":4742,"activeCount":98},[],{"trials":4744,"activeCount":98},[4745],{"nctId":438,"briefTitle":439,"status":398,"phases":4746,"primaryCompletion":441,"completion":442,"start":443,"enrollment":356,"conditions":4747,"interventions":4748},[88],[403,445,446,447,408],[449,450,323],{"trials":4750,"activeCount":98},[],{"trials":4752,"activeCount":98},[],{"trials":4754,"activeCount":98},[],{"intervention":764,"totalTrials":94,"cells":4756},{"EARLY_PHASE1":4757,"PHASE1":4759,"PHASE2":4761,"PHASE3":4767,"PHASE4":4769,"NA":4771},{"trials":4758,"activeCount":98},[],{"trials":4760,"activeCount":98},[],{"trials":4762,"activeCount":98},[4763],{"nctId":756,"briefTitle":757,"status":385,"phases":4764,"primaryCompletion":759,"completion":760,"start":761,"enrollment":98,"conditions":4765,"interventions":4766},[88],[730,745],[415,764,765],{"trials":4768,"activeCount":98},[],{"trials":4770,"activeCount":98},[],{"trials":4772,"activeCount":98},[],{"intervention":765,"totalTrials":94,"cells":4774},{"EARLY_PHASE1":4775,"PHASE1":4777,"PHASE2":4779,"PHASE3":4785,"PHASE4":4787,"NA":4789},{"trials":4776,"activeCount":98},[],{"trials":4778,"activeCount":98},[],{"trials":4780,"activeCount":98},[4781],{"nctId":756,"briefTitle":757,"status":385,"phases":4782,"primaryCompletion":759,"completion":760,"start":761,"enrollment":98,"conditions":4783,"interventions":4784},[88],[730,745],[415,764,765],{"trials":4786,"activeCount":98},[],{"trials":4788,"activeCount":98},[],{"trials":4790,"activeCount":98},[],{"intervention":4792,"totalTrials":94,"cells":4793},"Acamprosate",{"EARLY_PHASE1":4794,"PHASE1":4796,"PHASE2":4798,"PHASE3":4810,"PHASE4":4812,"NA":4814},{"trials":4795,"activeCount":98},[],{"trials":4797,"activeCount":98},[],{"trials":4799,"activeCount":98},[4800],{"nctId":4801,"briefTitle":4802,"status":304,"phases":4803,"primaryCompletion":4804,"completion":4805,"start":4806,"enrollment":972,"conditions":4807,"interventions":4809},"NCT06471686","Safety of Acamprosate in Treating Alcohol Use Disorder in the Post Liver Transplant Populations",[88],"2023-07-30","2023-10-30","2021-12-01",[554,4808],"Liver Transplant; Complications",[4792],{"trials":4811,"activeCount":98},[],{"trials":4813,"activeCount":98},[],{"trials":4815,"activeCount":98},[],{"intervention":4817,"totalTrials":94,"cells":4818},"Gemcitabine",{"EARLY_PHASE1":4819,"PHASE1":4821,"PHASE2":4823,"PHASE3":4833,"PHASE4":4835,"NA":4837},{"trials":4820,"activeCount":98},[],{"trials":4822,"activeCount":98},[],{"trials":4824,"activeCount":98},[4825],{"nctId":4826,"briefTitle":4827,"status":304,"phases":4828,"primaryCompletion":4829,"completion":2487,"start":1672,"enrollment":593,"conditions":4830,"interventions":4832},"NCT00184093","Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma",[87,88],"2008-05",[4831],"Uterine Cervical Cancer",[4817],{"trials":4834,"activeCount":98},[],{"trials":4836,"activeCount":98},[],{"trials":4838,"activeCount":98},[],{"intervention":4840,"totalTrials":94,"cells":4841},"orteronel",{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4846,"PHASE3":4858,"PHASE4":4860,"NA":4862},{"trials":4843,"activeCount":98},[],{"trials":4845,"activeCount":98},[],{"trials":4847,"activeCount":98},[4848],{"nctId":4849,"briefTitle":4850,"status":398,"phases":4851,"primaryCompletion":4852,"completion":4853,"start":4854,"enrollment":631,"conditions":4855,"interventions":4857},"NCT01866423","Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",[88],"2015-07-23","2016-07-26","2013-10-25",[4856,3435,3436,976],"Adenocarcinoma of the Prostate",[4840],{"trials":4859,"activeCount":98},[],{"trials":4861,"activeCount":98},[],{"trials":4863,"activeCount":98},[],{"intervention":3339,"totalTrials":94,"cells":4865},{"EARLY_PHASE1":4866,"PHASE1":4868,"PHASE2":4870,"PHASE3":4876,"PHASE4":4878,"NA":4880},{"trials":4867,"activeCount":98},[],{"trials":4869,"activeCount":98},[],{"trials":4871,"activeCount":98},[4872],{"nctId":3331,"briefTitle":3332,"status":398,"phases":4873,"primaryCompletion":3334,"completion":3334,"start":3335,"enrollment":3336,"conditions":4874,"interventions":4875},[88],[24],[3303,3339,3340],{"trials":4877,"activeCount":98},[],{"trials":4879,"activeCount":98},[],{"trials":4881,"activeCount":98},[],{"intervention":1635,"totalTrials":94,"cells":4883},{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4888,"PHASE3":4894,"PHASE4":4896,"NA":4898},{"trials":4885,"activeCount":98},[],{"trials":4887,"activeCount":98},[],{"trials":4889,"activeCount":98},[4890],{"nctId":1621,"briefTitle":1622,"status":385,"phases":4891,"primaryCompletion":1624,"completion":1624,"start":1624,"enrollment":98,"conditions":4892,"interventions":4893},[88],[1626,1627,1628,1535,1629,1630,1536,1538,1631,1632],[1634,1431,1635,1636,1596,1637],{"trials":4895,"activeCount":98},[],{"trials":4897,"activeCount":98},[],{"trials":4899,"activeCount":98},[],{"intervention":1636,"totalTrials":94,"cells":4901},{"EARLY_PHASE1":4902,"PHASE1":4904,"PHASE2":4906,"PHASE3":4912,"PHASE4":4914,"NA":4916},{"trials":4903,"activeCount":98},[],{"trials":4905,"activeCount":98},[],{"trials":4907,"activeCount":98},[4908],{"nctId":1621,"briefTitle":1622,"status":385,"phases":4909,"primaryCompletion":1624,"completion":1624,"start":1624,"enrollment":98,"conditions":4910,"interventions":4911},[88],[1626,1627,1628,1535,1629,1630,1536,1538,1631,1632],[1634,1431,1635,1636,1596,1637],{"trials":4913,"activeCount":98},[],{"trials":4915,"activeCount":98},[],{"trials":4917,"activeCount":98},[],{"intervention":1637,"totalTrials":94,"cells":4919},{"EARLY_PHASE1":4920,"PHASE1":4922,"PHASE2":4924,"PHASE3":4930,"PHASE4":4932,"NA":4934},{"trials":4921,"activeCount":98},[],{"trials":4923,"activeCount":98},[],{"trials":4925,"activeCount":98},[4926],{"nctId":1621,"briefTitle":1622,"status":385,"phases":4927,"primaryCompletion":1624,"completion":1624,"start":1624,"enrollment":98,"conditions":4928,"interventions":4929},[88],[1626,1627,1628,1535,1629,1630,1536,1538,1631,1632],[1634,1431,1635,1636,1596,1637],{"trials":4931,"activeCount":98},[],{"trials":4933,"activeCount":98},[],{"trials":4935,"activeCount":98},[],{"intervention":4253,"totalTrials":94,"cells":4937},{"EARLY_PHASE1":4938,"PHASE1":4940,"PHASE2":4942,"PHASE3":4948,"PHASE4":4950,"NA":4952},{"trials":4939,"activeCount":98},[],{"trials":4941,"activeCount":98},[],{"trials":4943,"activeCount":98},[4944],{"nctId":4245,"briefTitle":4246,"status":2435,"phases":4945,"primaryCompletion":4248,"completion":2575,"start":4249,"enrollment":4250,"conditions":4946,"interventions":4947},[88],[3435,3436,976],[4253,4254,4236],{"trials":4949,"activeCount":98},[],{"trials":4951,"activeCount":98},[],{"trials":4953,"activeCount":98},[],{"intervention":4254,"totalTrials":94,"cells":4955},{"EARLY_PHASE1":4956,"PHASE1":4958,"PHASE2":4960,"PHASE3":4966,"PHASE4":4968,"NA":4970},{"trials":4957,"activeCount":98},[],{"trials":4959,"activeCount":98},[],{"trials":4961,"activeCount":98},[4962],{"nctId":4245,"briefTitle":4246,"status":2435,"phases":4963,"primaryCompletion":4248,"completion":2575,"start":4249,"enrollment":4250,"conditions":4964,"interventions":4965},[88],[3435,3436,976],[4253,4254,4236],{"trials":4967,"activeCount":98},[],{"trials":4969,"activeCount":98},[],{"trials":4971,"activeCount":98},[],{"intervention":1679,"totalTrials":94,"cells":4973},{"EARLY_PHASE1":4974,"PHASE1":4976,"PHASE2":4978,"PHASE3":4984,"PHASE4":4986,"NA":4988},{"trials":4975,"activeCount":98},[],{"trials":4977,"activeCount":98},[],{"trials":4979,"activeCount":98},[4980],{"nctId":1667,"briefTitle":1668,"status":398,"phases":4981,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":4982,"interventions":4983},[88],[1675],[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],{"trials":4985,"activeCount":98},[],{"trials":4987,"activeCount":98},[],{"trials":4989,"activeCount":98},[],{"intervention":1680,"totalTrials":94,"cells":4991},{"EARLY_PHASE1":4992,"PHASE1":4994,"PHASE2":4996,"PHASE3":5002,"PHASE4":5004,"NA":5006},{"trials":4993,"activeCount":98},[],{"trials":4995,"activeCount":98},[],{"trials":4997,"activeCount":98},[4998],{"nctId":1667,"briefTitle":1668,"status":398,"phases":4999,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":5000,"interventions":5001},[88],[1675],[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],{"trials":5003,"activeCount":98},[],{"trials":5005,"activeCount":98},[],{"trials":5007,"activeCount":98},[],{"intervention":1681,"totalTrials":94,"cells":5009},{"EARLY_PHASE1":5010,"PHASE1":5012,"PHASE2":5014,"PHASE3":5020,"PHASE4":5022,"NA":5024},{"trials":5011,"activeCount":98},[],{"trials":5013,"activeCount":98},[],{"trials":5015,"activeCount":98},[5016],{"nctId":1667,"briefTitle":1668,"status":398,"phases":5017,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":5018,"interventions":5019},[88],[1675],[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],{"trials":5021,"activeCount":98},[],{"trials":5023,"activeCount":98},[],{"trials":5025,"activeCount":98},[],{"intervention":1684,"totalTrials":94,"cells":5027},{"EARLY_PHASE1":5028,"PHASE1":5030,"PHASE2":5032,"PHASE3":5038,"PHASE4":5040,"NA":5042},{"trials":5029,"activeCount":98},[],{"trials":5031,"activeCount":98},[],{"trials":5033,"activeCount":98},[5034],{"nctId":1667,"briefTitle":1668,"status":398,"phases":5035,"primaryCompletion":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":5036,"interventions":5037},[88],[1675],[1677,1645,1678,1679,1680,1681,1682,1683,1684,1685],{"trials":5039,"activeCount":98},[],{"trials":5041,"activeCount":98},[],{"trials":5043,"activeCount":98},[],{"intervention":5045,"totalTrials":94,"cells":5046},"Gemcitabine and oxaliplatin",{"EARLY_PHASE1":5047,"PHASE1":5049,"PHASE2":5051,"PHASE3":5063,"PHASE4":5065,"NA":5067},{"trials":5048,"activeCount":98},[],{"trials":5050,"activeCount":98},[],{"trials":5052,"activeCount":98},[5053],{"nctId":5054,"briefTitle":5055,"status":398,"phases":5056,"primaryCompletion":5057,"completion":5058,"start":5059,"enrollment":356,"conditions":5060,"interventions":5062},"NCT00159458","Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer",[88],"2006-11","2006-12","2003-07",[663,5061],"Metastastic Breast Cancer",[5045],{"trials":5064,"activeCount":98},[],{"trials":5066,"activeCount":98},[],{"trials":5068,"activeCount":98},[],{"intervention":5070,"totalTrials":94,"cells":5071},"Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949",{"EARLY_PHASE1":5072,"PHASE1":5074,"PHASE2":5076,"PHASE3":5090,"PHASE4":5092,"NA":5094},{"trials":5073,"activeCount":98},[],{"trials":5075,"activeCount":98},[],{"trials":5077,"activeCount":98},[5078],{"nctId":5079,"briefTitle":5080,"status":398,"phases":5081,"primaryCompletion":5082,"completion":5082,"start":5083,"enrollment":289,"conditions":5084,"interventions":5088},"NCT04387071","CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma",[87,88],"2022-12-28","2021-04-29",[5085,367,5086,5087],"Locally Advanced Malignant Solid Neoplasm","Stage IV Pancreatic Cancer AJCC v8","Unresectable Malignant Solid Neoplasm",[5070,5089],"VLP-encapsulated TLR9 Agonist CMP-001",{"trials":5091,"activeCount":98},[],{"trials":5093,"activeCount":98},[],{"trials":5095,"activeCount":98},[],{"intervention":5089,"totalTrials":94,"cells":5097},{"EARLY_PHASE1":5098,"PHASE1":5100,"PHASE2":5102,"PHASE3":5108,"PHASE4":5110,"NA":5112},{"trials":5099,"activeCount":98},[],{"trials":5101,"activeCount":98},[],{"trials":5103,"activeCount":98},[5104],{"nctId":5079,"briefTitle":5080,"status":398,"phases":5105,"primaryCompletion":5082,"completion":5082,"start":5083,"enrollment":289,"conditions":5106,"interventions":5107},[87,88],[5085,367,5086,5087],[5070,5089],{"trials":5109,"activeCount":98},[],{"trials":5111,"activeCount":98},[],{"trials":5113,"activeCount":98},[],{"intervention":5115,"totalTrials":94,"cells":5116},"RAD001, Docetaxel, Bevacizumab",{"EARLY_PHASE1":5117,"PHASE1":5119,"PHASE2":5121,"PHASE3":5133,"PHASE4":5135,"NA":5137},{"trials":5118,"activeCount":98},[],{"trials":5120,"activeCount":98},[],{"trials":5122,"activeCount":98},[5123],{"nctId":5124,"briefTitle":5125,"status":304,"phases":5126,"primaryCompletion":5127,"completion":5128,"start":5129,"enrollment":5130,"conditions":5131,"interventions":5132},"NCT00574769","Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer",[87,88],"2016-02-17","2017-02-17","2010-02-17",27,[331],[5115],{"trials":5134,"activeCount":98},[],{"trials":5136,"activeCount":98},[],{"trials":5138,"activeCount":98},[],{"intervention":1580,"totalTrials":94,"cells":5140},{"EARLY_PHASE1":5141,"PHASE1":5143,"PHASE2":5145,"PHASE3":5151,"PHASE4":5153,"NA":5155},{"trials":5142,"activeCount":98},[],{"trials":5144,"activeCount":98},[],{"trials":5146,"activeCount":98},[5147],{"nctId":1570,"briefTitle":1571,"status":398,"phases":5148,"primaryCompletion":1573,"completion":1574,"start":1575,"enrollment":32,"conditions":5149,"interventions":5150},[88],[1577,1578],[1549,1580,1581,1582],{"trials":5152,"activeCount":98},[],{"trials":5154,"activeCount":98},[],{"trials":5156,"activeCount":98},[],{"intervention":1581,"totalTrials":94,"cells":5158},{"EARLY_PHASE1":5159,"PHASE1":5161,"PHASE2":5163,"PHASE3":5169,"PHASE4":5171,"NA":5173},{"trials":5160,"activeCount":98},[],{"trials":5162,"activeCount":98},[],{"trials":5164,"activeCount":98},[5165],{"nctId":1570,"briefTitle":1571,"status":398,"phases":5166,"primaryCompletion":1573,"completion":1574,"start":1575,"enrollment":32,"conditions":5167,"interventions":5168},[88],[1577,1578],[1549,1580,1581,1582],{"trials":5170,"activeCount":98},[],{"trials":5172,"activeCount":98},[],{"trials":5174,"activeCount":98},[],{"intervention":1582,"totalTrials":94,"cells":5176},{"EARLY_PHASE1":5177,"PHASE1":5179,"PHASE2":5181,"PHASE3":5187,"PHASE4":5189,"NA":5191},{"trials":5178,"activeCount":98},[],{"trials":5180,"activeCount":98},[],{"trials":5182,"activeCount":98},[5183],{"nctId":1570,"briefTitle":1571,"status":398,"phases":5184,"primaryCompletion":1573,"completion":1574,"start":1575,"enrollment":32,"conditions":5185,"interventions":5186},[88],[1577,1578],[1549,1580,1581,1582],{"trials":5188,"activeCount":98},[],{"trials":5190,"activeCount":98},[],{"trials":5192,"activeCount":98},[],{"intervention":5194,"totalTrials":94,"cells":5195},"doxorubicin-GnRH agonist conjugate AEZS-108",{"EARLY_PHASE1":5196,"PHASE1":5198,"PHASE2":5200,"PHASE3":5209,"PHASE4":5211,"NA":5213},{"trials":5197,"activeCount":98},[],{"trials":5199,"activeCount":98},[],{"trials":5201,"activeCount":98},[5202],{"nctId":5203,"briefTitle":5204,"status":304,"phases":5205,"primaryCompletion":798,"completion":798,"start":5206,"enrollment":4176,"conditions":5207,"interventions":5208},"NCT01240629","Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",[87,88],"2010-11-02",[331,3435,3436,976],[5194],{"trials":5210,"activeCount":98},[],{"trials":5212,"activeCount":98},[],{"trials":5214,"activeCount":98},[],{"intervention":5216,"totalTrials":94,"cells":5217},"Docetaxel and Gemcitabine",{"EARLY_PHASE1":5218,"PHASE1":5220,"PHASE2":5222,"PHASE3":5232,"PHASE4":5234,"NA":5236},{"trials":5219,"activeCount":98},[],{"trials":5221,"activeCount":98},[],{"trials":5223,"activeCount":98},[5224],{"nctId":5225,"briefTitle":5226,"status":304,"phases":5227,"primaryCompletion":2487,"completion":4098,"start":3843,"enrollment":1046,"conditions":5228,"interventions":5231},"NCT00183794","Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma",[88],[5229,5230],"Ovarian Carcinoma","Peritoneal Neoplasms",[5216],{"trials":5233,"activeCount":98},[],{"trials":5235,"activeCount":98},[],{"trials":5237,"activeCount":98},[],{"intervention":5239,"totalTrials":94,"cells":5240},"Pegylated Liposomal Doxorubicin (Doxil) and Rituximab",{"EARLY_PHASE1":5241,"PHASE1":5243,"PHASE2":5245,"PHASE3":5259,"PHASE4":5261,"NA":5263},{"trials":5242,"activeCount":98},[],{"trials":5244,"activeCount":98},[],{"trials":5246,"activeCount":98},[5247],{"nctId":5248,"briefTitle":5249,"status":398,"phases":5250,"primaryCompletion":5251,"completion":5252,"start":5253,"enrollment":1523,"conditions":5254,"interventions":5258},"NCT00183976","Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas",[88],"2005-09","2006-01","2005-04",[5255,5256,5257],"Non-Hodgkin's Lymphoma","Burkitt Lymphoma","Primary Effusion Lymphomas",[5239],{"trials":5260,"activeCount":98},[],{"trials":5262,"activeCount":98},[],{"trials":5264,"activeCount":98},[],{"intervention":1445,"totalTrials":94,"cells":5266},{"EARLY_PHASE1":5267,"PHASE1":5269,"PHASE2":5271,"PHASE3":5277,"PHASE4":5279,"NA":5281},{"trials":5268,"activeCount":98},[],{"trials":5270,"activeCount":98},[],{"trials":5272,"activeCount":98},[5273],{"nctId":1434,"briefTitle":1435,"status":398,"phases":5274,"primaryCompletion":1437,"completion":1438,"start":1439,"enrollment":22,"conditions":5275,"interventions":5276},[88],[1441,1442,1443],[1445,1446,1430],{"trials":5278,"activeCount":98},[],{"trials":5280,"activeCount":98},[],{"trials":5282,"activeCount":98},[],{"intervention":1446,"totalTrials":94,"cells":5284},{"EARLY_PHASE1":5285,"PHASE1":5287,"PHASE2":5289,"PHASE3":5295,"PHASE4":5297,"NA":5299},{"trials":5286,"activeCount":98},[],{"trials":5288,"activeCount":98},[],{"trials":5290,"activeCount":98},[5291],{"nctId":1434,"briefTitle":1435,"status":398,"phases":5292,"primaryCompletion":1437,"completion":1438,"start":1439,"enrollment":22,"conditions":5293,"interventions":5294},[88],[1441,1442,1443],[1445,1446,1430],{"trials":5296,"activeCount":98},[],{"trials":5298,"activeCount":98},[],{"trials":5300,"activeCount":98},[],{"intervention":5302,"totalTrials":94,"cells":5303},"Prostate Health Cocktail",{"EARLY_PHASE1":5304,"PHASE1":5306,"PHASE2":5308,"PHASE3":5319,"PHASE4":5321,"NA":5323},{"trials":5305,"activeCount":98},[],{"trials":5307,"activeCount":98},[],{"trials":5309,"activeCount":98},[5310],{"nctId":5311,"briefTitle":5312,"status":304,"phases":5313,"primaryCompletion":5314,"completion":5315,"start":5316,"enrollment":4176,"conditions":5317,"interventions":5318},"NCT00669656","Herbal Therapy for Treatment of Recurrent Prostate Cancer",[88],"2014-07-08","2014-10-14","2008-07-06",[331],[5302],{"trials":5320,"activeCount":98},[],{"trials":5322,"activeCount":98},[],{"trials":5324,"activeCount":98},[],{"intervention":3808,"totalTrials":94,"cells":5326},{"EARLY_PHASE1":5327,"PHASE1":5329,"PHASE2":5331,"PHASE3":5337,"PHASE4":5339,"NA":5341},{"trials":5328,"activeCount":98},[],{"trials":5330,"activeCount":98},[],{"trials":5332,"activeCount":98},[5333],{"nctId":3802,"briefTitle":3803,"status":304,"phases":5334,"primaryCompletion":3769,"completion":3769,"start":3805,"enrollment":236,"conditions":5335,"interventions":5336},[88],[3772,1675],[1677,3808,1683,1685],{"trials":5338,"activeCount":98},[],{"trials":5340,"activeCount":98},[],{"trials":5342,"activeCount":98},[],{"intervention":5344,"totalTrials":94,"cells":5345},"Dasatinib Anhydrous",{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5350,"PHASE3":5362,"PHASE4":5364,"NA":5366},{"trials":5347,"activeCount":98},[],{"trials":5349,"activeCount":98},[],{"trials":5351,"activeCount":98},[5352],{"nctId":5353,"briefTitle":5354,"status":385,"phases":5355,"primaryCompletion":5356,"completion":5357,"start":5358,"enrollment":98,"conditions":5359,"interventions":5361},"NCT04830735","Dasatinib for the Treatment of Moderate and Severe COVID-19",[88],"2023-12-15","2024-12-15","2022-08-05",[5360],"Symptomatic COVID-19 Infection Laboratory-Confirmed",[5344],{"trials":5363,"activeCount":98},[],{"trials":5365,"activeCount":98},[],{"trials":5367,"activeCount":98},[],{"intervention":5369,"totalTrials":94,"cells":5370},"Ticagrelor",{"EARLY_PHASE1":5371,"PHASE1":5373,"PHASE2":5375,"PHASE3":5386,"PHASE4":5388,"NA":5390},{"trials":5372,"activeCount":98},[],{"trials":5374,"activeCount":98},[],{"trials":5376,"activeCount":98},[5377],{"nctId":5378,"briefTitle":5379,"status":304,"phases":5380,"primaryCompletion":5381,"completion":5381,"start":5382,"enrollment":771,"conditions":5383,"interventions":5385},"NCT02091921","Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study",[87,88],"2016-11-30","2014-02-16",[5384],"Critical Limb Ischemia",[5369],{"trials":5387,"activeCount":98},[],{"trials":5389,"activeCount":98},[],{"trials":5391,"activeCount":98},[],{"intervention":3370,"totalTrials":94,"cells":5393},{"EARLY_PHASE1":5394,"PHASE1":5396,"PHASE2":5398,"PHASE3":5404,"PHASE4":5406,"NA":5408},{"trials":5395,"activeCount":98},[],{"trials":5397,"activeCount":98},[],{"trials":5399,"activeCount":98},[5400],{"nctId":3361,"briefTitle":3362,"status":304,"phases":5401,"primaryCompletion":3364,"completion":3365,"start":3366,"enrollment":2552,"conditions":5402,"interventions":5403},[88],[3368],[3303,3322,3370],{"trials":5405,"activeCount":98},[],{"trials":5407,"activeCount":98},[],{"trials":5409,"activeCount":98},[],{"intervention":5411,"totalTrials":94,"cells":5412},"Fludarabine, Mitoxantrone and Rituximab",{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5417,"PHASE3":5426,"PHASE4":5428,"NA":5430},{"trials":5414,"activeCount":98},[],{"trials":5416,"activeCount":98},[],{"trials":5418,"activeCount":98},[5419],{"nctId":5420,"briefTitle":5421,"status":398,"phases":5422,"primaryCompletion":5058,"completion":5058,"start":1655,"enrollment":972,"conditions":5423,"interventions":5425},"NCT00183989","Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma",[88],[5424],"Mantle Cell Lymphoma",[5411],{"trials":5427,"activeCount":98},[],{"trials":5429,"activeCount":98},[],{"trials":5431,"activeCount":98},[],{"intervention":669,"totalTrials":94,"cells":5433},{"EARLY_PHASE1":5434,"PHASE1":5436,"PHASE2":5438,"PHASE3":5444,"PHASE4":5446,"NA":5448},{"trials":5435,"activeCount":98},[],{"trials":5437,"activeCount":98},[],{"trials":5439,"activeCount":98},[5440],{"nctId":656,"briefTitle":657,"status":398,"phases":5441,"primaryCompletion":659,"completion":659,"start":660,"enrollment":32,"conditions":5442,"interventions":5443},[88],[662,663,664],[666,667,668,669],{"trials":5445,"activeCount":98},[],{"trials":5447,"activeCount":98},[],{"trials":5449,"activeCount":98},[],{"intervention":5451,"totalTrials":94,"cells":5452},"Gentamicin Sulfate, Injectable",{"EARLY_PHASE1":5453,"PHASE1":5455,"PHASE2":5457,"PHASE3":5466,"PHASE4":5468,"NA":5470},{"trials":5454,"activeCount":98},[],{"trials":5456,"activeCount":98},[],{"trials":5458,"activeCount":98},[5459],{"nctId":5460,"briefTitle":5461,"status":2435,"phases":5462,"primaryCompletion":3697,"completion":3697,"start":5463,"enrollment":236,"conditions":5464,"interventions":5465},"NCT04140786","Optimizing IV Gentamicin in JEB",[87,88],"2019-10-31",[807],[5451],{"trials":5467,"activeCount":98},[],{"trials":5469,"activeCount":98},[],{"trials":5471,"activeCount":98},[],{"intervention":5473,"totalTrials":94,"cells":5474},"Clindamycin 1% Gel",{"EARLY_PHASE1":5475,"PHASE1":5477,"PHASE2":5479,"PHASE3":5492,"PHASE4":5494,"NA":5496},{"trials":5476,"activeCount":98},[],{"trials":5478,"activeCount":98},[],{"trials":5480,"activeCount":98},[5481],{"nctId":5482,"briefTitle":5483,"status":304,"phases":5484,"primaryCompletion":5485,"completion":5485,"start":5486,"enrollment":1828,"conditions":5487,"interventions":5489},"NCT03257202","Topical Treatment and Prevalence of P. Acnes",[88],"2018-01-01","2017-09-11",[5488],"Surgical Site Infection",[5473,5490,5491],"Benzoyl peroxide 5% gel","BenzaClin 5%-1% Topical Gel",{"trials":5493,"activeCount":98},[],{"trials":5495,"activeCount":98},[],{"trials":5497,"activeCount":98},[],{"intervention":5490,"totalTrials":94,"cells":5499},{"EARLY_PHASE1":5500,"PHASE1":5502,"PHASE2":5504,"PHASE3":5510,"PHASE4":5512,"NA":5514},{"trials":5501,"activeCount":98},[],{"trials":5503,"activeCount":98},[],{"trials":5505,"activeCount":98},[5506],{"nctId":5482,"briefTitle":5483,"status":304,"phases":5507,"primaryCompletion":5485,"completion":5485,"start":5486,"enrollment":1828,"conditions":5508,"interventions":5509},[88],[5488],[5473,5490,5491],{"trials":5511,"activeCount":98},[],{"trials":5513,"activeCount":98},[],{"trials":5515,"activeCount":98},[],{"intervention":5491,"totalTrials":94,"cells":5517},{"EARLY_PHASE1":5518,"PHASE1":5520,"PHASE2":5522,"PHASE3":5528,"PHASE4":5530,"NA":5532},{"trials":5519,"activeCount":98},[],{"trials":5521,"activeCount":98},[],{"trials":5523,"activeCount":98},[5524],{"nctId":5482,"briefTitle":5483,"status":304,"phases":5525,"primaryCompletion":5485,"completion":5485,"start":5486,"enrollment":1828,"conditions":5526,"interventions":5527},[88],[5488],[5473,5490,5491],{"trials":5529,"activeCount":98},[],{"trials":5531,"activeCount":98},[],{"trials":5533,"activeCount":98},[],{"intervention":5535,"totalTrials":94,"cells":5536},"megestrol acetate",{"EARLY_PHASE1":5537,"PHASE1":5539,"PHASE2":5541,"PHASE3":5561,"PHASE4":5563,"NA":5565},{"trials":5538,"activeCount":98},[],{"trials":5540,"activeCount":98},[],{"trials":5542,"activeCount":98},[5543],{"nctId":5544,"briefTitle":5545,"status":385,"phases":5546,"primaryCompletion":2368,"completion":2366,"start":5547,"enrollment":98,"conditions":5548,"interventions":5560},"NCT01943058","Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer",[88],"2014-03",[5549,5550,5551,5552,5553,5554,5555,5556,5557,5558,5559],"Atypical Endometrial Hyperplasia","Endometrial Adenocarcinoma","Recurrent Endometrial Carcinoma","Stage IA Endometrial Carcinoma","Stage IB Endometrial Carcinoma","Stage II Endometrial Carcinoma","Stage IIIA Endometrial Carcinoma","Stage IIIB Endometrial Carcinoma","Stage IIIC Endometrial Carcinoma","Stage IVA Endometrial Carcinoma","Stage IVB Endometrial Carcinoma",[5535],{"trials":5562,"activeCount":98},[],{"trials":5564,"activeCount":98},[],{"trials":5566,"activeCount":98},[],{"intervention":3834,"totalTrials":94,"cells":5568},{"EARLY_PHASE1":5569,"PHASE1":5571,"PHASE2":5573,"PHASE3":5579,"PHASE4":5581,"NA":5583},{"trials":5570,"activeCount":98},[],{"trials":5572,"activeCount":98},[],{"trials":5574,"activeCount":98},[5575],{"nctId":3810,"briefTitle":3811,"status":304,"phases":5576,"primaryCompletion":3813,"completion":3813,"start":3814,"enrollment":308,"conditions":5577,"interventions":5578},[88],[3816,3817,3818,3819,3820,3821,3822,3823,3824,3825,3826,3827,3828,3829,3830,3831,3832],[1678,1685,3834,3835,3774,3836,3837],{"trials":5580,"activeCount":98},[],{"trials":5582,"activeCount":98},[],{"trials":5584,"activeCount":98},[],{"intervention":3835,"totalTrials":94,"cells":5586},{"EARLY_PHASE1":5587,"PHASE1":5589,"PHASE2":5591,"PHASE3":5597,"PHASE4":5599,"NA":5601},{"trials":5588,"activeCount":98},[],{"trials":5590,"activeCount":98},[],{"trials":5592,"activeCount":98},[5593],{"nctId":3810,"briefTitle":3811,"status":304,"phases":5594,"primaryCompletion":3813,"completion":3813,"start":3814,"enrollment":308,"conditions":5595,"interventions":5596},[88],[3816,3817,3818,3819,3820,3821,3822,3823,3824,3825,3826,3827,3828,3829,3830,3831,3832],[1678,1685,3834,3835,3774,3836,3837],{"trials":5598,"activeCount":98},[],{"trials":5600,"activeCount":98},[],{"trials":5602,"activeCount":98},[],{"intervention":3836,"totalTrials":94,"cells":5604},{"EARLY_PHASE1":5605,"PHASE1":5607,"PHASE2":5609,"PHASE3":5615,"PHASE4":5617,"NA":5619},{"trials":5606,"activeCount":98},[],{"trials":5608,"activeCount":98},[],{"trials":5610,"activeCount":98},[5611],{"nctId":3810,"briefTitle":3811,"status":304,"phases":5612,"primaryCompletion":3813,"completion":3813,"start":3814,"enrollment":308,"conditions":5613,"interventions":5614},[88],[3816,3817,3818,3819,3820,3821,3822,3823,3824,3825,3826,3827,3828,3829,3830,3831,3832],[1678,1685,3834,3835,3774,3836,3837],{"trials":5616,"activeCount":98},[],{"trials":5618,"activeCount":98},[],{"trials":5620,"activeCount":98},[],{"intervention":3837,"totalTrials":94,"cells":5622},{"EARLY_PHASE1":5623,"PHASE1":5625,"PHASE2":5627,"PHASE3":5633,"PHASE4":5635,"NA":5637},{"trials":5624,"activeCount":98},[],{"trials":5626,"activeCount":98},[],{"trials":5628,"activeCount":98},[5629],{"nctId":3810,"briefTitle":3811,"status":304,"phases":5630,"primaryCompletion":3813,"completion":3813,"start":3814,"enrollment":308,"conditions":5631,"interventions":5632},[88],[3816,3817,3818,3819,3820,3821,3822,3823,3824,3825,3826,3827,3828,3829,3830,3831,3832],[1678,1685,3834,3835,3774,3836,3837],{"trials":5634,"activeCount":98},[],{"trials":5636,"activeCount":98},[],{"trials":5638,"activeCount":98},[],{"intervention":5640,"totalTrials":94,"cells":5641},"Elsamitrusin",{"EARLY_PHASE1":5642,"PHASE1":5644,"PHASE2":5646,"PHASE3":5654,"PHASE4":5656,"NA":5658},{"trials":5643,"activeCount":98},[],{"trials":5645,"activeCount":98},[],{"trials":5647,"activeCount":98},[5648],{"nctId":5649,"briefTitle":5650,"status":304,"phases":5651,"primaryCompletion":1671,"completion":1671,"start":3814,"enrollment":356,"conditions":5652,"interventions":5653},"NCT00184080","Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[88],[5255],[5640],{"trials":5655,"activeCount":98},[],{"trials":5657,"activeCount":98},[],{"trials":5659,"activeCount":98},[],{"intervention":5661,"totalTrials":94,"cells":5662},"floxuridine, 5-Fluorouracil, leucovorin",{"EARLY_PHASE1":5663,"PHASE1":5665,"PHASE2":5667,"PHASE3":5678,"PHASE4":5680,"NA":5682},{"trials":5664,"activeCount":98},[],{"trials":5666,"activeCount":98},[],{"trials":5668,"activeCount":98},[5669],{"nctId":5670,"briefTitle":5671,"status":304,"phases":5672,"primaryCompletion":5058,"completion":4656,"start":5673,"enrollment":1673,"conditions":5674,"interventions":5677},"NCT00183911","Study of 5-Fluorouracil and Leucovorin and Intra-abdominal Floxuridine Chemoradiation in Patients With Fully Resected Locally Advanced Gastric Adenocarcinoma",[88],"2003-11",[5675,5676],"Gastric Adenocarcinoma","Gastric Cancer",[5661],{"trials":5679,"activeCount":98},[],{"trials":5681,"activeCount":98},[],{"trials":5683,"activeCount":98},[],{"intervention":5685,"totalTrials":94,"cells":5686},"Topical testosterone gel 10 g\u002Fday",{"EARLY_PHASE1":5687,"PHASE1":5689,"PHASE2":5691,"PHASE3":5704,"PHASE4":5706,"NA":5708},{"trials":5688,"activeCount":98},[],{"trials":5690,"activeCount":98},[],{"trials":5692,"activeCount":98},[5693],{"nctId":5694,"briefTitle":5695,"status":304,"phases":5696,"primaryCompletion":5697,"completion":2462,"start":5698,"enrollment":5699,"conditions":5700,"interventions":5703},"NCT00365794","Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men",[88],"2013-12","2006-08",22,[4352,15,5701,5702],"Insulin Resistance","Hypogonadism",[5685],{"trials":5705,"activeCount":98},[],{"trials":5707,"activeCount":98},[],{"trials":5709,"activeCount":98},[],{"intervention":5711,"totalTrials":94,"cells":5712},"eribulin mesylate",{"EARLY_PHASE1":5713,"PHASE1":5715,"PHASE2":5717,"PHASE3":5734,"PHASE4":5736,"NA":5738},{"trials":5714,"activeCount":98},[],{"trials":5716,"activeCount":98},[],{"trials":5718,"activeCount":98},[5719],{"nctId":5720,"briefTitle":5721,"status":304,"phases":5722,"primaryCompletion":5723,"completion":5724,"start":5725,"enrollment":5726,"conditions":5727,"interventions":5733},"NCT01676818","Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer",[88],"2021-02-21","2021-12-22","2012-08-09",32,[5728,5729,5730,5731,5732],"Recurrent Cervical Cancer","Stage IIIA Cervical Cancer","Stage IIIB Cervical Cancer","Stage IVA Cervical Cancer","Stage IVB Cervical Cancer",[5711],{"trials":5735,"activeCount":98},[],{"trials":5737,"activeCount":98},[],{"trials":5739,"activeCount":98},[],{"intervention":5741,"totalTrials":94,"cells":5742},"Liposomal Irinotecan",{"EARLY_PHASE1":5743,"PHASE1":5745,"PHASE2":5747,"PHASE3":5764,"PHASE4":5766,"NA":5768},{"trials":5744,"activeCount":98},[],{"trials":5746,"activeCount":98},[],{"trials":5748,"activeCount":98},[5749],{"nctId":5750,"briefTitle":5751,"status":385,"phases":5752,"primaryCompletion":5753,"completion":5754,"start":5755,"enrollment":98,"conditions":5756,"interventions":5762},"NCT03739801","MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",[87,88],"2022-04-06","2023-04-06","2020-04-06",[5757,5758,5759,5760,5675,5761],"Locally Advanced Unresectable Gastric Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Metastatic Unresectable Gastric Adenocarcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[5741,5763],"Ramucirumab",{"trials":5765,"activeCount":98},[],{"trials":5767,"activeCount":98},[],{"trials":5769,"activeCount":98},[],{"intervention":5763,"totalTrials":94,"cells":5771},{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5776,"PHASE3":5782,"PHASE4":5784,"NA":5786},{"trials":5773,"activeCount":98},[],{"trials":5775,"activeCount":98},[],{"trials":5777,"activeCount":98},[5778],{"nctId":5750,"briefTitle":5751,"status":385,"phases":5779,"primaryCompletion":5753,"completion":5754,"start":5755,"enrollment":98,"conditions":5780,"interventions":5781},[87,88],[5757,5758,5759,5760,5675,5761],[5741,5763],{"trials":5783,"activeCount":98},[],{"trials":5785,"activeCount":98},[],{"trials":5787,"activeCount":98},[],{"intervention":5789,"totalTrials":94,"cells":5790},"Noscapine",{"EARLY_PHASE1":5791,"PHASE1":5793,"PHASE2":5795,"PHASE3":5804,"PHASE4":5806,"NA":5808},{"trials":5792,"activeCount":98},[],{"trials":5794,"activeCount":98},[],{"trials":5796,"activeCount":98},[5797],{"nctId":5798,"briefTitle":5799,"status":398,"phases":5800,"primaryCompletion":5058,"completion":5058,"start":1591,"enrollment":1828,"conditions":5801,"interventions":5803},"NCT00183950","Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy",[87,88],[5255,5802],"Chronic Lymphocytic Leukemia",[5789],{"trials":5805,"activeCount":98},[],{"trials":5807,"activeCount":98},[],{"trials":5809,"activeCount":98},[],{"intervention":5811,"totalTrials":94,"cells":5812},"Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone",{"EARLY_PHASE1":5813,"PHASE1":5815,"PHASE2":5817,"PHASE3":5829,"PHASE4":5831,"NA":5833},{"trials":5814,"activeCount":98},[],{"trials":5816,"activeCount":98},[],{"trials":5818,"activeCount":98},[5819],{"nctId":5820,"briefTitle":5821,"status":304,"phases":5822,"primaryCompletion":5823,"completion":5824,"start":5825,"enrollment":5826,"conditions":5827,"interventions":5828},"NCT00184002","Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas",[88],"2012-12-19","2013-05-07","2003-01-10",68,[5255],[5811],{"trials":5830,"activeCount":98},[],{"trials":5832,"activeCount":98},[],{"trials":5834,"activeCount":98},[],{"intervention":5836,"totalTrials":94,"cells":5837},"Mx-dnG1 Retroviral Vector",{"EARLY_PHASE1":5838,"PHASE1":5840,"PHASE2":5842,"PHASE3":5851,"PHASE4":5853,"NA":5855},{"trials":5839,"activeCount":98},[],{"trials":5841,"activeCount":98},[],{"trials":5843,"activeCount":98},[5844],{"nctId":5845,"briefTitle":5846,"status":385,"phases":5847,"completion":3805,"start":3843,"enrollment":98,"conditions":5848,"interventions":5850},"NCT00035919","Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver",[87,88],[5849],"Colorectal Neoplasms",[5836],{"trials":5852,"activeCount":98},[],{"trials":5854,"activeCount":98},[],{"trials":5856,"activeCount":98},[],{"intervention":1514,"totalTrials":94,"cells":5858},{"EARLY_PHASE1":5859,"PHASE1":5861,"PHASE2":5863,"PHASE3":5869,"PHASE4":5871,"NA":5873},{"trials":5860,"activeCount":98},[],{"trials":5862,"activeCount":98},[],{"trials":5864,"activeCount":98},[5865],{"nctId":1505,"briefTitle":1506,"status":304,"phases":5866,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":1046,"conditions":5867,"interventions":5868},[88],[1512],[1514,379,1515],{"trials":5870,"activeCount":98},[],{"trials":5872,"activeCount":98},[],{"trials":5874,"activeCount":98},[],{"intervention":1515,"totalTrials":94,"cells":5876},{"EARLY_PHASE1":5877,"PHASE1":5879,"PHASE2":5881,"PHASE3":5887,"PHASE4":5889,"NA":5891},{"trials":5878,"activeCount":98},[],{"trials":5880,"activeCount":98},[],{"trials":5882,"activeCount":98},[5883],{"nctId":1505,"briefTitle":1506,"status":304,"phases":5884,"primaryCompletion":1508,"completion":1509,"start":1510,"enrollment":1046,"conditions":5885,"interventions":5886},[88],[1512],[1514,379,1515],{"trials":5888,"activeCount":98},[],{"trials":5890,"activeCount":98},[],{"trials":5892,"activeCount":98},[],{"intervention":1526,"totalTrials":94,"cells":5894},{"EARLY_PHASE1":5895,"PHASE1":5897,"PHASE2":5899,"PHASE3":5905,"PHASE4":5907,"NA":5909},{"trials":5896,"activeCount":98},[],{"trials":5898,"activeCount":98},[],{"trials":5900,"activeCount":98},[5901],{"nctId":1517,"briefTitle":1518,"status":398,"phases":5902,"primaryCompletion":1520,"completion":1521,"start":1522,"enrollment":1523,"conditions":5903,"interventions":5904},[88],[331],[1526,379],{"trials":5906,"activeCount":98},[],{"trials":5908,"activeCount":98},[],{"trials":5910,"activeCount":98},[],{"intervention":5912,"totalTrials":94,"cells":5913},"Pravastatin",{"EARLY_PHASE1":5914,"PHASE1":5916,"PHASE2":5918,"PHASE3":5930,"PHASE4":5932,"NA":5934},{"trials":5915,"activeCount":98},[],{"trials":5917,"activeCount":98},[],{"trials":5919,"activeCount":98},[5920],{"nctId":5921,"briefTitle":5922,"status":304,"phases":5923,"primaryCompletion":5924,"completion":5924,"start":5925,"enrollment":94,"conditions":5926,"interventions":5928},"NCT04284657","Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease",[88],"2025-08-04","2019-01-30",[5927],"Autosomal Dominant Polycystic Kidney Disease",[5912,5929],"sodium citrate",{"trials":5931,"activeCount":98},[],{"trials":5933,"activeCount":98},[],{"trials":5935,"activeCount":98},[],{"intervention":5929,"totalTrials":94,"cells":5937},{"EARLY_PHASE1":5938,"PHASE1":5940,"PHASE2":5942,"PHASE3":5948,"PHASE4":5950,"NA":5952},{"trials":5939,"activeCount":98},[],{"trials":5941,"activeCount":98},[],{"trials":5943,"activeCount":98},[5944],{"nctId":5921,"briefTitle":5922,"status":304,"phases":5945,"primaryCompletion":5924,"completion":5924,"start":5925,"enrollment":94,"conditions":5946,"interventions":5947},[88],[5927],[5912,5929],{"trials":5949,"activeCount":98},[],{"trials":5951,"activeCount":98},[],{"trials":5953,"activeCount":98},[],{"intervention":5955,"totalTrials":94,"cells":5956},"Tinzaparin sodium",{"EARLY_PHASE1":5957,"PHASE1":5959,"PHASE2":5961,"PHASE3":5974,"PHASE4":5976,"NA":5978},{"trials":5958,"activeCount":98},[],{"trials":5960,"activeCount":98},[],{"trials":5962,"activeCount":98},[5963],{"nctId":5964,"briefTitle":5965,"status":398,"phases":5966,"primaryCompletion":5967,"completion":5968,"start":5969,"enrollment":5970,"conditions":5971,"interventions":5973},"NCT00981903","Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer",[88],"2012-10","2015-10","2005-07",131,[5972,31],"Venous Thromboembolism",[5955],{"trials":5975,"activeCount":98},[],{"trials":5977,"activeCount":98},[],{"trials":5979,"activeCount":98},[],{"intervention":5981,"totalTrials":94,"cells":5982},"Bupropion Hydrochloride",{"EARLY_PHASE1":5983,"PHASE1":5985,"PHASE2":5987,"PHASE3":6001,"PHASE4":6003,"NA":6005},{"trials":5984,"activeCount":98},[],{"trials":5986,"activeCount":98},[],{"trials":5988,"activeCount":98},[5989],{"nctId":5990,"briefTitle":5991,"status":398,"phases":5992,"primaryCompletion":5993,"completion":5993,"start":5994,"enrollment":1828,"conditions":5995,"interventions":6000},"NCT03326128","High Dose Bupropion for Smoking Cessation - Pilot Study",[88],"2023-07-01","2021-09-01",[567,5996,5997,5998,5999],"Smoking, Tobacco","Smoking (Tobacco) Addiction","Cessation, Tobacco","Cigarette Smoking",[5981],{"trials":6002,"activeCount":98},[],{"trials":6004,"activeCount":98},[],{"trials":6006,"activeCount":98},[],{"intervention":6008,"totalTrials":94,"cells":6009},"mitomycin-c, cisplatin",{"EARLY_PHASE1":6010,"PHASE1":6012,"PHASE2":6014,"PHASE3":6027,"PHASE4":6029,"NA":6031},{"trials":6011,"activeCount":98},[],{"trials":6013,"activeCount":98},[],{"trials":6015,"activeCount":98},[6016],{"nctId":6017,"briefTitle":6018,"status":304,"phases":6019,"primaryCompletion":6020,"completion":6021,"start":6022,"enrollment":6023,"conditions":6024,"interventions":6026},"NCT00183885","A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma",[88],"2013-05-28","2023-03-06","2004-10-18",76,[2189,6025],"Liver Cancer",[6008],{"trials":6028,"activeCount":98},[],{"trials":6030,"activeCount":98},[],{"trials":6032,"activeCount":98},[],{"intervention":2323,"totalTrials":94,"cells":6034},{"EARLY_PHASE1":6035,"PHASE1":6037,"PHASE2":6039,"PHASE3":6045,"PHASE4":6047,"NA":6049},{"trials":6036,"activeCount":98},[],{"trials":6038,"activeCount":98},[],{"trials":6040,"activeCount":98},[6041],{"nctId":2314,"briefTitle":2315,"status":304,"phases":6042,"primaryCompletion":2317,"completion":2318,"start":2319,"enrollment":296,"conditions":6043,"interventions":6044},[87,88],[2321,24],[2323,2305],{"trials":6046,"activeCount":98},[],{"trials":6048,"activeCount":98},[],{"trials":6050,"activeCount":98},[],{"intervention":6052,"totalTrials":94,"cells":6053},"DHA",{"EARLY_PHASE1":6054,"PHASE1":6056,"PHASE2":6058,"PHASE3":6070,"PHASE4":6072,"NA":6074},{"trials":6055,"activeCount":98},[],{"trials":6057,"activeCount":98},[],{"trials":6059,"activeCount":98},[6060],{"nctId":6061,"briefTitle":6062,"status":304,"phases":6063,"primaryCompletion":6064,"completion":6064,"start":6065,"enrollment":6066,"conditions":6067,"interventions":6069},"NCT03613844","DHA Brain Delivery Trial",[88],"2024-05-16","2018-09-01",365,[6068],"Brain DHA Delivery and Alzheimer's Disease Risk",[6052],{"trials":6071,"activeCount":98},[],{"trials":6073,"activeCount":98},[],{"trials":6075,"activeCount":98},[],{"intervention":3857,"totalTrials":94,"cells":6077},{"EARLY_PHASE1":6078,"PHASE1":6080,"PHASE2":6082,"PHASE3":6088,"PHASE4":6090,"NA":6092},{"trials":6079,"activeCount":98},[],{"trials":6081,"activeCount":98},[],{"trials":6083,"activeCount":98},[6084],{"nctId":3848,"briefTitle":3849,"status":304,"phases":6085,"primaryCompletion":3851,"completion":3852,"start":3853,"enrollment":3854,"conditions":6086,"interventions":6087},[88],[3772,1675],[1677,1678,3774,3796,1682,1685,3857],{"trials":6089,"activeCount":98},[],{"trials":6091,"activeCount":98},[],{"trials":6093,"activeCount":98},[],{"intervention":6095,"totalTrials":94,"cells":6096},"Nerve block",{"EARLY_PHASE1":6097,"PHASE1":6099,"PHASE2":6101,"PHASE3":6115,"PHASE4":6117,"NA":6119},{"trials":6098,"activeCount":98},[],{"trials":6100,"activeCount":98},[],{"trials":6102,"activeCount":98},[6103],{"nctId":6104,"briefTitle":6105,"status":2435,"phases":6106,"primaryCompletion":6107,"completion":6108,"start":6109,"enrollment":6110,"conditions":6111,"interventions":6114},"NCT03780478","Preoperative Nerve Block for Rhinoplasty\u002FSeptoplasty",[87,88],"2021-12-31","2022-03-01","2019-06-17",70,[6112,6113],"Nasal Fracture","Deviated Nasal Septum",[6095],{"trials":6116,"activeCount":98},[],{"trials":6118,"activeCount":98},[],{"trials":6120,"activeCount":98},[],{"intervention":6122,"totalTrials":94,"cells":6123},"Sitagliptin",{"EARLY_PHASE1":6124,"PHASE1":6126,"PHASE2":6128,"PHASE3":6138,"PHASE4":6140,"NA":6142},{"trials":6125,"activeCount":98},[],{"trials":6127,"activeCount":98},[],{"trials":6129,"activeCount":98},[6130],{"nctId":6131,"briefTitle":6132,"status":304,"phases":6133,"primaryCompletion":2393,"completion":2393,"start":6134,"enrollment":2552,"conditions":6135,"interventions":6137},"NCT02576288","Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity",[88],"2016-01",[1112,6136],"Inflammation",[6122],{"trials":6139,"activeCount":98},[],{"trials":6141,"activeCount":98},[],{"trials":6143,"activeCount":98},[],{"intervention":6145,"totalTrials":94,"cells":6146},"doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate",{"EARLY_PHASE1":6147,"PHASE1":6149,"PHASE2":6151,"PHASE3":6162,"PHASE4":6164,"NA":6166},{"trials":6148,"activeCount":98},[],{"trials":6150,"activeCount":98},[],{"trials":6152,"activeCount":98},[6153],{"nctId":6154,"briefTitle":6155,"status":385,"phases":6156,"primaryCompletion":6157,"completion":6158,"start":6159,"enrollment":98,"conditions":6160,"interventions":6161},"NCT01227408","Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer",[88],"2010-02","2011-02","2009-02",[1594],[6145],{"trials":6163,"activeCount":98},[],{"trials":6165,"activeCount":98},[],{"trials":6167,"activeCount":98},[],{"intervention":3385,"totalTrials":94,"cells":6169},{"EARLY_PHASE1":6170,"PHASE1":6172,"PHASE2":6174,"PHASE3":6180,"PHASE4":6182,"NA":6184},{"trials":6171,"activeCount":98},[],{"trials":6173,"activeCount":98},[],{"trials":6175,"activeCount":98},[6176],{"nctId":3372,"briefTitle":3373,"status":385,"phases":6177,"primaryCompletion":3375,"completion":2575,"start":3376,"enrollment":98,"conditions":6178,"interventions":6179},[88],[3378,3349,3316,3317,3379,3350,3380,3381,3382,3383],[3385,3322,3303],{"trials":6181,"activeCount":98},[],{"trials":6183,"activeCount":98},[],{"trials":6185,"activeCount":98},[],{"intervention":6187,"totalTrials":94,"cells":6188},"Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab",{"EARLY_PHASE1":6189,"PHASE1":6191,"PHASE2":6193,"PHASE3":6201,"PHASE4":6203,"NA":6205},{"trials":6190,"activeCount":98},[],{"trials":6192,"activeCount":98},[],{"trials":6194,"activeCount":98},[6195],{"nctId":6196,"briefTitle":6197,"status":398,"phases":6198,"completion":3852,"start":2488,"enrollment":1251,"conditions":6199,"interventions":6200},"NCT00323011","FOLFIRI + Bevacizumab With or Without Dalteparin in First Line Treatment of Advanced Colorectal Cancer",[88],[24],[6187],{"trials":6202,"activeCount":98},[],{"trials":6204,"activeCount":98},[],{"trials":6206,"activeCount":98},[],{"intervention":6208,"totalTrials":94,"cells":6209},"Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine",{"EARLY_PHASE1":6210,"PHASE1":6212,"PHASE2":6214,"PHASE3":6223,"PHASE4":6225,"NA":6227},{"trials":6211,"activeCount":98},[],{"trials":6213,"activeCount":98},[],{"trials":6215,"activeCount":98},[6216],{"nctId":6217,"briefTitle":6218,"status":304,"phases":6219,"primaryCompletion":3431,"completion":3432,"start":4477,"enrollment":3433,"conditions":6220,"interventions":6222},"NCT00184041","Intensified Post Remission Therapy Containing PEG-Asparaginase",[88],[6221],"Acute Lymphoblastic Leukemia",[6208],{"trials":6224,"activeCount":98},[],{"trials":6226,"activeCount":98},[],{"trials":6228,"activeCount":98},[],{"intervention":4112,"totalTrials":94,"cells":6230},{"EARLY_PHASE1":6231,"PHASE1":6233,"PHASE2":6235,"PHASE3":6241,"PHASE4":6243,"NA":6245},{"trials":6232,"activeCount":98},[],{"trials":6234,"activeCount":98},[],{"trials":6236,"activeCount":98},[6237],{"nctId":4104,"briefTitle":4105,"status":398,"phases":6238,"primaryCompletion":674,"completion":4107,"start":4108,"enrollment":25,"conditions":6239,"interventions":6240},[88],[4110],[4085,4112],{"trials":6242,"activeCount":98},[],{"trials":6244,"activeCount":98},[],{"trials":6246,"activeCount":98},[],{"intervention":6248,"totalTrials":94,"cells":6249},"romiplostim",{"EARLY_PHASE1":6250,"PHASE1":6252,"PHASE2":6254,"PHASE3":6269,"PHASE4":6271,"NA":6273},{"trials":6251,"activeCount":98},[],{"trials":6253,"activeCount":98},[],{"trials":6255,"activeCount":98},[6256],{"nctId":6257,"briefTitle":6258,"status":398,"phases":6259,"primaryCompletion":6260,"completion":6261,"start":6262,"enrollment":5130,"conditions":6263,"interventions":6266},"NCT01153919","Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia",[88],"2014-07-14","2018-07-14","2010-06-30",[6264,6265],"Hepatitis C Infection","Thrombocytopenia",[6248,6267,6268],"ribavirin","PEG-interferon alfa-2a",{"trials":6270,"activeCount":98},[],{"trials":6272,"activeCount":98},[],{"trials":6274,"activeCount":98},[],{"intervention":6267,"totalTrials":94,"cells":6276},{"EARLY_PHASE1":6277,"PHASE1":6279,"PHASE2":6281,"PHASE3":6287,"PHASE4":6289,"NA":6291},{"trials":6278,"activeCount":98},[],{"trials":6280,"activeCount":98},[],{"trials":6282,"activeCount":98},[6283],{"nctId":6257,"briefTitle":6258,"status":398,"phases":6284,"primaryCompletion":6260,"completion":6261,"start":6262,"enrollment":5130,"conditions":6285,"interventions":6286},[88],[6264,6265],[6248,6267,6268],{"trials":6288,"activeCount":98},[],{"trials":6290,"activeCount":98},[],{"trials":6292,"activeCount":98},[],{"intervention":6268,"totalTrials":94,"cells":6294},{"EARLY_PHASE1":6295,"PHASE1":6297,"PHASE2":6299,"PHASE3":6305,"PHASE4":6307,"NA":6309},{"trials":6296,"activeCount":98},[],{"trials":6298,"activeCount":98},[],{"trials":6300,"activeCount":98},[6301],{"nctId":6257,"briefTitle":6258,"status":398,"phases":6302,"primaryCompletion":6260,"completion":6261,"start":6262,"enrollment":5130,"conditions":6303,"interventions":6304},[88],[6264,6265],[6248,6267,6268],{"trials":6306,"activeCount":98},[],{"trials":6308,"activeCount":98},[],{"trials":6310,"activeCount":98},[],{"intervention":1597,"totalTrials":94,"cells":6312},{"EARLY_PHASE1":6313,"PHASE1":6315,"PHASE2":6317,"PHASE3":6323,"PHASE4":6325,"NA":6327},{"trials":6314,"activeCount":98},[],{"trials":6316,"activeCount":98},[],{"trials":6318,"activeCount":98},[6319],{"nctId":1588,"briefTitle":1589,"status":304,"phases":6320,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":112,"conditions":6321,"interventions":6322},[88],[1594],[667,1596,1432,1597],{"trials":6324,"activeCount":98},[],{"trials":6326,"activeCount":98},[],{"trials":6328,"activeCount":98},[],{"intervention":1541,"totalTrials":94,"cells":6330},{"EARLY_PHASE1":6331,"PHASE1":6333,"PHASE2":6335,"PHASE3":6341,"PHASE4":6343,"NA":6345},{"trials":6332,"activeCount":98},[],{"trials":6334,"activeCount":98},[],{"trials":6336,"activeCount":98},[6337],{"nctId":1528,"briefTitle":1529,"status":398,"phases":6338,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":1523,"conditions":6339,"interventions":6340},[88],[1535,1536,1537,1538],[1540,668,1541],{"trials":6342,"activeCount":98},[],{"trials":6344,"activeCount":98},[],{"trials":6346,"activeCount":98},[],{"intervention":6348,"totalTrials":94,"cells":6349},"irinotecan, docetaxel",{"EARLY_PHASE1":6350,"PHASE1":6352,"PHASE2":6354,"PHASE3":6366,"PHASE4":6368,"NA":6370},{"trials":6351,"activeCount":98},[],{"trials":6353,"activeCount":98},[],{"trials":6355,"activeCount":98},[6356],{"nctId":6357,"briefTitle":6358,"status":304,"phases":6359,"primaryCompletion":6360,"completion":6361,"start":6362,"enrollment":1286,"conditions":6363,"interventions":6365},"NCT00183872","Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma",[88],"2014-10-20","2015-10-20","2005-04-14",[5676,6364],"Esophageal Neoplasms",[6348],{"trials":6367,"activeCount":98},[],{"trials":6369,"activeCount":98},[],{"trials":6371,"activeCount":98},[],{"intervention":6373,"totalTrials":94,"cells":6374},"Bevacizumab and Bortezomib",{"EARLY_PHASE1":6375,"PHASE1":6377,"PHASE2":6379,"PHASE3":6391,"PHASE4":6393,"NA":6395},{"trials":6376,"activeCount":98},[],{"trials":6378,"activeCount":98},[],{"trials":6380,"activeCount":98},[6381],{"nctId":6382,"briefTitle":6383,"status":2435,"phases":6384,"primaryCompletion":6385,"completion":6386,"start":6387,"enrollment":1758,"conditions":6388,"interventions":6390},"NCT00184015","Bortezomib and Bevacizumab (\"BB-mib-mab\") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",[87,88],"2016-08-21","2018-08-21","2005-08-18",[6389],"Renal Cell Cancer",[6373,6373],{"trials":6392,"activeCount":98},[],{"trials":6394,"activeCount":98},[],{"trials":6396,"activeCount":98},[],{"intervention":6398,"totalTrials":94,"cells":6399},"Cilostazol",{"EARLY_PHASE1":6400,"PHASE1":6402,"PHASE2":6404,"PHASE3":6413,"PHASE4":6415,"NA":6417},{"trials":6401,"activeCount":98},[],{"trials":6403,"activeCount":98},[],{"trials":6405,"activeCount":98},[6406],{"nctId":6407,"briefTitle":6408,"status":304,"phases":6409,"primaryCompletion":3611,"completion":3611,"start":6410,"enrollment":631,"conditions":6411,"interventions":6412},"NCT01915069","Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary",[88],"2013-07",[2998],[6398],{"trials":6414,"activeCount":98},[],{"trials":6416,"activeCount":98},[],{"trials":6418,"activeCount":98},[],{"intervention":6420,"totalTrials":94,"cells":6421},"Bortezomib, Docetaxel and Cisplatin",{"EARLY_PHASE1":6422,"PHASE1":6424,"PHASE2":6426,"PHASE3":6435,"PHASE4":6437,"NA":6439},{"trials":6423,"activeCount":98},[],{"trials":6425,"activeCount":98},[],{"trials":6427,"activeCount":98},[6428],{"nctId":6429,"briefTitle":6430,"status":385,"phases":6431,"start":1671,"enrollment":98,"conditions":6432,"interventions":6434},"NCT00313690","Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer",[87,88],[6433],"Lung Cancer",[6420],{"trials":6436,"activeCount":98},[],{"trials":6438,"activeCount":98},[],{"trials":6440,"activeCount":98},[],{"intervention":6442,"totalTrials":94,"cells":6443},"Seasonal influenza (flu) vaccine",{"EARLY_PHASE1":6444,"PHASE1":6446,"PHASE2":6448,"PHASE3":6458,"PHASE4":6460,"NA":6462},{"trials":6445,"activeCount":98},[],{"trials":6447,"activeCount":98},[],{"trials":6449,"activeCount":98},[6450],{"nctId":6451,"briefTitle":6452,"status":385,"phases":6453,"primaryCompletion":6454,"completion":6454,"start":6454,"enrollment":98,"conditions":6455,"interventions":6457},"NCT02554188","Fasting-mimicking Diet and Immunosenescence",[88],"2019-05-01",[6456],"Immunosenescence",[6442],{"trials":6459,"activeCount":98},[],{"trials":6461,"activeCount":98},[],{"trials":6463,"activeCount":98},[],{"intervention":6465,"totalTrials":94,"cells":6466},"Tamoxifen",{"EARLY_PHASE1":6467,"PHASE1":6469,"PHASE2":6471,"PHASE3":6481,"PHASE4":6483,"NA":6485},{"trials":6468,"activeCount":98},[],{"trials":6470,"activeCount":98},[],{"trials":6472,"activeCount":98},[6473],{"nctId":6474,"briefTitle":6475,"status":398,"phases":6476,"primaryCompletion":6477,"completion":6477,"start":5698,"enrollment":631,"conditions":6478,"interventions":6479},"NCT00183963","A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)",[88],"2008-06",[2170],[6465,6480,6480],"Fulvestrant",{"trials":6482,"activeCount":98},[],{"trials":6484,"activeCount":98},[],{"trials":6486,"activeCount":98},[],{"intervention":6480,"totalTrials":94,"cells":6488},{"EARLY_PHASE1":6489,"PHASE1":6491,"PHASE2":6493,"PHASE3":6499,"PHASE4":6501,"NA":6503},{"trials":6490,"activeCount":98},[],{"trials":6492,"activeCount":98},[],{"trials":6494,"activeCount":98},[6495],{"nctId":6474,"briefTitle":6475,"status":398,"phases":6496,"primaryCompletion":6477,"completion":6477,"start":5698,"enrollment":631,"conditions":6497,"interventions":6498},[88],[2170],[6465,6480,6480],{"trials":6500,"activeCount":98},[],{"trials":6502,"activeCount":98},[],{"trials":6504,"activeCount":98},[],{"intervention":6506,"totalTrials":94,"cells":6507},"trihexyphenidyl",{"EARLY_PHASE1":6508,"PHASE1":6510,"PHASE2":6512,"PHASE3":6521,"PHASE4":6523,"NA":6525},{"trials":6509,"activeCount":98},[],{"trials":6511,"activeCount":98},[],{"trials":6513,"activeCount":98},[6514],{"nctId":6515,"briefTitle":6516,"status":304,"phases":6517,"primaryCompletion":3851,"completion":3851,"start":3768,"enrollment":593,"conditions":6518,"interventions":6520},"NCT00122044","Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects",[88],[6519],"Dystonia",[6506],{"trials":6522,"activeCount":98},[],{"trials":6524,"activeCount":98},[],{"trials":6526,"activeCount":98},[],{"intervention":6528,"totalTrials":94,"cells":6529},"VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin",{"EARLY_PHASE1":6530,"PHASE1":6532,"PHASE2":6534,"PHASE3":6544,"PHASE4":6546,"NA":6548},{"trials":6531,"activeCount":98},[],{"trials":6533,"activeCount":98},[],{"trials":6535,"activeCount":98},[6536],{"nctId":6537,"briefTitle":6538,"status":385,"phases":6539,"primaryCompletion":6540,"completion":6540,"start":2551,"enrollment":98,"conditions":6541,"interventions":6543},"NCT00668499","A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma",[87,88],"2011-04",[6542],"Mesothelioma",[6528],{"trials":6545,"activeCount":98},[],{"trials":6547,"activeCount":98},[],{"trials":6549,"activeCount":98},[],{"intervention":6551,"totalTrials":94,"cells":6552},"phenelzine sulfate",{"EARLY_PHASE1":6553,"PHASE1":6555,"PHASE2":6557,"PHASE3":6567,"PHASE4":6569,"NA":6571},{"trials":6554,"activeCount":98},[],{"trials":6556,"activeCount":98},[],{"trials":6558,"activeCount":98},[6559],{"nctId":6560,"briefTitle":6561,"status":304,"phases":6562,"primaryCompletion":6563,"completion":6563,"start":6564,"enrollment":16,"conditions":6565,"interventions":6566},"NCT02217709","Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer",[88],"2020-06-29","2014-09-08",[4856,3436,426,430,431,432],[6551],{"trials":6568,"activeCount":98},[],{"trials":6570,"activeCount":98},[],{"trials":6572,"activeCount":98},[],{"intervention":6574,"totalTrials":94,"cells":6575},"oxaliplatin, capecitabine",{"EARLY_PHASE1":6576,"PHASE1":6578,"PHASE2":6580,"PHASE3":6591,"PHASE4":6593,"NA":6595},{"trials":6577,"activeCount":98},[],{"trials":6579,"activeCount":98},[],{"trials":6581,"activeCount":98},[6582],{"nctId":6583,"briefTitle":6584,"status":2435,"phases":6585,"primaryCompletion":6586,"completion":6587,"start":6588,"enrollment":296,"conditions":6589,"interventions":6590},"NCT00183898","Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer",[88],"2013-02-04","2019-12-28","2004-12-28",[5676,4635],[6574],{"trials":6592,"activeCount":98},[],{"trials":6594,"activeCount":98},[],{"trials":6596,"activeCount":98},[],{"intervention":6598,"totalTrials":94,"cells":6599},"Oxycodone Hcl 5Mg",{"EARLY_PHASE1":6600,"PHASE1":6602,"PHASE2":6604,"PHASE3":6619,"PHASE4":6621,"NA":6623},{"trials":6601,"activeCount":98},[],{"trials":6603,"activeCount":98},[],{"trials":6605,"activeCount":98},[6606],{"nctId":6607,"briefTitle":6608,"status":304,"phases":6609,"primaryCompletion":6454,"completion":6454,"start":2300,"enrollment":1286,"conditions":6610,"interventions":6616},"NCT03111186","Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Hand Surgery",[88],[6611,6612,6613,6614,6615],"Carpal Tunnel Syndrome","Dupuytren Contracture","Trigger Digit","Ganglion Cysts","De Quervain Disease",[6598,6617,6618],"Ibuprofen 400 mg","Acetaminophen 650 mg",{"trials":6620,"activeCount":98},[],{"trials":6622,"activeCount":98},[],{"trials":6624,"activeCount":98},[],{"intervention":6617,"totalTrials":94,"cells":6626},{"EARLY_PHASE1":6627,"PHASE1":6629,"PHASE2":6631,"PHASE3":6637,"PHASE4":6639,"NA":6641},{"trials":6628,"activeCount":98},[],{"trials":6630,"activeCount":98},[],{"trials":6632,"activeCount":98},[6633],{"nctId":6607,"briefTitle":6608,"status":304,"phases":6634,"primaryCompletion":6454,"completion":6454,"start":2300,"enrollment":1286,"conditions":6635,"interventions":6636},[88],[6611,6612,6613,6614,6615],[6598,6617,6618],{"trials":6638,"activeCount":98},[],{"trials":6640,"activeCount":98},[],{"trials":6642,"activeCount":98},[],{"intervention":6618,"totalTrials":94,"cells":6644},{"EARLY_PHASE1":6645,"PHASE1":6647,"PHASE2":6649,"PHASE3":6655,"PHASE4":6657,"NA":6659},{"trials":6646,"activeCount":98},[],{"trials":6648,"activeCount":98},[],{"trials":6650,"activeCount":98},[6651],{"nctId":6607,"briefTitle":6608,"status":304,"phases":6652,"primaryCompletion":6454,"completion":6454,"start":2300,"enrollment":1286,"conditions":6653,"interventions":6654},[88],[6611,6612,6613,6614,6615],[6598,6617,6618],{"trials":6656,"activeCount":98},[],{"trials":6658,"activeCount":98},[],{"trials":6660,"activeCount":98},[],{"intervention":3397,"totalTrials":94,"cells":6662},{"EARLY_PHASE1":6663,"PHASE1":6665,"PHASE2":6667,"PHASE3":6673,"PHASE4":6675,"NA":6677},{"trials":6664,"activeCount":98},[],{"trials":6666,"activeCount":98},[],{"trials":6668,"activeCount":98},[6669],{"nctId":3387,"briefTitle":3388,"status":385,"phases":6670,"primaryCompletion":3390,"completion":3391,"start":3392,"enrollment":98,"conditions":6671,"interventions":6672},[88],[523,3394,3395],[3397,681,701,680,702],{"trials":6674,"activeCount":98},[],{"trials":6676,"activeCount":98},[],{"trials":6678,"activeCount":98},[],{"intervention":6680,"totalTrials":94,"cells":6681},"Baricitinib",{"EARLY_PHASE1":6682,"PHASE1":6684,"PHASE2":6686,"PHASE3":6697,"PHASE4":6699,"NA":6701},{"trials":6683,"activeCount":98},[],{"trials":6685,"activeCount":98},[],{"trials":6687,"activeCount":98},[6688],{"nctId":6689,"briefTitle":6690,"status":398,"phases":6691,"primaryCompletion":6692,"completion":6692,"start":6693,"enrollment":236,"conditions":6694,"interventions":6695},"NCT04373044","Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",[88],"2021-05-12","2020-05-01",[5360],[6680,6696],"Hydroxychloroquine",{"trials":6698,"activeCount":98},[],{"trials":6700,"activeCount":98},[],{"trials":6702,"activeCount":98},[],{"intervention":6696,"totalTrials":94,"cells":6704},{"EARLY_PHASE1":6705,"PHASE1":6707,"PHASE2":6709,"PHASE3":6715,"PHASE4":6717,"NA":6719},{"trials":6706,"activeCount":98},[],{"trials":6708,"activeCount":98},[],{"trials":6710,"activeCount":98},[6711],{"nctId":6689,"briefTitle":6690,"status":398,"phases":6712,"primaryCompletion":6692,"completion":6692,"start":6693,"enrollment":236,"conditions":6713,"interventions":6714},[88],[5360],[6680,6696],{"trials":6716,"activeCount":98},[],{"trials":6718,"activeCount":98},[],{"trials":6720,"activeCount":98},[],{"intervention":4265,"totalTrials":94,"cells":6722},{"EARLY_PHASE1":6723,"PHASE1":6725,"PHASE2":6727,"PHASE3":6733,"PHASE4":6735,"NA":6737},{"trials":6724,"activeCount":98},[],{"trials":6726,"activeCount":98},[],{"trials":6728,"activeCount":98},[6729],{"nctId":4256,"briefTitle":4257,"status":398,"phases":6730,"primaryCompletion":4259,"completion":4260,"start":4261,"enrollment":4075,"conditions":6731,"interventions":6732},[88],[4263,3435,3436,426,430,431,432,976],[4265,4236,4266,4267],{"trials":6734,"activeCount":98},[],{"trials":6736,"activeCount":98},[],{"trials":6738,"activeCount":98},[],{"intervention":4266,"totalTrials":94,"cells":6740},{"EARLY_PHASE1":6741,"PHASE1":6743,"PHASE2":6745,"PHASE3":6751,"PHASE4":6753,"NA":6755},{"trials":6742,"activeCount":98},[],{"trials":6744,"activeCount":98},[],{"trials":6746,"activeCount":98},[6747],{"nctId":4256,"briefTitle":4257,"status":398,"phases":6748,"primaryCompletion":4259,"completion":4260,"start":4261,"enrollment":4075,"conditions":6749,"interventions":6750},[88],[4263,3435,3436,426,430,431,432,976],[4265,4236,4266,4267],{"trials":6752,"activeCount":98},[],{"trials":6754,"activeCount":98},[],{"trials":6756,"activeCount":98},[],{"intervention":4267,"totalTrials":94,"cells":6758},{"EARLY_PHASE1":6759,"PHASE1":6761,"PHASE2":6763,"PHASE3":6769,"PHASE4":6771,"NA":6773},{"trials":6760,"activeCount":98},[],{"trials":6762,"activeCount":98},[],{"trials":6764,"activeCount":98},[6765],{"nctId":4256,"briefTitle":4257,"status":398,"phases":6766,"primaryCompletion":4259,"completion":4260,"start":4261,"enrollment":4075,"conditions":6767,"interventions":6768},[88],[4263,3435,3436,426,430,431,432,976],[4265,4236,4266,4267],{"trials":6770,"activeCount":98},[],{"trials":6772,"activeCount":98},[],{"trials":6774,"activeCount":98},[],{"intervention":6776,"totalTrials":289,"cells":6777},"irinotecan",{"EARLY_PHASE1":6778,"PHASE1":6780,"PHASE2":6800,"PHASE3":6802,"PHASE4":6804,"NA":6806},{"trials":6779,"activeCount":98},[],{"trials":6781,"activeCount":98},[6782,6791],{"nctId":6783,"briefTitle":6784,"status":304,"phases":6785,"primaryCompletion":6786,"completion":3420,"start":3780,"enrollment":5699,"conditions":6787,"interventions":6790},"NCT00183846","Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers",[87],"2007-10",[3368,5676,6788,6789],"Duodenum Cancer","Bile Duct Cancer",[6776],{"nctId":6792,"briefTitle":6793,"status":304,"phases":6794,"primaryCompletion":6795,"completion":6795,"start":6796,"enrollment":308,"conditions":6797,"interventions":6799},"NCT00183859","Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan",[87],"2009-04","1999-09",[6798,5676],"Adenocarcinoma",[6776],{"trials":6801,"activeCount":98},[],{"trials":6803,"activeCount":98},[],{"trials":6805,"activeCount":98},[],{"trials":6807,"activeCount":98},[],{"intervention":6809,"totalTrials":289,"cells":6810},"18F-FMAU",{"EARLY_PHASE1":6811,"PHASE1":6834,"PHASE2":6845,"PHASE3":6847,"PHASE4":6849,"NA":6851},{"trials":6812,"activeCount":98},[6813],{"nctId":6814,"briefTitle":6815,"status":304,"phases":6816,"primaryCompletion":6817,"completion":6817,"start":6818,"enrollment":32,"conditions":6819,"interventions":6833},"NCT04752267","18F-FMAU PET\u002FCT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases",[86],"2023-09-18","2021-02-15",[252,6820,6821,6822,253,6823,6824,6825,6826,256,6827,254,6828,1261,6829,6830,1262,6831,1263,6832],"Clinical Stage IV Cutaneous Melanoma AJCC v8","Glioma","Malignant Brain Neoplasm","Metastatic Colon Carcinoma","Metastatic Kidney Carcinoma","Metastatic Lung Carcinoma","Metastatic Malignant Neoplasm in the Brain","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IVA Colon Cancer AJCC v8","Stage IVB Colon Cancer AJCC v8","Stage IVC Colon Cancer AJCC v8",[6809],{"trials":6835,"activeCount":98},[6836],{"nctId":6837,"briefTitle":6838,"status":398,"phases":6839,"primaryCompletion":6840,"completion":6840,"start":6841,"enrollment":3336,"conditions":6842,"interventions":6844},"NCT02809690","18F-FMAU PET\u002FCT in Diagnosing and Characterizing Prostate Cancer",[87],"2021-07-21","2016-09-12",[6843],"Prostate Neoplasm",[6809],{"trials":6846,"activeCount":98},[],{"trials":6848,"activeCount":98},[],{"trials":6850,"activeCount":98},[],{"trials":6852,"activeCount":98},[],{"intervention":6854,"totalTrials":94,"cells":6855},"NRX 194204",{"EARLY_PHASE1":6856,"PHASE1":6858,"PHASE2":6868,"PHASE3":6870,"PHASE4":6872,"NA":6874},{"trials":6857,"activeCount":98},[],{"trials":6859,"activeCount":98},[6860],{"nctId":6861,"briefTitle":6862,"status":398,"phases":6863,"primaryCompletion":6864,"completion":6864,"start":2848,"enrollment":929,"conditions":6865,"interventions":6867},"NCT00630760","Oral NRX 194204 in Patients With Refractory Malignancies",[87],"2010-06",[6866],"Refractory Malignancies",[6854],{"trials":6869,"activeCount":98},[],{"trials":6871,"activeCount":98},[],{"trials":6873,"activeCount":98},[],{"trials":6875,"activeCount":98},[],{"intervention":416,"totalTrials":94,"cells":6877},{"EARLY_PHASE1":6878,"PHASE1":6880,"PHASE2":6886,"PHASE3":6888,"PHASE4":6890,"NA":6892},{"trials":6879,"activeCount":98},[],{"trials":6881,"activeCount":98},[6882],{"nctId":396,"briefTitle":397,"status":398,"phases":6883,"primaryCompletion":400,"completion":400,"start":401,"enrollment":348,"conditions":6884,"interventions":6885},[87],[403,404,405,406,407,408,409,410,411,412,413],[415,323,416],{"trials":6887,"activeCount":98},[],{"trials":6889,"activeCount":98},[],{"trials":6891,"activeCount":98},[],{"trials":6893,"activeCount":98},[],{"intervention":6895,"totalTrials":94,"cells":6896},"capecitabine, imatinib mesylate",{"EARLY_PHASE1":6897,"PHASE1":6899,"PHASE2":6908,"PHASE3":6910,"PHASE4":6912,"NA":6914},{"trials":6898,"activeCount":98},[],{"trials":6900,"activeCount":98},[6901],{"nctId":6902,"briefTitle":6903,"status":304,"phases":6904,"primaryCompletion":3420,"completion":4097,"start":6905,"enrollment":1286,"conditions":6906,"interventions":6907},"NCT00183833","Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors",[87],"2002-12",[2321,24],[6895],{"trials":6909,"activeCount":98},[],{"trials":6911,"activeCount":98},[],{"trials":6913,"activeCount":98},[],{"trials":6915,"activeCount":98},[],{"intervention":6917,"totalTrials":94,"cells":6918},"recombinant albumin fusion protein sEphB4-HSA",{"EARLY_PHASE1":6919,"PHASE1":6921,"PHASE2":6932,"PHASE3":6934,"PHASE4":6936,"NA":6938},{"trials":6920,"activeCount":98},[],{"trials":6922,"activeCount":98},[6923],{"nctId":6924,"briefTitle":6925,"status":398,"phases":6926,"primaryCompletion":6927,"completion":6927,"start":6928,"enrollment":6929,"conditions":6930,"interventions":6931},"NCT01642342","Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors",[87],"2019-05-29","2012-09-06",102,[1658],[6917],{"trials":6933,"activeCount":98},[],{"trials":6935,"activeCount":98},[],{"trials":6937,"activeCount":98},[],{"trials":6939,"activeCount":98},[],{"intervention":6941,"totalTrials":94,"cells":6942},"Suberoylanilide hydroxamic acid",{"EARLY_PHASE1":6943,"PHASE1":6945,"PHASE2":6953,"PHASE3":6955,"PHASE4":6957,"NA":6959},{"trials":6944,"activeCount":98},[],{"trials":6946,"activeCount":98},[6947],{"nctId":6948,"briefTitle":6949,"status":304,"phases":6950,"primaryCompletion":6795,"completion":6795,"start":3365,"enrollment":32,"conditions":6951,"interventions":6952},"NCT00336141","Vorinostat and IV Fluorouracil\u002FLeucovorin (5FU\u002FLV) in Patients With Metastatic Colorectal Cancer",[87],[24],[6941],{"trials":6954,"activeCount":98},[],{"trials":6956,"activeCount":98},[],{"trials":6958,"activeCount":98},[],{"trials":6960,"activeCount":98},[],{"intervention":6962,"totalTrials":94,"cells":6963},"Denosumab",{"EARLY_PHASE1":6964,"PHASE1":6966,"PHASE2":6977,"PHASE3":6979,"PHASE4":6981,"NA":6983},{"trials":6965,"activeCount":98},[],{"trials":6967,"activeCount":98},[6968],{"nctId":6969,"briefTitle":6970,"status":385,"phases":6971,"primaryCompletion":6972,"completion":6972,"start":6973,"enrollment":98,"conditions":6974,"interventions":6976},"NCT02444585","Longjohn Amgen Study - Effect of Denosumab...",[87],"2019-12","2017-02-28",[6975],"Arthroplasty, Replacement, Hip",[6962],{"trials":6978,"activeCount":98},[],{"trials":6980,"activeCount":98},[],{"trials":6982,"activeCount":98},[],{"trials":6984,"activeCount":98},[],{"intervention":6986,"totalTrials":94,"cells":6987},"liposomal doxorubicin and docetaxel",{"EARLY_PHASE1":6988,"PHASE1":6990,"PHASE2":7000,"PHASE3":7002,"PHASE4":7004,"NA":7006},{"trials":6989,"activeCount":98},[],{"trials":6991,"activeCount":98},[6992],{"nctId":6993,"briefTitle":6994,"status":304,"phases":6995,"primaryCompletion":6996,"completion":2488,"start":3780,"enrollment":593,"conditions":6997,"interventions":6999},"NCT00183742","Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)",[87],"2005-10",[31,6998],"Carcinoma",[6986],{"trials":7001,"activeCount":98},[],{"trials":7003,"activeCount":98},[],{"trials":7005,"activeCount":98},[],{"trials":7007,"activeCount":98},[],{"intervention":7009,"totalTrials":94,"cells":7010},"nanosomal docetaxel lipid suspension",{"EARLY_PHASE1":7011,"PHASE1":7013,"PHASE2":7024,"PHASE3":7026,"PHASE4":7028,"NA":7030},{"trials":7012,"activeCount":98},[],{"trials":7014,"activeCount":98},[7015],{"nctId":7016,"briefTitle":7017,"status":304,"phases":7018,"primaryCompletion":7019,"completion":7020,"start":7021,"enrollment":22,"conditions":7022,"interventions":7023},"NCT01957995","Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors",[87],"2014-05-29","2016-07-14","2013-11-08",[1658],[7009],{"trials":7025,"activeCount":98},[],{"trials":7027,"activeCount":98},[],{"trials":7029,"activeCount":98},[],{"trials":7031,"activeCount":98},[],{"intervention":751,"totalTrials":94,"cells":7033},{"EARLY_PHASE1":7034,"PHASE1":7036,"PHASE2":7042,"PHASE3":7044,"PHASE4":7046,"NA":7048},{"trials":7035,"activeCount":98},[],{"trials":7037,"activeCount":98},[7038],{"nctId":718,"briefTitle":719,"status":398,"phases":7039,"primaryCompletion":721,"completion":722,"start":723,"enrollment":32,"conditions":7040,"interventions":7041},[87],[725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744,745,746,408,747,412,748,749],[751,752],{"trials":7043,"activeCount":98},[],{"trials":7045,"activeCount":98},[],{"trials":7047,"activeCount":98},[],{"trials":7049,"activeCount":98},[],{"intervention":7051,"totalTrials":94,"cells":7052},"granisetron transdermal system",{"EARLY_PHASE1":7053,"PHASE1":7055,"PHASE2":7070,"PHASE3":7072,"PHASE4":7074,"NA":7076},{"trials":7054,"activeCount":98},[],{"trials":7056,"activeCount":98},[7057],{"nctId":7058,"briefTitle":7059,"status":398,"phases":7060,"primaryCompletion":7061,"completion":7062,"start":7063,"enrollment":7064,"conditions":7065,"interventions":7068},"NCT01649258","Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy",[87],"2017-05-22","2017-09-30","2012-09-04",29,[1594,7066,7067],"Nausea","Vomiting",[7051,7069],"fosaprepitant dimeglumine",{"trials":7071,"activeCount":98},[],{"trials":7073,"activeCount":98},[],{"trials":7075,"activeCount":98},[],{"trials":7077,"activeCount":98},[],{"intervention":7069,"totalTrials":94,"cells":7079},{"EARLY_PHASE1":7080,"PHASE1":7082,"PHASE2":7088,"PHASE3":7090,"PHASE4":7092,"NA":7094},{"trials":7081,"activeCount":98},[],{"trials":7083,"activeCount":98},[7084],{"nctId":7058,"briefTitle":7059,"status":398,"phases":7085,"primaryCompletion":7061,"completion":7062,"start":7063,"enrollment":7064,"conditions":7086,"interventions":7087},[87],[1594,7066,7067],[7051,7069],{"trials":7089,"activeCount":98},[],{"trials":7091,"activeCount":98},[],{"trials":7093,"activeCount":98},[],{"trials":7095,"activeCount":98},[],{"intervention":7097,"totalTrials":94,"cells":7098},"Paclitaxel Poliglumex",{"EARLY_PHASE1":7099,"PHASE1":7101,"PHASE2":7112,"PHASE3":7114,"PHASE4":7116,"NA":7118},{"trials":7100,"activeCount":98},[],{"trials":7102,"activeCount":98},[7103],{"nctId":7104,"briefTitle":7105,"status":304,"phases":7106,"primaryCompletion":7107,"completion":7108,"start":4349,"enrollment":1523,"conditions":7109,"interventions":7111},"NCT00598247","A Pilot Study of PPX in Women With Metastatic Colorectal Cancer",[87],"2008-09","2011-07",[7110],"Advanced Colorectal Cancer",[7097],{"trials":7113,"activeCount":98},[],{"trials":7115,"activeCount":98},[],{"trials":7117,"activeCount":98},[],{"trials":7119,"activeCount":98},[],{"intervention":7121,"totalTrials":94,"cells":7122},"temsirolimus",{"EARLY_PHASE1":7123,"PHASE1":7125,"PHASE2":7167,"PHASE3":7169,"PHASE4":7171,"NA":7173},{"trials":7124,"activeCount":98},[],{"trials":7126,"activeCount":98},[7127],{"nctId":7128,"briefTitle":7129,"status":304,"phases":7130,"primaryCompletion":7131,"completion":7132,"start":6864,"enrollment":1463,"conditions":7133,"interventions":7165},"NCT01155258","Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors",[87],"2013-01","2014-05",[7134,7135,7136,7137,837,7138,838,663,5728,5551,840,841,7139,7140,7141,7142,7143,3436,7144,7145,7146,7147,7148,7149,7150,7151,7152,7153,432,433,7154,21,7155,29,7156,7157,664,7158,7159,7160,7161,7162,976,1004,7163,5731,5732,7164],"Extensive Stage Small Cell Lung Cancer","Hereditary Paraganglioma","Male Breast Cancer","Malignant Paraganglioma","Metastatic Pheochromocytoma","Recurrent Neuroendocrine Carcinoma of the Skin","Recurrent Non-small Cell Lung Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Ovarian Germ Cell Tumor","Recurrent Pheochromocytoma","Recurrent Renal Cell Cancer","Recurrent Small Cell Lung Cancer","Recurrent Uterine Sarcoma","Regional Gastrointestinal Carcinoid Tumor","Regional Pheochromocytoma","Stage III Cervical Cancer","Stage III Endometrial Carcinoma","Stage III Neuroendocrine Carcinoma of the Skin","Stage III Ovarian Epithelial Cancer","Stage III Ovarian Germ Cell Tumor","Stage III Uterine Sarcoma","Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer","Stage IIIC Breast Cancer","Stage IV Endometrial Carcinoma","Stage IV Neuroendocrine Carcinoma of the Skin","Stage IV Non-small Cell Lung Cancer","Stage IV Ovarian Epithelial Cancer","Stage IV Ovarian Germ Cell Tumor","Stage IV Uterine Sarcoma","Thyroid Gland Medullary Carcinoma",[7121,7166],"vinorelbine ditartrate",{"trials":7168,"activeCount":98},[],{"trials":7170,"activeCount":98},[],{"trials":7172,"activeCount":98},[],{"trials":7174,"activeCount":98},[],{"intervention":7166,"totalTrials":94,"cells":7176},{"EARLY_PHASE1":7177,"PHASE1":7179,"PHASE2":7185,"PHASE3":7187,"PHASE4":7189,"NA":7191},{"trials":7178,"activeCount":98},[],{"trials":7180,"activeCount":98},[7181],{"nctId":7128,"briefTitle":7129,"status":304,"phases":7182,"primaryCompletion":7131,"completion":7132,"start":6864,"enrollment":1463,"conditions":7183,"interventions":7184},[87],[7134,7135,7136,7137,837,7138,838,663,5728,5551,840,841,7139,7140,7141,7142,7143,3436,7144,7145,7146,7147,7148,7149,7150,7151,7152,7153,432,433,7154,21,7155,29,7156,7157,664,7158,7159,7160,7161,7162,976,1004,7163,5731,5732,7164],[7121,7166],{"trials":7186,"activeCount":98},[],{"trials":7188,"activeCount":98},[],{"trials":7190,"activeCount":98},[],{"trials":7192,"activeCount":98},[],{"intervention":7194,"totalTrials":94,"cells":7195},"Cigarette 1",{"EARLY_PHASE1":7196,"PHASE1":7198,"PHASE2":7211,"PHASE3":7213,"PHASE4":7215,"NA":7217},{"trials":7197,"activeCount":98},[],{"trials":7199,"activeCount":98},[7200],{"nctId":7201,"briefTitle":7202,"status":304,"phases":7203,"primaryCompletion":2318,"completion":2318,"start":7204,"enrollment":7205,"conditions":7206,"interventions":7207},"NCT03651869","Effects of Nicotine in Tobacco Smokers",[87],"2019-02-04",221,[5996,5997],[7194,7208,7209,7210],"Cigarette 2","Patch 1","Patch 2",{"trials":7212,"activeCount":98},[],{"trials":7214,"activeCount":98},[],{"trials":7216,"activeCount":98},[],{"trials":7218,"activeCount":98},[],{"intervention":7208,"totalTrials":94,"cells":7220},{"EARLY_PHASE1":7221,"PHASE1":7223,"PHASE2":7229,"PHASE3":7231,"PHASE4":7233,"NA":7235},{"trials":7222,"activeCount":98},[],{"trials":7224,"activeCount":98},[7225],{"nctId":7201,"briefTitle":7202,"status":304,"phases":7226,"primaryCompletion":2318,"completion":2318,"start":7204,"enrollment":7205,"conditions":7227,"interventions":7228},[87],[5996,5997],[7194,7208,7209,7210],{"trials":7230,"activeCount":98},[],{"trials":7232,"activeCount":98},[],{"trials":7234,"activeCount":98},[],{"trials":7236,"activeCount":98},[],{"intervention":7209,"totalTrials":94,"cells":7238},{"EARLY_PHASE1":7239,"PHASE1":7241,"PHASE2":7247,"PHASE3":7249,"PHASE4":7251,"NA":7253},{"trials":7240,"activeCount":98},[],{"trials":7242,"activeCount":98},[7243],{"nctId":7201,"briefTitle":7202,"status":304,"phases":7244,"primaryCompletion":2318,"completion":2318,"start":7204,"enrollment":7205,"conditions":7245,"interventions":7246},[87],[5996,5997],[7194,7208,7209,7210],{"trials":7248,"activeCount":98},[],{"trials":7250,"activeCount":98},[],{"trials":7252,"activeCount":98},[],{"trials":7254,"activeCount":98},[],{"intervention":7210,"totalTrials":94,"cells":7256},{"EARLY_PHASE1":7257,"PHASE1":7259,"PHASE2":7265,"PHASE3":7267,"PHASE4":7269,"NA":7271},{"trials":7258,"activeCount":98},[],{"trials":7260,"activeCount":98},[7261],{"nctId":7201,"briefTitle":7202,"status":304,"phases":7262,"primaryCompletion":2318,"completion":2318,"start":7204,"enrollment":7205,"conditions":7263,"interventions":7264},[87],[5996,5997],[7194,7208,7209,7210],{"trials":7266,"activeCount":98},[],{"trials":7268,"activeCount":98},[],{"trials":7270,"activeCount":98},[],{"trials":7272,"activeCount":98},[],{"intervention":865,"totalTrials":94,"cells":7274},{"EARLY_PHASE1":7275,"PHASE1":7277,"PHASE2":7283,"PHASE3":7285,"PHASE4":7287,"NA":7289},{"trials":7276,"activeCount":98},[],{"trials":7278,"activeCount":98},[7279],{"nctId":858,"briefTitle":859,"status":304,"phases":7280,"primaryCompletion":861,"completion":861,"start":862,"enrollment":250,"conditions":7281,"interventions":7282},[87],[342,343],[345,346,865],{"trials":7284,"activeCount":98},[],{"trials":7286,"activeCount":98},[],{"trials":7288,"activeCount":98},[],{"trials":7290,"activeCount":98},[],{"intervention":7292,"totalTrials":94,"cells":7293},"MDX-CTLA4 Antibody; Tyrosinase\u002Fgp100\u002FMART-1 Peptides Melanoma Vaccine",{"EARLY_PHASE1":7294,"PHASE1":7296,"PHASE2":7304,"PHASE3":7306,"PHASE4":7308,"NA":7310},{"trials":7295,"activeCount":98},[],{"trials":7297,"activeCount":98},[7298],{"nctId":7299,"briefTitle":7300,"status":304,"phases":7301,"primaryCompletion":3768,"completion":3769,"start":4174,"enrollment":1463,"conditions":7302,"interventions":7303},"NCT00028431","Novel Adjuvants for Peptide-Based Melanoma Vaccines",[87],[4659],[7292],{"trials":7305,"activeCount":98},[],{"trials":7307,"activeCount":98},[],{"trials":7309,"activeCount":98},[],{"trials":7311,"activeCount":98},[],{"intervention":7313,"totalTrials":94,"cells":7314},"Weekly Abraxane and Daily Vandetanib",{"EARLY_PHASE1":7315,"PHASE1":7317,"PHASE2":7328,"PHASE3":7330,"PHASE4":7332,"NA":7334},{"trials":7316,"activeCount":98},[],{"trials":7318,"activeCount":98},[7319],{"nctId":7320,"briefTitle":7321,"status":304,"phases":7322,"primaryCompletion":2463,"completion":7323,"start":4633,"enrollment":646,"conditions":7324,"interventions":7326},"NCT00667147","Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib",[87],"2014-06",[7325],"Solid Tumors",[7313,7327],"Abraxane every three weeks and daily vandetanib",{"trials":7329,"activeCount":98},[],{"trials":7331,"activeCount":98},[],{"trials":7333,"activeCount":98},[],{"trials":7335,"activeCount":98},[],{"intervention":7327,"totalTrials":94,"cells":7337},{"EARLY_PHASE1":7338,"PHASE1":7340,"PHASE2":7346,"PHASE3":7348,"PHASE4":7350,"NA":7352},{"trials":7339,"activeCount":98},[],{"trials":7341,"activeCount":98},[7342],{"nctId":7320,"briefTitle":7321,"status":304,"phases":7343,"primaryCompletion":2463,"completion":7323,"start":4633,"enrollment":646,"conditions":7344,"interventions":7345},[87],[7325],[7313,7327],{"trials":7347,"activeCount":98},[],{"trials":7349,"activeCount":98},[],{"trials":7351,"activeCount":98},[],{"trials":7353,"activeCount":98},[],{"intervention":7355,"totalTrials":94,"cells":7356},"Salsalate",{"EARLY_PHASE1":7357,"PHASE1":7359,"PHASE2":7369,"PHASE3":7371,"PHASE4":7373,"NA":7375},{"trials":7358,"activeCount":98},[],{"trials":7360,"activeCount":98},[7361],{"nctId":7362,"briefTitle":7363,"status":304,"phases":7364,"primaryCompletion":7365,"completion":7365,"start":7108,"enrollment":972,"conditions":7366,"interventions":7368},"NCT02130804","Using Salsalate to Target Adipocyte Macrophage Infiltration",[87],"2013-10",[7367],"Diabetes Risk",[7355],{"trials":7370,"activeCount":98},[],{"trials":7372,"activeCount":98},[],{"trials":7374,"activeCount":98},[],{"trials":7376,"activeCount":98},[],{"intervention":7378,"totalTrials":94,"cells":7379},"Allopregnanolone",{"EARLY_PHASE1":7380,"PHASE1":7382,"PHASE2":7391,"PHASE3":7393,"PHASE4":7395,"NA":7397},{"trials":7381,"activeCount":98},[],{"trials":7383,"activeCount":98},[7384],{"nctId":7385,"briefTitle":7386,"status":304,"phases":7387,"primaryCompletion":2574,"completion":2574,"start":3611,"enrollment":929,"conditions":7388,"interventions":7390},"NCT02221622","Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD",[87],[4454,7389],"Alzheimer Disease",[7378],{"trials":7392,"activeCount":98},[],{"trials":7394,"activeCount":98},[],{"trials":7396,"activeCount":98},[],{"trials":7398,"activeCount":98},[],{"intervention":7400,"totalTrials":94,"cells":7401},"ACTH",{"EARLY_PHASE1":7402,"PHASE1":7404,"PHASE2":7416,"PHASE3":7418,"PHASE4":7420,"NA":7422},{"trials":7403,"activeCount":98},[],{"trials":7405,"activeCount":98},[7406],{"nctId":7407,"briefTitle":7408,"status":304,"phases":7409,"primaryCompletion":7410,"completion":6410,"start":7411,"enrollment":2334,"conditions":7412,"interventions":7414},"NCT01049451","Pulse ACTH vs. MP for MS",[87],"2013-06","2009-11",[7413],"Multiple Sclerosis",[7400,7415],"Methylprednisolone",{"trials":7417,"activeCount":98},[],{"trials":7419,"activeCount":98},[],{"trials":7421,"activeCount":98},[],{"trials":7423,"activeCount":98},[],{"intervention":7415,"totalTrials":94,"cells":7425},{"EARLY_PHASE1":7426,"PHASE1":7428,"PHASE2":7434,"PHASE3":7436,"PHASE4":7438,"NA":7440},{"trials":7427,"activeCount":98},[],{"trials":7429,"activeCount":98},[7430],{"nctId":7407,"briefTitle":7408,"status":304,"phases":7431,"primaryCompletion":7410,"completion":6410,"start":7411,"enrollment":2334,"conditions":7432,"interventions":7433},[87],[7413],[7400,7415],{"trials":7435,"activeCount":98},[],{"trials":7437,"activeCount":98},[],{"trials":7439,"activeCount":98},[],{"trials":7441,"activeCount":98},[],{"intervention":3321,"totalTrials":94,"cells":7443},{"EARLY_PHASE1":7444,"PHASE1":7446,"PHASE2":7452,"PHASE3":7454,"PHASE4":7456,"NA":7458},{"trials":7445,"activeCount":98},[],{"trials":7447,"activeCount":98},[7448],{"nctId":3310,"briefTitle":3311,"status":398,"phases":7449,"primaryCompletion":2462,"completion":3313,"start":3314,"enrollment":356,"conditions":7450,"interventions":7451},[87],[3316,3317,3318,3319],[3321,3303,3322,3323,3324,3325,3326,3327],{"trials":7453,"activeCount":98},[],{"trials":7455,"activeCount":98},[],{"trials":7457,"activeCount":98},[],{"trials":7459,"activeCount":98},[],{"intervention":3325,"totalTrials":94,"cells":7461},{"EARLY_PHASE1":7462,"PHASE1":7464,"PHASE2":7470,"PHASE3":7472,"PHASE4":7474,"NA":7476},{"trials":7463,"activeCount":98},[],{"trials":7465,"activeCount":98},[7466],{"nctId":3310,"briefTitle":3311,"status":398,"phases":7467,"primaryCompletion":2462,"completion":3313,"start":3314,"enrollment":356,"conditions":7468,"interventions":7469},[87],[3316,3317,3318,3319],[3321,3303,3322,3323,3324,3325,3326,3327],{"trials":7471,"activeCount":98},[],{"trials":7473,"activeCount":98},[],{"trials":7475,"activeCount":98},[],{"trials":7477,"activeCount":98},[],{"intervention":3326,"totalTrials":94,"cells":7479},{"EARLY_PHASE1":7480,"PHASE1":7482,"PHASE2":7488,"PHASE3":7490,"PHASE4":7492,"NA":7494},{"trials":7481,"activeCount":98},[],{"trials":7483,"activeCount":98},[7484],{"nctId":3310,"briefTitle":3311,"status":398,"phases":7485,"primaryCompletion":2462,"completion":3313,"start":3314,"enrollment":356,"conditions":7486,"interventions":7487},[87],[3316,3317,3318,3319],[3321,3303,3322,3323,3324,3325,3326,3327],{"trials":7489,"activeCount":98},[],{"trials":7491,"activeCount":98},[],{"trials":7493,"activeCount":98},[],{"trials":7495,"activeCount":98},[],{"intervention":7497,"totalTrials":94,"cells":7498},"Definity, (Lipid Microspheres) Intravenous Suspension",{"EARLY_PHASE1":7499,"PHASE1":7501,"PHASE2":7512,"PHASE3":7514,"PHASE4":7516,"NA":7518},{"trials":7500,"activeCount":98},[],{"trials":7502,"activeCount":98},[7503],{"nctId":7504,"briefTitle":7505,"status":398,"phases":7506,"primaryCompletion":7507,"completion":7507,"start":7508,"enrollment":7509,"conditions":7510,"interventions":7511},"NCT02067884","Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery",[87],"2016-09-25","2013-12-19",34,[1594],[7497],{"trials":7513,"activeCount":98},[],{"trials":7515,"activeCount":98},[],{"trials":7517,"activeCount":98},[],{"trials":7519,"activeCount":98},[],{"intervention":7521,"totalTrials":94,"cells":7522},"Sonazoid",{"EARLY_PHASE1":7523,"PHASE1":7525,"PHASE2":7537,"PHASE3":7539,"PHASE4":7541,"NA":7543},{"trials":7524,"activeCount":98},[],{"trials":7526,"activeCount":98},[7527],{"nctId":7528,"briefTitle":7529,"status":398,"phases":7530,"primaryCompletion":7531,"completion":7532,"start":7533,"enrollment":1251,"conditions":7534,"interventions":7536},"NCT02968680","Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma",[87],"2019-06-28","2020-01-09","2017-04-26",[7535,4659],"Cutaneous Melanoma",[7521],{"trials":7538,"activeCount":98},[],{"trials":7540,"activeCount":98},[],{"trials":7542,"activeCount":98},[],{"trials":7544,"activeCount":98},[],{"intervention":7546,"totalTrials":94,"cells":7547},"Gadoxetate Disodium",{"EARLY_PHASE1":7548,"PHASE1":7550,"PHASE2":7568,"PHASE3":7570,"PHASE4":7572,"NA":7574},{"trials":7549,"activeCount":98},[],{"trials":7551,"activeCount":98},[7552],{"nctId":7553,"briefTitle":7554,"status":304,"phases":7555,"primaryCompletion":4260,"completion":7556,"start":3314,"enrollment":16,"conditions":7557,"interventions":7567},"NCT02578602","MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer",[87],"2015-06",[7558,7559,7560,7561,7562,7563,7564,7565,7566],"Adult Hepatocellular Carcinoma","Advanced Adult Hepatocellular Carcinoma","BCLC Stage 0 Adult Hepatocellular Carcinoma","BCLC Stage A Adult Hepatocellular Carcinoma","BCLC Stage B Adult Hepatocellular Carcinoma","BCLC Stage C Adult Hepatocellular Carcinoma","BCLC Stage D Adult Hepatocellular Carcinoma","Localized Non-Resectable Adult Liver Carcinoma","Localized Resectable Adult Liver Carcinoma",[7546],{"trials":7569,"activeCount":98},[],{"trials":7571,"activeCount":98},[],{"trials":7573,"activeCount":98},[],{"trials":7575,"activeCount":98},[],{"intervention":7577,"totalTrials":94,"cells":7578},"Ixabepilone",{"EARLY_PHASE1":7579,"PHASE1":7581,"PHASE2":7591,"PHASE3":7593,"PHASE4":7595,"NA":7597},{"trials":7580,"activeCount":98},[],{"trials":7582,"activeCount":98},[7583],{"nctId":7584,"briefTitle":7585,"status":385,"phases":7586,"enrollment":98,"conditions":7587,"interventions":7589},"NCT01170871","Ixabepilone and Pemetrexed\u002FSolid Tumors",[87],[7588],"Advanced Solid Tumors",[7577,7590],"Pemetrexed",{"trials":7592,"activeCount":98},[],{"trials":7594,"activeCount":98},[],{"trials":7596,"activeCount":98},[],{"trials":7598,"activeCount":98},[],{"intervention":7590,"totalTrials":94,"cells":7600},{"EARLY_PHASE1":7601,"PHASE1":7603,"PHASE2":7609,"PHASE3":7611,"PHASE4":7613,"NA":7615},{"trials":7602,"activeCount":98},[],{"trials":7604,"activeCount":98},[7605],{"nctId":7584,"briefTitle":7585,"status":385,"phases":7606,"enrollment":98,"conditions":7607,"interventions":7608},[87],[7588],[7577,7590],{"trials":7610,"activeCount":98},[],{"trials":7612,"activeCount":98},[],{"trials":7614,"activeCount":98},[],{"trials":7616,"activeCount":98},[],{"intervention":3775,"totalTrials":94,"cells":7618},{"EARLY_PHASE1":7619,"PHASE1":7621,"PHASE2":7627,"PHASE3":7629,"PHASE4":7631,"NA":7633},{"trials":7620,"activeCount":98},[],{"trials":7622,"activeCount":98},[7623],{"nctId":3765,"briefTitle":3766,"status":304,"phases":7624,"primaryCompletion":3768,"completion":3769,"start":3770,"enrollment":1463,"conditions":7625,"interventions":7626},[87],[3772,1675],[1677,1678,3774,3775,1685],{"trials":7628,"activeCount":98},[],{"trials":7630,"activeCount":98},[],{"trials":7632,"activeCount":98},[],{"trials":7634,"activeCount":98},[],{"intervention":3785,"totalTrials":94,"cells":7636},{"EARLY_PHASE1":7637,"PHASE1":7639,"PHASE2":7645,"PHASE3":7647,"PHASE4":7649,"NA":7651},{"trials":7638,"activeCount":98},[],{"trials":7640,"activeCount":98},[7641],{"nctId":3777,"briefTitle":3778,"status":398,"phases":7642,"primaryCompletion":3780,"completion":3781,"start":3782,"enrollment":1523,"conditions":7643,"interventions":7644},[87],[3772,1675],[1677,1678,3774,3785,1685],{"trials":7646,"activeCount":98},[],{"trials":7648,"activeCount":98},[],{"trials":7650,"activeCount":98},[],{"trials":7652,"activeCount":98},[],{"intervention":7654,"totalTrials":94,"cells":7655},"18F-AV-1451",{"EARLY_PHASE1":7656,"PHASE1":7658,"PHASE2":7668,"PHASE3":7670,"PHASE4":7672,"NA":7674},{"trials":7657,"activeCount":98},[],{"trials":7659,"activeCount":98},[7660],{"nctId":7661,"briefTitle":7662,"status":304,"phases":7663,"primaryCompletion":7664,"completion":7664,"start":4524,"enrollment":475,"conditions":7665,"interventions":7667},"NCT02850146","18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study",[87],"2023-09-29",[7666],"Cognition Disorders",[7654],{"trials":7669,"activeCount":98},[],{"trials":7671,"activeCount":98},[],{"trials":7673,"activeCount":98},[],{"trials":7675,"activeCount":98},[],{"intervention":7677,"totalTrials":94,"cells":7678},"chemotherapy",{"EARLY_PHASE1":7679,"PHASE1":7681,"PHASE2":7691,"PHASE3":7693,"PHASE4":7695,"NA":7697},{"trials":7680,"activeCount":98},[],{"trials":7682,"activeCount":98},[7683],{"nctId":7684,"briefTitle":7685,"status":398,"phases":7686,"primaryCompletion":4173,"completion":4173,"start":7687,"enrollment":1463,"conditions":7688,"interventions":7690},"NCT00002863","Cryosurgery in Treating Patients With Soft Tissue Sarcoma",[87],"1996-06",[7689],"Sarcoma",[7677],{"trials":7692,"activeCount":98},[],{"trials":7694,"activeCount":98},[],{"trials":7696,"activeCount":98},[],{"trials":7698,"activeCount":98},[],{"intervention":7700,"totalTrials":94,"cells":7701},"Definity Suspension for",{"EARLY_PHASE1":7702,"PHASE1":7714,"PHASE2":7716,"PHASE3":7718,"PHASE4":7720,"NA":7722},{"trials":7703,"activeCount":98},[7704],{"nctId":7705,"briefTitle":7706,"status":304,"phases":7707,"primaryCompletion":7708,"completion":7708,"start":7709,"enrollment":1673,"conditions":7710,"interventions":7713},"NCT02384473","Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma",[86],"2024-01-19","2014-12-24",[7711,261,7712],"Adult Soft Tissue Sarcoma","Retroperitoneal Sarcoma",[7700],{"trials":7715,"activeCount":98},[],{"trials":7717,"activeCount":98},[],{"trials":7719,"activeCount":98},[],{"trials":7721,"activeCount":98},[],{"trials":7723,"activeCount":98},[],{"intervention":7725,"totalTrials":94,"cells":7726},"Depot-Medroxyprogestereone Acetate",{"EARLY_PHASE1":7727,"PHASE1":7735,"PHASE2":7737,"PHASE3":7739,"PHASE4":7741,"NA":7743},{"trials":7728,"activeCount":98},[7729],{"nctId":7730,"briefTitle":7731,"status":304,"phases":7732,"primaryCompletion":2437,"completion":2437,"start":797,"enrollment":972,"conditions":7733,"interventions":7734},"NCT03395756","Depot Medroxyprogesterone Acetate as Emergency Contraception",[86],[3297,2998],[7725],{"trials":7736,"activeCount":98},[],{"trials":7738,"activeCount":98},[],{"trials":7740,"activeCount":98},[],{"trials":7742,"activeCount":98},[],{"trials":7744,"activeCount":98},[],{"intervention":7746,"totalTrials":94,"cells":7747},"Cyanocobalamin",{"EARLY_PHASE1":7748,"PHASE1":7759,"PHASE2":7761,"PHASE3":7763,"PHASE4":7765,"NA":7767},{"trials":7749,"activeCount":98},[7750],{"nctId":7751,"briefTitle":7752,"status":304,"phases":7753,"primaryCompletion":7754,"completion":7754,"start":7755,"enrollment":1046,"conditions":7756,"interventions":7758},"NCT03437824","Effects of Vitamin B12 Treatment in Singers",[86],"2019-04-01","2017-10-01",[7757],"Vitamin B 12 Deficiency",[7746],{"trials":7760,"activeCount":98},[],{"trials":7762,"activeCount":98},[],{"trials":7764,"activeCount":98},[],{"trials":7766,"activeCount":98},[],{"trials":7768,"activeCount":98},[],{"intervention":7770,"totalTrials":94,"cells":7771},"EMLA 5% cream",{"EARLY_PHASE1":7772,"PHASE1":7785,"PHASE2":7787,"PHASE3":7789,"PHASE4":7791,"NA":7793},{"trials":7773,"activeCount":98},[7774],{"nctId":7775,"briefTitle":7776,"status":2435,"phases":7777,"primaryCompletion":7778,"completion":7779,"start":7780,"enrollment":32,"conditions":7781,"interventions":7784},"NCT05580029","Fractional CO2 Laser Fenestration and Steroid Delivery in HS Lesions",[86],"2023-01-20","2023-03-01","2022-11-01",[7782,7783],"Scar","Hidradenitis Suppurativa",[7770],{"trials":7786,"activeCount":98},[],{"trials":7788,"activeCount":98},[],{"trials":7790,"activeCount":98},[],{"trials":7792,"activeCount":98},[],{"trials":7794,"activeCount":98},[],{"intervention":7796,"totalTrials":94,"cells":7797},"PrabotulinumtoxinA",{"EARLY_PHASE1":7798,"PHASE1":7811,"PHASE2":7813,"PHASE3":7815,"PHASE4":7817,"NA":7819},{"trials":7799,"activeCount":98},[7800],{"nctId":7801,"briefTitle":7802,"status":2435,"phases":7803,"primaryCompletion":7804,"completion":7805,"start":7806,"enrollment":1046,"conditions":7807,"interventions":7809},"NCT04715048","Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines",[86],"2025-05","2025-06","2021-01-01",[7808],"Glabellar Frown Lines",[7796,7810],"Onabotulinum toxin A",{"trials":7812,"activeCount":98},[],{"trials":7814,"activeCount":98},[],{"trials":7816,"activeCount":98},[],{"trials":7818,"activeCount":98},[],{"trials":7820,"activeCount":98},[],{"intervention":7810,"totalTrials":94,"cells":7822},{"EARLY_PHASE1":7823,"PHASE1":7829,"PHASE2":7831,"PHASE3":7833,"PHASE4":7835,"NA":7837},{"trials":7824,"activeCount":98},[7825],{"nctId":7801,"briefTitle":7802,"status":2435,"phases":7826,"primaryCompletion":7804,"completion":7805,"start":7806,"enrollment":1046,"conditions":7827,"interventions":7828},[86],[7808],[7796,7810],{"trials":7830,"activeCount":98},[],{"trials":7832,"activeCount":98},[],{"trials":7834,"activeCount":98},[],{"trials":7836,"activeCount":98},[],{"trials":7838,"activeCount":98},[],{"intervention":7840,"totalTrials":94,"cells":7841},"Nicotine",{"EARLY_PHASE1":7842,"PHASE1":7854,"PHASE2":7856,"PHASE3":7858,"PHASE4":7860,"NA":7862},{"trials":7843,"activeCount":98},[7844],{"nctId":7845,"briefTitle":7846,"status":2435,"phases":7847,"primaryCompletion":7848,"completion":7849,"start":7850,"enrollment":1286,"conditions":7851,"interventions":7853},"NCT06027723","Nicotine and Pavlovian Bias",[86],"2024-08-31","2024-10-31","2023-10-25",[7852,1945],"Nicotine Vaping",[7840],{"trials":7855,"activeCount":98},[],{"trials":7857,"activeCount":98},[],{"trials":7859,"activeCount":98},[],{"trials":7861,"activeCount":98},[],{"trials":7863,"activeCount":98},[],{"intervention":2338,"totalTrials":348,"cells":7865},{"EARLY_PHASE1":7866,"PHASE1":7868,"PHASE2":7870,"PHASE3":7872,"PHASE4":7874,"NA":7884},{"trials":7867,"activeCount":98},[],{"trials":7869,"activeCount":98},[],{"trials":7871,"activeCount":98},[],{"trials":7873,"activeCount":98},[],{"trials":7875,"activeCount":98},[7876,7880],{"nctId":2329,"briefTitle":2330,"status":398,"phases":7877,"primaryCompletion":2332,"completion":2332,"start":2333,"enrollment":2334,"conditions":7878,"interventions":7879},[90],[162],[2337,2338,2339,2305,2340,2341,2342,2343],{"nctId":2363,"briefTitle":2364,"status":398,"phases":7881,"primaryCompletion":2366,"completion":2367,"start":2368,"enrollment":2369,"conditions":7882,"interventions":7883},[90],[2371],[2373,2338,2343],{"trials":7885,"activeCount":98},[7886],{"nctId":7887,"briefTitle":7888,"status":385,"phases":7889,"primaryCompletion":7890,"completion":7890,"start":7323,"enrollment":98,"conditions":7891,"interventions":7893},"NCT02194894","The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients",[91],"2015-03-19",[7892],"Non-alcoholic Fatty Liver Disease (NAFLD)",[2338],{"intervention":2492,"totalTrials":348,"cells":7895},{"EARLY_PHASE1":7896,"PHASE1":7898,"PHASE2":7900,"PHASE3":7902,"PHASE4":7904,"NA":7925},{"trials":7897,"activeCount":98},[],{"trials":7899,"activeCount":98},[],{"trials":7901,"activeCount":98},[],{"trials":7903,"activeCount":98},[],{"trials":7905,"activeCount":98},[7906,7910],{"nctId":2483,"briefTitle":2484,"status":304,"phases":7907,"primaryCompletion":2486,"completion":2487,"start":2488,"enrollment":2489,"conditions":7908,"interventions":7909},[90],[1349],[2492,2470,2493,2494],{"nctId":7911,"briefTitle":7912,"status":385,"phases":7913,"primaryCompletion":7914,"completion":7915,"start":7916,"enrollment":98,"conditions":7917,"interventions":7923},"NCT05085808","RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ)",[90],"2029-07-01","2030-12-01","2028-03-01",[7918,7919,7920,7921,7922],"Delirium","Morality","Quality of Life","Psych","Treatment Side Effects",[7924,2492],"Trazodone",{"trials":7926,"activeCount":98},[7927],{"nctId":7928,"briefTitle":7929,"status":398,"phases":7930,"primaryCompletion":7931,"completion":7931,"start":7931,"enrollment":32,"conditions":7932,"interventions":7937},"NCT05307003","Trazodone vs. Quetiapine for the Treatment of ICU Delirium",[],"2024-06-01",[7918,7933,7934,7935,7936,7921,7919,7922],"Delirium of Mixed Origin","Delirium, Sepsis Associated","Delirium in Old Age","Delirium Confusional State",[7924,2492],{"intervention":3659,"totalTrials":348,"cells":7939},{"EARLY_PHASE1":7940,"PHASE1":7942,"PHASE2":7944,"PHASE3":7946,"PHASE4":7952,"NA":7964},{"trials":7941,"activeCount":98},[],{"trials":7943,"activeCount":98},[],{"trials":7945,"activeCount":98},[],{"trials":7947,"activeCount":98},[7948],{"nctId":3651,"briefTitle":3652,"status":398,"phases":7949,"primaryCompletion":3654,"completion":3654,"start":3655,"enrollment":1046,"conditions":7950,"interventions":7951},[88,89],[3657,567],[3659,3640],{"trials":7953,"activeCount":98},[7954],{"nctId":7955,"briefTitle":7956,"status":304,"phases":7957,"primaryCompletion":7958,"completion":7958,"start":7959,"enrollment":7960,"conditions":7961,"interventions":7963},"NCT02595749","Effects of Intranasal Oxytocin on Cigarette Smoking",[90],"2019-07","2016-07",83,[1945,7962],"Tobacco Smoking",[3659],{"trials":7965,"activeCount":98},[7966],{"nctId":7967,"briefTitle":7968,"status":2435,"phases":7969,"primaryCompletion":2332,"start":5547,"enrollment":7970,"conditions":7971,"interventions":7974},"NCT02210598","Outpatient Labor Induction With the Transcervical Foley Balloon",[91],64,[7972,7973],"Pregnancy","Labor; Forced or Induced, Affecting Fetus or Newborn",[3659],{"intervention":7924,"totalTrials":289,"cells":7976},{"EARLY_PHASE1":7977,"PHASE1":7979,"PHASE2":7981,"PHASE3":7983,"PHASE4":7985,"NA":7991},{"trials":7978,"activeCount":98},[],{"trials":7980,"activeCount":98},[],{"trials":7982,"activeCount":98},[],{"trials":7984,"activeCount":98},[],{"trials":7986,"activeCount":98},[7987],{"nctId":7911,"briefTitle":7912,"status":385,"phases":7988,"primaryCompletion":7914,"completion":7915,"start":7916,"enrollment":98,"conditions":7989,"interventions":7990},[90],[7918,7919,7920,7921,7922],[7924,2492],{"trials":7992,"activeCount":98},[7993],{"nctId":7928,"briefTitle":7929,"status":398,"phases":7994,"primaryCompletion":7931,"completion":7931,"start":7931,"enrollment":32,"conditions":7995,"interventions":7996},[],[7918,7933,7934,7935,7936,7921,7919,7922],[7924,2492],{"intervention":449,"totalTrials":289,"cells":7998},{"EARLY_PHASE1":7999,"PHASE1":8001,"PHASE2":8003,"PHASE3":8009,"PHASE4":8011,"NA":8013},{"trials":8000,"activeCount":98},[],{"trials":8002,"activeCount":98},[],{"trials":8004,"activeCount":98},[8005],{"nctId":438,"briefTitle":439,"status":398,"phases":8006,"primaryCompletion":441,"completion":442,"start":443,"enrollment":356,"conditions":8007,"interventions":8008},[88],[403,445,446,447,408],[449,450,323],{"trials":8010,"activeCount":98},[],{"trials":8012,"activeCount":98},[],{"trials":8014,"activeCount":98},[8015],{"nctId":8016,"briefTitle":8017,"status":385,"phases":8018,"primaryCompletion":675,"completion":675,"start":8019,"enrollment":98,"conditions":8020,"interventions":8022},"NCT01292083","Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery",[91],"2011-01",[663,4683,4684,27,21,29,7157,664,8021],"Triple-negative Breast Cancer",[8023,8024,3324,8025],"azacitidine","polymerase chain reaction","nucleic acid sequencing",{"intervention":3324,"totalTrials":289,"cells":8027},{"EARLY_PHASE1":8028,"PHASE1":8030,"PHASE2":8036,"PHASE3":8038,"PHASE4":8040,"NA":8042},{"trials":8029,"activeCount":98},[],{"trials":8031,"activeCount":98},[8032],{"nctId":3310,"briefTitle":3311,"status":398,"phases":8033,"primaryCompletion":2462,"completion":3313,"start":3314,"enrollment":356,"conditions":8034,"interventions":8035},[87],[3316,3317,3318,3319],[3321,3303,3322,3323,3324,3325,3326,3327],{"trials":8037,"activeCount":98},[],{"trials":8039,"activeCount":98},[],{"trials":8041,"activeCount":98},[],{"trials":8043,"activeCount":98},[8044],{"nctId":8016,"briefTitle":8017,"status":385,"phases":8045,"primaryCompletion":675,"completion":675,"start":8019,"enrollment":98,"conditions":8046,"interventions":8047},[91],[663,4683,4684,27,21,29,7157,664,8021],[8023,8024,3324,8025],{"intervention":8049,"totalTrials":289,"cells":8050},"Oral Contraceptive: Ortho-Novum® 1\u002F35",{"EARLY_PHASE1":8051,"PHASE1":8053,"PHASE2":8055,"PHASE3":8057,"PHASE4":8059,"NA":8061},{"trials":8052,"activeCount":98},[],{"trials":8054,"activeCount":98},[],{"trials":8056,"activeCount":98},[],{"trials":8058,"activeCount":98},[],{"trials":8060,"activeCount":98},[],{"trials":8062,"activeCount":98},[8063,8076],{"nctId":8064,"briefTitle":8065,"status":304,"phases":8066,"primaryCompletion":8067,"completion":8068,"start":8069,"enrollment":8070,"conditions":8071,"interventions":8073},"NCT01318005","Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation",[91],"2014-06-30","2015-06-30","2011-02-14",82,[8072],"Oral Contraceptive",[8049,8074,8075],"Oral Contraceptive: Ovcon® 35","Oral Contraceptive: Microgestin Fe® 1\u002F20",{"nctId":8077,"briefTitle":8078,"status":304,"phases":8079,"primaryCompletion":8080,"completion":8080,"start":8081,"enrollment":511,"conditions":8082,"interventions":8083},"NCT00972439","Oral Contraceptive (OC) Progestin Dose and Breast Proliferation",[91],"2008-11","2007-08",[8072],[8049,8084],"Oral Contraceptive: Ovcon Fe®",{"intervention":8086,"totalTrials":289,"cells":8087},"Gadobenate Dimeglumine",{"EARLY_PHASE1":8088,"PHASE1":8090,"PHASE2":8092,"PHASE3":8094,"PHASE4":8096,"NA":8098},{"trials":8089,"activeCount":98},[],{"trials":8091,"activeCount":98},[],{"trials":8093,"activeCount":98},[],{"trials":8095,"activeCount":98},[],{"trials":8097,"activeCount":98},[],{"trials":8099,"activeCount":98},[8100,8111],{"nctId":8101,"briefTitle":8102,"status":385,"phases":8103,"primaryCompletion":8104,"completion":8105,"start":8106,"enrollment":98,"conditions":8107,"interventions":8109},"NCT03091803","QSM and Regional DCE MRI Permeability Using GOCART Technique",[],"2020-04-04","2021-04-04","2017-04-04",[8108],"Intracranial Neoplasm",[8086,8110],"Gadoterate Meglumine",{"nctId":8112,"briefTitle":8113,"status":398,"phases":8114,"primaryCompletion":5315,"completion":8115,"start":8116,"enrollment":250,"conditions":8117,"interventions":8141},"NCT02967380","Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases",[91],"2015-10-14","2011-12-14",[8118,8119,8120,8121,8122,8123,8124,8125,8126,8127,8128,8129,8130,8131,8132,8133,8134,8135,8136,8137,8138,8139,6826,7413,8140],"Adult Anaplastic (Malignant) Meningioma","Adult Anaplastic Astrocytoma","Adult Anaplastic Ependymoma","Adult Anaplastic Oligodendroglioma","Adult Brain Stem Glioma","Adult Choroid Plexus Neoplasm","Adult Diffuse Astrocytoma","Adult Ependymoblastoma","Adult Ependymoma","Adult Giant Cell Glioblastoma","Adult Glioblastoma","Adult Gliosarcoma","Adult Grade II Meningioma","Adult Medulloblastoma","Adult Mixed Glioma","Adult Oligodendroglioma","Adult Papillary Meningioma","Adult Pineal Gland Astrocytoma","Adult Pineoblastoma","Adult Primary Melanocytic Lesion of Meninges","Adult Supratentorial Primitive Neuroectodermal Tumor","Malignant Adult Intracranial Hemangiopericytoma","Recurrent Adult Brain Neoplasm",[8086,8142],"Gadobutrol",{"intervention":8144,"totalTrials":94,"cells":8145},"E-cigarette e-liquid",{"EARLY_PHASE1":8146,"PHASE1":8148,"PHASE2":8150,"PHASE3":8152,"PHASE4":8154,"NA":8156},{"trials":8147,"activeCount":98},[],{"trials":8149,"activeCount":98},[],{"trials":8151,"activeCount":98},[],{"trials":8153,"activeCount":98},[],{"trials":8155,"activeCount":98},[],{"trials":8157,"activeCount":98},[8158],{"nctId":8159,"briefTitle":8160,"status":304,"phases":8161,"primaryCompletion":8162,"completion":8162,"start":8163,"enrollment":8164,"conditions":8165,"interventions":8169},"NCT04399031","Effects of e-Cigarettes on Perceptions and Behavior - Substudy 1",[91],"2020-03-01","2019-12-01",124,[8166,8167,8168,5999],"Electronic Cigarette Use","Cigarette Use, Electronic","Vaping",[8144],{"intervention":8171,"totalTrials":94,"cells":8172},"AlloGen-LI",{"EARLY_PHASE1":8173,"PHASE1":8175,"PHASE2":8177,"PHASE3":8179,"PHASE4":8181,"NA":8183},{"trials":8174,"activeCount":98},[],{"trials":8176,"activeCount":98},[],{"trials":8178,"activeCount":98},[],{"trials":8180,"activeCount":98},[],{"trials":8182,"activeCount":98},[],{"trials":8184,"activeCount":98},[8185],{"nctId":8186,"briefTitle":8187,"status":385,"phases":8188,"primaryCompletion":8189,"completion":8189,"start":2368,"enrollment":98,"conditions":8190,"interventions":8192},"NCT02932020","AlloGen-LI Treatment of Spinal Stenosis",[91],"2017-09",[8191],"Low Back Pain",[8171,8193,8194],"depomedrol","0.5% marcaine",{"intervention":8193,"totalTrials":94,"cells":8196},{"EARLY_PHASE1":8197,"PHASE1":8199,"PHASE2":8201,"PHASE3":8203,"PHASE4":8205,"NA":8207},{"trials":8198,"activeCount":98},[],{"trials":8200,"activeCount":98},[],{"trials":8202,"activeCount":98},[],{"trials":8204,"activeCount":98},[],{"trials":8206,"activeCount":98},[],{"trials":8208,"activeCount":98},[8209],{"nctId":8186,"briefTitle":8187,"status":385,"phases":8210,"primaryCompletion":8189,"completion":8189,"start":2368,"enrollment":98,"conditions":8211,"interventions":8212},[91],[8191],[8171,8193,8194],{"intervention":8194,"totalTrials":94,"cells":8214},{"EARLY_PHASE1":8215,"PHASE1":8217,"PHASE2":8219,"PHASE3":8221,"PHASE4":8223,"NA":8225},{"trials":8216,"activeCount":98},[],{"trials":8218,"activeCount":98},[],{"trials":8220,"activeCount":98},[],{"trials":8222,"activeCount":98},[],{"trials":8224,"activeCount":98},[],{"trials":8226,"activeCount":98},[8227],{"nctId":8186,"briefTitle":8187,"status":385,"phases":8228,"primaryCompletion":8189,"completion":8189,"start":2368,"enrollment":98,"conditions":8229,"interventions":8230},[91],[8191],[8171,8193,8194],{"intervention":8232,"totalTrials":94,"cells":8233},"Definity",{"EARLY_PHASE1":8234,"PHASE1":8236,"PHASE2":8238,"PHASE3":8240,"PHASE4":8242,"NA":8244},{"trials":8235,"activeCount":98},[],{"trials":8237,"activeCount":98},[],{"trials":8239,"activeCount":98},[],{"trials":8241,"activeCount":98},[],{"trials":8243,"activeCount":98},[],{"trials":8245,"activeCount":98},[8246],{"nctId":8247,"briefTitle":8248,"status":304,"phases":8249,"primaryCompletion":8250,"completion":8250,"start":832,"enrollment":8251,"conditions":8252,"interventions":8253},"NCT02887937","Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)",[],"2018-04-29",135,[1594],[8232],{"intervention":8255,"totalTrials":94,"cells":8256},"Ceftriaxone sodium",{"EARLY_PHASE1":8257,"PHASE1":8259,"PHASE2":8261,"PHASE3":8263,"PHASE4":8265,"NA":8267},{"trials":8258,"activeCount":98},[],{"trials":8260,"activeCount":98},[],{"trials":8262,"activeCount":98},[],{"trials":8264,"activeCount":98},[],{"trials":8266,"activeCount":98},[],{"trials":8268,"activeCount":98},[8269],{"nctId":8270,"briefTitle":8271,"status":304,"phases":8272,"conditions":8273,"interventions":8276},"NCT00002052","Prospective Comparison of Ampicillin \u002F Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients",[91],[8274,8275],"HIV Infections","Salmonella Infections",[8255,8277,8278],"Ampicillin sodium","Amoxicillin trihydrate",{"intervention":8277,"totalTrials":94,"cells":8280},{"EARLY_PHASE1":8281,"PHASE1":8283,"PHASE2":8285,"PHASE3":8287,"PHASE4":8289,"NA":8291},{"trials":8282,"activeCount":98},[],{"trials":8284,"activeCount":98},[],{"trials":8286,"activeCount":98},[],{"trials":8288,"activeCount":98},[],{"trials":8290,"activeCount":98},[],{"trials":8292,"activeCount":98},[8293],{"nctId":8270,"briefTitle":8271,"status":304,"phases":8294,"conditions":8295,"interventions":8296},[91],[8274,8275],[8255,8277,8278],{"intervention":8278,"totalTrials":94,"cells":8298},{"EARLY_PHASE1":8299,"PHASE1":8301,"PHASE2":8303,"PHASE3":8305,"PHASE4":8307,"NA":8309},{"trials":8300,"activeCount":98},[],{"trials":8302,"activeCount":98},[],{"trials":8304,"activeCount":98},[],{"trials":8306,"activeCount":98},[],{"trials":8308,"activeCount":98},[],{"trials":8310,"activeCount":98},[8311],{"nctId":8270,"briefTitle":8271,"status":304,"phases":8312,"conditions":8313,"interventions":8314},[91],[8274,8275],[8255,8277,8278],{"intervention":8316,"totalTrials":94,"cells":8317},"Mifepristone",{"EARLY_PHASE1":8318,"PHASE1":8320,"PHASE2":8322,"PHASE3":8324,"PHASE4":8326,"NA":8328},{"trials":8319,"activeCount":98},[],{"trials":8321,"activeCount":98},[],{"trials":8323,"activeCount":98},[],{"trials":8325,"activeCount":98},[],{"trials":8327,"activeCount":98},[],{"trials":8329,"activeCount":98},[8330],{"nctId":8331,"briefTitle":8332,"status":398,"phases":8333,"completion":8334,"start":3422,"enrollment":3336,"conditions":8335,"interventions":8337},"NCT01224509","The Effect of Mifepristone on the Expression of Cervical Prostaglandin EP3 Receptors",[91],"2005-03",[8336,7972],"Cervical Prostaglandin EP3 Receptors",[8316],{"intervention":8339,"totalTrials":94,"cells":8340},"Oxandrolone",{"EARLY_PHASE1":8341,"PHASE1":8343,"PHASE2":8345,"PHASE3":8347,"PHASE4":8349,"NA":8351},{"trials":8342,"activeCount":98},[],{"trials":8344,"activeCount":98},[],{"trials":8346,"activeCount":98},[],{"trials":8348,"activeCount":98},[],{"trials":8350,"activeCount":98},[],{"trials":8352,"activeCount":98},[8353],{"nctId":8354,"briefTitle":8355,"status":398,"phases":8356,"primaryCompletion":8357,"completion":8357,"start":8358,"enrollment":631,"conditions":8359,"interventions":8361},"NCT03091075","Oxandrolone Rotator Cuff Trial",[91],"2026-01-06","2018-09-23",[8360],"Rotator Cuff Tear",[8339],{"intervention":8363,"totalTrials":94,"cells":8364},"IV Analgesia",{"EARLY_PHASE1":8365,"PHASE1":8367,"PHASE2":8369,"PHASE3":8371,"PHASE4":8373,"NA":8375},{"trials":8366,"activeCount":98},[],{"trials":8368,"activeCount":98},[],{"trials":8370,"activeCount":98},[],{"trials":8372,"activeCount":98},[],{"trials":8374,"activeCount":98},[],{"trials":8376,"activeCount":98},[8377],{"nctId":8378,"briefTitle":8379,"status":2435,"phases":8380,"primaryCompletion":8381,"completion":8382,"start":2438,"enrollment":1286,"conditions":8383,"interventions":8385},"NCT04892563","Erector Spinae Plane Block for Rib Fracture Analgesia in the Emergency Department",[91],"2022-06-30","2022-08-31",[8384],"Rib Fracture Multiple",[8363],{"intervention":8387,"totalTrials":94,"cells":8388},"Etravirine pharmacokinetics in breast milk and plasma",{"EARLY_PHASE1":8389,"PHASE1":8391,"PHASE2":8393,"PHASE3":8395,"PHASE4":8397,"NA":8399},{"trials":8390,"activeCount":98},[],{"trials":8392,"activeCount":98},[],{"trials":8394,"activeCount":98},[],{"trials":8396,"activeCount":98},[],{"trials":8398,"activeCount":98},[],{"trials":8400,"activeCount":98},[8401],{"nctId":8402,"briefTitle":8403,"status":304,"phases":8404,"primaryCompletion":3432,"completion":3432,"start":8405,"enrollment":4075,"conditions":8406,"interventions":8407},"NCT01625169","Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma",[91],"2010-04",[2999],[8387],{"intervention":8409,"totalTrials":94,"cells":8410},"PPI",{"EARLY_PHASE1":8411,"PHASE1":8413,"PHASE2":8415,"PHASE3":8417,"PHASE4":8419,"NA":8421},{"trials":8412,"activeCount":98},[],{"trials":8414,"activeCount":98},[],{"trials":8416,"activeCount":98},[],{"trials":8418,"activeCount":98},[],{"trials":8420,"activeCount":98},[],{"trials":8422,"activeCount":98},[8423],{"nctId":8424,"briefTitle":8425,"status":385,"phases":8426,"primaryCompletion":8427,"completion":8427,"start":3805,"enrollment":98,"conditions":8428,"interventions":8430},"NCT00222989","PPI Versus Placebo in Severe Functional Heartburn",[91],"2100-12-01",[8429],"GERD",[8409],{"intervention":8432,"totalTrials":94,"cells":8433},"zoledronic acid",{"EARLY_PHASE1":8434,"PHASE1":8436,"PHASE2":8438,"PHASE3":8440,"PHASE4":8442,"NA":8444},{"trials":8435,"activeCount":98},[],{"trials":8437,"activeCount":98},[],{"trials":8439,"activeCount":98},[],{"trials":8441,"activeCount":98},[],{"trials":8443,"activeCount":98},[],{"trials":8445,"activeCount":98},[8446],{"nctId":8447,"briefTitle":8448,"status":385,"phases":8449,"primaryCompletion":8450,"completion":8451,"start":8452,"enrollment":98,"conditions":8453,"interventions":8455},"NCT02069340","Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid",[91],"2020-12","2021-06","2016-06",[34,8454],"Musculoskeletal Complications",[8432],{"intervention":8024,"totalTrials":94,"cells":8457},{"EARLY_PHASE1":8458,"PHASE1":8460,"PHASE2":8462,"PHASE3":8464,"PHASE4":8466,"NA":8468},{"trials":8459,"activeCount":98},[],{"trials":8461,"activeCount":98},[],{"trials":8463,"activeCount":98},[],{"trials":8465,"activeCount":98},[],{"trials":8467,"activeCount":98},[],{"trials":8469,"activeCount":98},[8470],{"nctId":8016,"briefTitle":8017,"status":385,"phases":8471,"primaryCompletion":675,"completion":675,"start":8019,"enrollment":98,"conditions":8472,"interventions":8473},[91],[663,4683,4684,27,21,29,7157,664,8021],[8023,8024,3324,8025],{"intervention":8025,"totalTrials":94,"cells":8475},{"EARLY_PHASE1":8476,"PHASE1":8478,"PHASE2":8480,"PHASE3":8482,"PHASE4":8484,"NA":8486},{"trials":8477,"activeCount":98},[],{"trials":8479,"activeCount":98},[],{"trials":8481,"activeCount":98},[],{"trials":8483,"activeCount":98},[],{"trials":8485,"activeCount":98},[],{"trials":8487,"activeCount":98},[8488],{"nctId":8016,"briefTitle":8017,"status":385,"phases":8489,"primaryCompletion":675,"completion":675,"start":8019,"enrollment":98,"conditions":8490,"interventions":8491},[91],[663,4683,4684,27,21,29,7157,664,8021],[8023,8024,3324,8025],{"intervention":8074,"totalTrials":94,"cells":8493},{"EARLY_PHASE1":8494,"PHASE1":8496,"PHASE2":8498,"PHASE3":8500,"PHASE4":8502,"NA":8504},{"trials":8495,"activeCount":98},[],{"trials":8497,"activeCount":98},[],{"trials":8499,"activeCount":98},[],{"trials":8501,"activeCount":98},[],{"trials":8503,"activeCount":98},[],{"trials":8505,"activeCount":98},[8506],{"nctId":8064,"briefTitle":8065,"status":304,"phases":8507,"primaryCompletion":8067,"completion":8068,"start":8069,"enrollment":8070,"conditions":8508,"interventions":8509},[91],[8072],[8049,8074,8075],{"intervention":8075,"totalTrials":94,"cells":8511},{"EARLY_PHASE1":8512,"PHASE1":8514,"PHASE2":8516,"PHASE3":8518,"PHASE4":8520,"NA":8522},{"trials":8513,"activeCount":98},[],{"trials":8515,"activeCount":98},[],{"trials":8517,"activeCount":98},[],{"trials":8519,"activeCount":98},[],{"trials":8521,"activeCount":98},[],{"trials":8523,"activeCount":98},[8524],{"nctId":8064,"briefTitle":8065,"status":304,"phases":8525,"primaryCompletion":8067,"completion":8068,"start":8069,"enrollment":8070,"conditions":8526,"interventions":8527},[91],[8072],[8049,8074,8075],{"intervention":8110,"totalTrials":94,"cells":8529},{"EARLY_PHASE1":8530,"PHASE1":8532,"PHASE2":8534,"PHASE3":8536,"PHASE4":8538,"NA":8540},{"trials":8531,"activeCount":98},[],{"trials":8533,"activeCount":98},[],{"trials":8535,"activeCount":98},[],{"trials":8537,"activeCount":98},[],{"trials":8539,"activeCount":98},[],{"trials":8541,"activeCount":98},[8542],{"nctId":8101,"briefTitle":8102,"status":385,"phases":8543,"primaryCompletion":8104,"completion":8105,"start":8106,"enrollment":98,"conditions":8544,"interventions":8545},[],[8108],[8086,8110],{"intervention":8547,"totalTrials":94,"cells":8548},"Florbetapir",{"EARLY_PHASE1":8549,"PHASE1":8551,"PHASE2":8553,"PHASE3":8555,"PHASE4":8557,"NA":8559},{"trials":8550,"activeCount":98},[],{"trials":8552,"activeCount":98},[],{"trials":8554,"activeCount":98},[],{"trials":8556,"activeCount":98},[],{"trials":8558,"activeCount":98},[],{"trials":8560,"activeCount":98},[8561],{"nctId":8562,"briefTitle":8563,"status":304,"phases":8564,"primaryCompletion":8565,"completion":8565,"start":8069,"enrollment":8566,"conditions":8567,"interventions":8573},"NCT01231971","Alzheimer's Disease Neuroimaging Initiative 2",[],"2017-11-29",1182,[8568,8569,8570,8571,8572],"Mild Cognitive Impairment (MCI)","Alzheimer's Disease (AD)","Significant Memory Concern (SMC)","Early Mild Cognitive Impairment (EMCI)","Late Mild Cognitive Impairment (LMCI)",[8547,8574],"Flortaucipir",{"intervention":8574,"totalTrials":94,"cells":8576},{"EARLY_PHASE1":8577,"PHASE1":8579,"PHASE2":8581,"PHASE3":8583,"PHASE4":8585,"NA":8587},{"trials":8578,"activeCount":98},[],{"trials":8580,"activeCount":98},[],{"trials":8582,"activeCount":98},[],{"trials":8584,"activeCount":98},[],{"trials":8586,"activeCount":98},[],{"trials":8588,"activeCount":98},[8589],{"nctId":8562,"briefTitle":8563,"status":304,"phases":8590,"primaryCompletion":8565,"completion":8565,"start":8069,"enrollment":8566,"conditions":8591,"interventions":8592},[],[8568,8569,8570,8571,8572],[8547,8574],{"intervention":8594,"totalTrials":94,"cells":8595},"Ketamine",{"EARLY_PHASE1":8596,"PHASE1":8598,"PHASE2":8600,"PHASE3":8602,"PHASE4":8604,"NA":8606},{"trials":8597,"activeCount":98},[],{"trials":8599,"activeCount":98},[],{"trials":8601,"activeCount":98},[],{"trials":8603,"activeCount":98},[],{"trials":8605,"activeCount":98},[],{"trials":8607,"activeCount":98},[8608],{"nctId":8609,"briefTitle":8610,"status":385,"phases":8611,"primaryCompletion":8612,"completion":8613,"start":204,"enrollment":98,"conditions":8614,"interventions":8616},"NCT04291521","Prospective Study of Induction Medications Used in the Trauma RSI",[],"2029-04-30","2029-07-30",[3544,8615],"Rapid Sequence Intubation",[8594,8617,8618],"Etomidate","Propofol",{"intervention":8617,"totalTrials":94,"cells":8620},{"EARLY_PHASE1":8621,"PHASE1":8623,"PHASE2":8625,"PHASE3":8627,"PHASE4":8629,"NA":8631},{"trials":8622,"activeCount":98},[],{"trials":8624,"activeCount":98},[],{"trials":8626,"activeCount":98},[],{"trials":8628,"activeCount":98},[],{"trials":8630,"activeCount":98},[],{"trials":8632,"activeCount":98},[8633],{"nctId":8609,"briefTitle":8610,"status":385,"phases":8634,"primaryCompletion":8612,"completion":8613,"start":204,"enrollment":98,"conditions":8635,"interventions":8636},[],[3544,8615],[8594,8617,8618],{"intervention":8618,"totalTrials":94,"cells":8638},{"EARLY_PHASE1":8639,"PHASE1":8641,"PHASE2":8643,"PHASE3":8645,"PHASE4":8647,"NA":8649},{"trials":8640,"activeCount":98},[],{"trials":8642,"activeCount":98},[],{"trials":8644,"activeCount":98},[],{"trials":8646,"activeCount":98},[],{"trials":8648,"activeCount":98},[],{"trials":8650,"activeCount":98},[8651],{"nctId":8609,"briefTitle":8610,"status":385,"phases":8652,"primaryCompletion":8612,"completion":8613,"start":204,"enrollment":98,"conditions":8653,"interventions":8654},[],[3544,8615],[8594,8617,8618],{"intervention":2191,"totalTrials":94,"cells":8656},{"EARLY_PHASE1":8657,"PHASE1":8659,"PHASE2":8661,"PHASE3":8663,"PHASE4":8665,"NA":8667},{"trials":8658,"activeCount":98},[],{"trials":8660,"activeCount":98},[],{"trials":8662,"activeCount":98},[],{"trials":8664,"activeCount":98},[],{"trials":8666,"activeCount":98},[],{"trials":8668,"activeCount":98},[8669],{"nctId":2182,"briefTitle":2183,"status":385,"phases":8670,"primaryCompletion":2185,"completion":2186,"start":2187,"enrollment":98,"conditions":8671,"interventions":8672},[91],[2189],[2155,2172,2191],{"intervention":8674,"totalTrials":94,"cells":8675},"Levonorgestrel 1.5mg by mouth once",{"EARLY_PHASE1":8676,"PHASE1":8678,"PHASE2":8680,"PHASE3":8682,"PHASE4":8684,"NA":8686},{"trials":8677,"activeCount":98},[],{"trials":8679,"activeCount":98},[],{"trials":8681,"activeCount":98},[],{"trials":8683,"activeCount":98},[],{"trials":8685,"activeCount":98},[],{"trials":8687,"activeCount":98},[8688],{"nctId":8689,"briefTitle":8690,"status":304,"phases":8691,"primaryCompletion":4608,"completion":4608,"start":8692,"enrollment":16,"conditions":8693,"interventions":8694},"NCT02104609","Effects of Obesity on Pharmacokinetics of the Levonorgestrel Emergency Contraceptive Pill",[],"2013-04",[15],[8674],{"intervention":8696,"totalTrials":94,"cells":8697},"Avastin",{"EARLY_PHASE1":8698,"PHASE1":8700,"PHASE2":8702,"PHASE3":8704,"PHASE4":8706,"NA":8708},{"trials":8699,"activeCount":98},[],{"trials":8701,"activeCount":98},[],{"trials":8703,"activeCount":98},[],{"trials":8705,"activeCount":98},[],{"trials":8707,"activeCount":98},[],{"trials":8709,"activeCount":98},[8710],{"nctId":8711,"briefTitle":8712,"status":304,"phases":8713,"primaryCompletion":7108,"completion":4261,"start":674,"enrollment":1046,"conditions":8714,"interventions":8717},"NCT01270542","Avastin for PDR (Proliferative Diabetic Retinopathy)",[91],[8715,8716],"Retinal Detachment","Diabetic Retinopathy",[8696],{"intervention":8719,"totalTrials":94,"cells":8720},"Proton pump inhibitor",{"EARLY_PHASE1":8721,"PHASE1":8723,"PHASE2":8725,"PHASE3":8727,"PHASE4":8729,"NA":8731},{"trials":8722,"activeCount":98},[],{"trials":8724,"activeCount":98},[],{"trials":8726,"activeCount":98},[],{"trials":8728,"activeCount":98},[],{"trials":8730,"activeCount":98},[],{"trials":8732,"activeCount":98},[8733],{"nctId":8734,"briefTitle":8735,"status":304,"phases":8736,"completion":8737,"start":4632,"enrollment":8738,"conditions":8739,"interventions":8741},"NCT00573924","Trial of Oral Versus Intravenous Proton Pump Inhibitor on Intragastric pH in Patients With Bleeding Ulcers",[91],"2007-12",66,[8740],"Peptic Ulcer Hemorrhage",[8719],{"intervention":8743,"totalTrials":94,"cells":8744},"Metformin",{"EARLY_PHASE1":8745,"PHASE1":8747,"PHASE2":8749,"PHASE3":8751,"PHASE4":8753,"NA":8755},{"trials":8746,"activeCount":98},[],{"trials":8748,"activeCount":98},[],{"trials":8750,"activeCount":98},[],{"trials":8752,"activeCount":98},[],{"trials":8754,"activeCount":98},[],{"trials":8756,"activeCount":98},[8757],{"nctId":8758,"briefTitle":8759,"status":304,"phases":8760,"primaryCompletion":8761,"completion":8761,"start":7410,"enrollment":8762,"conditions":8763,"interventions":8766},"NCT01763346","Beta Cell Restoration Through Fat Mitigation",[91],"2018-06",88,[8764,8765,15],"Prediabetes","Type 2 Diabetes",[8743],{"intervention":8768,"totalTrials":94,"cells":8769},"2% lidocaine gel",{"EARLY_PHASE1":8770,"PHASE1":8772,"PHASE2":8774,"PHASE3":8776,"PHASE4":8778,"NA":8780},{"trials":8771,"activeCount":98},[],{"trials":8773,"activeCount":98},[],{"trials":8775,"activeCount":98},[],{"trials":8777,"activeCount":98},[],{"trials":8779,"activeCount":98},[],{"trials":8781,"activeCount":98},[8782],{"nctId":8783,"briefTitle":8784,"status":304,"phases":8785,"primaryCompletion":3540,"completion":3540,"start":3431,"enrollment":2735,"conditions":8786,"interventions":8788},"NCT01612156","Lubricant Versus Lidocaine Gel for Pain Control During Urodynamics",[91],[8787],"Pelvic Floor Disorders",[8768,8789],"Water based lubricant",{"intervention":8789,"totalTrials":94,"cells":8791},{"EARLY_PHASE1":8792,"PHASE1":8794,"PHASE2":8796,"PHASE3":8798,"PHASE4":8800,"NA":8802},{"trials":8793,"activeCount":98},[],{"trials":8795,"activeCount":98},[],{"trials":8797,"activeCount":98},[],{"trials":8799,"activeCount":98},[],{"trials":8801,"activeCount":98},[],{"trials":8803,"activeCount":98},[8804],{"nctId":8783,"briefTitle":8784,"status":304,"phases":8805,"primaryCompletion":3540,"completion":3540,"start":3431,"enrollment":2735,"conditions":8806,"interventions":8807},[91],[8787],[8768,8789],{"intervention":8809,"totalTrials":94,"cells":8810},"combined oral contraceptives",{"EARLY_PHASE1":8811,"PHASE1":8813,"PHASE2":8815,"PHASE3":8817,"PHASE4":8819,"NA":8821},{"trials":8812,"activeCount":98},[],{"trials":8814,"activeCount":98},[],{"trials":8816,"activeCount":98},[],{"trials":8818,"activeCount":98},[],{"trials":8820,"activeCount":98},[],{"trials":8822,"activeCount":98},[8823],{"nctId":8824,"briefTitle":8825,"status":304,"phases":8826,"primaryCompletion":8827,"enrollment":7970,"conditions":8828,"interventions":8830},"NCT01953211","Oral Contraceptive Hormone-free Interval Pituitary\u002F Ovarian Activity",[],"1998-12",[8829],"Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy",[8809],{"intervention":8832,"totalTrials":94,"cells":8833},"Autologous adipose tissue",{"EARLY_PHASE1":8834,"PHASE1":8836,"PHASE2":8838,"PHASE3":8840,"PHASE4":8842,"NA":8844},{"trials":8835,"activeCount":98},[],{"trials":8837,"activeCount":98},[],{"trials":8839,"activeCount":98},[],{"trials":8841,"activeCount":98},[],{"trials":8843,"activeCount":98},[],{"trials":8845,"activeCount":98},[8846],{"nctId":8847,"briefTitle":8848,"status":2435,"phases":8849,"primaryCompletion":8163,"completion":8850,"start":3294,"enrollment":8851,"conditions":8852,"interventions":8854},"NCT03242707","Intra-articular Adipose Tissue Injections for Osteoarthritis",[91],"2020-12-01",54,[8853],"Osteoarthritis, Knee",[8832,8855],"Hyaluronic Acid",{"intervention":8855,"totalTrials":94,"cells":8857},{"EARLY_PHASE1":8858,"PHASE1":8860,"PHASE2":8862,"PHASE3":8864,"PHASE4":8866,"NA":8868},{"trials":8859,"activeCount":98},[],{"trials":8861,"activeCount":98},[],{"trials":8863,"activeCount":98},[],{"trials":8865,"activeCount":98},[],{"trials":8867,"activeCount":98},[],{"trials":8869,"activeCount":98},[8870],{"nctId":8847,"briefTitle":8848,"status":2435,"phases":8871,"primaryCompletion":8163,"completion":8850,"start":3294,"enrollment":8851,"conditions":8872,"interventions":8873},[91],[8853],[8832,8855],{"intervention":8875,"totalTrials":94,"cells":8876},"Norethindrone acetate",{"EARLY_PHASE1":8877,"PHASE1":8879,"PHASE2":8881,"PHASE3":8883,"PHASE4":8885,"NA":8887},{"trials":8878,"activeCount":98},[],{"trials":8880,"activeCount":98},[],{"trials":8882,"activeCount":98},[],{"trials":8884,"activeCount":98},[],{"trials":8886,"activeCount":98},[],{"trials":8888,"activeCount":98},[8889],{"nctId":8890,"briefTitle":8891,"status":304,"phases":8892,"primaryCompletion":8893,"completion":8894,"start":8895,"enrollment":593,"conditions":8896,"interventions":8898},"NCT01667978","The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception",[91],"2013-09","2014-09","2012-06",[7972,2999,8897],"AIDS",[8875],{"intervention":8900,"totalTrials":94,"cells":8901},"Ofatumumab",{"EARLY_PHASE1":8902,"PHASE1":8904,"PHASE2":8906,"PHASE3":8908,"PHASE4":8910,"NA":8912},{"trials":8903,"activeCount":98},[],{"trials":8905,"activeCount":98},[],{"trials":8907,"activeCount":98},[],{"trials":8909,"activeCount":98},[],{"trials":8911,"activeCount":98},[],{"trials":8913,"activeCount":98},[8914],{"nctId":8915,"briefTitle":8916,"status":304,"phases":8917,"primaryCompletion":3566,"completion":8918,"start":8919,"enrollment":1286,"conditions":8920,"interventions":8922},"NCT05171972","Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment",[],"2025-07-31","2022-01-29",[8921],"Relapsing Remitting Multiple Sclerosis",[8900],{"intervention":8084,"totalTrials":94,"cells":8924},{"EARLY_PHASE1":8925,"PHASE1":8927,"PHASE2":8929,"PHASE3":8931,"PHASE4":8933,"NA":8935},{"trials":8926,"activeCount":98},[],{"trials":8928,"activeCount":98},[],{"trials":8930,"activeCount":98},[],{"trials":8932,"activeCount":98},[],{"trials":8934,"activeCount":98},[],{"trials":8936,"activeCount":98},[8937],{"nctId":8077,"briefTitle":8078,"status":304,"phases":8938,"primaryCompletion":8080,"completion":8080,"start":8081,"enrollment":511,"conditions":8939,"interventions":8940},[91],[8072],[8049,8084],{"intervention":8142,"totalTrials":94,"cells":8942},{"EARLY_PHASE1":8943,"PHASE1":8945,"PHASE2":8947,"PHASE3":8949,"PHASE4":8951,"NA":8953},{"trials":8944,"activeCount":98},[],{"trials":8946,"activeCount":98},[],{"trials":8948,"activeCount":98},[],{"trials":8950,"activeCount":98},[],{"trials":8952,"activeCount":98},[],{"trials":8954,"activeCount":98},[8955],{"nctId":8112,"briefTitle":8113,"status":398,"phases":8956,"primaryCompletion":5315,"completion":8115,"start":8116,"enrollment":250,"conditions":8957,"interventions":8958},[91],[8118,8119,8120,8121,8122,8123,8124,8125,8126,8127,8128,8129,8130,8131,8132,8133,8134,8135,8136,8137,8138,8139,6826,7413,8140],[8086,8142],{"intervention":8960,"totalTrials":94,"cells":8961},"Vestibular Incision Subperiosteal Tunnel Access",{"EARLY_PHASE1":8962,"PHASE1":8964,"PHASE2":8966,"PHASE3":8968,"PHASE4":8970,"NA":8972},{"trials":8963,"activeCount":98},[],{"trials":8965,"activeCount":98},[],{"trials":8967,"activeCount":98},[],{"trials":8969,"activeCount":98},[],{"trials":8971,"activeCount":98},[],{"trials":8973,"activeCount":98},[8974],{"nctId":8975,"briefTitle":8976,"status":385,"phases":8977,"primaryCompletion":8978,"completion":8978,"start":8979,"enrollment":98,"conditions":8980,"interventions":8982},"NCT03124329","Efficacy of Methods to Treat Multiple Gingival Recession Defects",[91],"2019-06-19","2017-05-01",[8981],"Gingival Recession",[8960],{"intervention":8984,"totalTrials":94,"cells":8985},"Intra Plexus Triamcinolone and Bupivicaine",{"EARLY_PHASE1":8986,"PHASE1":8988,"PHASE2":8990,"PHASE3":8992,"PHASE4":8994,"NA":8996},{"trials":8987,"activeCount":98},[],{"trials":8989,"activeCount":98},[],{"trials":8991,"activeCount":98},[],{"trials":8993,"activeCount":98},[],{"trials":8995,"activeCount":98},[],{"trials":8997,"activeCount":98},[8998],{"nctId":8999,"briefTitle":9000,"status":398,"phases":9001,"primaryCompletion":9002,"completion":9002,"start":2462,"enrollment":94,"conditions":9003,"interventions":9006},"NCT02399800","Celiac Plexus Block for Chronic Pancreatitis RCT",[91],"2018-02-12",[9004,9005],"Pancreatitis, Chronic","Pancreatitis",[8984],{"intervention":9008,"totalTrials":94,"cells":9009},"capecitabine, gemcitabine, docetaxel",{"EARLY_PHASE1":9010,"PHASE1":9012,"PHASE2":9014,"PHASE3":9016,"PHASE4":9018,"NA":9020},{"trials":9011,"activeCount":98},[],{"trials":9013,"activeCount":98},[],{"trials":9015,"activeCount":98},[],{"trials":9017,"activeCount":98},[],{"trials":9019,"activeCount":98},[],{"trials":9021,"activeCount":98},[9022],{"nctId":9023,"briefTitle":9024,"status":398,"phases":9025,"primaryCompletion":3365,"completion":1508,"start":676,"enrollment":94,"conditions":9026,"interventions":9027},"NCT00159471","Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.",[91],[3368],[9008],{"intervention":9029,"totalTrials":94,"cells":9030},"vorinostat",{"EARLY_PHASE1":9031,"PHASE1":9033,"PHASE2":9035,"PHASE3":9037,"PHASE4":9039,"NA":9041},{"trials":9032,"activeCount":98},[],{"trials":9034,"activeCount":98},[],{"trials":9036,"activeCount":98},[],{"trials":9038,"activeCount":98},[],{"trials":9040,"activeCount":98},[],{"trials":9042,"activeCount":98},[9043],{"nctId":9044,"briefTitle":9045,"status":385,"phases":9046,"primaryCompletion":4259,"completion":5968,"start":5967,"enrollment":98,"conditions":9047,"interventions":9048},"NCT01695057","Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer",[91],[27,21,8021],[9029],{"intervention":9050,"totalTrials":94,"cells":9051},"Gilenya",{"EARLY_PHASE1":9052,"PHASE1":9054,"PHASE2":9056,"PHASE3":9058,"PHASE4":9060,"NA":9062},{"trials":9053,"activeCount":98},[],{"trials":9055,"activeCount":98},[],{"trials":9057,"activeCount":98},[],{"trials":9059,"activeCount":98},[],{"trials":9061,"activeCount":98},[],{"trials":9063,"activeCount":98},[9064],{"nctId":9065,"briefTitle":9066,"status":304,"phases":9067,"primaryCompletion":1437,"completion":9068,"start":9069,"enrollment":9070,"conditions":9071,"interventions":9072},"NCT02225977","Assessing Induction of Type II (M2) Monocytes\u002FMacrophages in Patients Receiving Gilenya.",[],"2017-04-30","2013-07-31",125,[7413],[9050],{"intervention":1468,"totalTrials":94,"cells":9074},{"EARLY_PHASE1":9075,"PHASE1":9077,"PHASE2":9079,"PHASE3":9081,"PHASE4":9083,"NA":9085},{"trials":9076,"activeCount":98},[],{"trials":9078,"activeCount":98},[],{"trials":9080,"activeCount":98},[],{"trials":9082,"activeCount":98},[],{"trials":9084,"activeCount":98},[],{"trials":9086,"activeCount":98},[9087],{"nctId":1458,"briefTitle":1459,"status":398,"phases":9088,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":1463,"conditions":9089,"interventions":9090},[91],[1465,1466],[1468,346,1469],{"intervention":1469,"totalTrials":94,"cells":9092},{"EARLY_PHASE1":9093,"PHASE1":9095,"PHASE2":9097,"PHASE3":9099,"PHASE4":9101,"NA":9103},{"trials":9094,"activeCount":98},[],{"trials":9096,"activeCount":98},[],{"trials":9098,"activeCount":98},[],{"trials":9100,"activeCount":98},[],{"trials":9102,"activeCount":98},[],{"trials":9104,"activeCount":98},[9105],{"nctId":1458,"briefTitle":1459,"status":398,"phases":9106,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":1463,"conditions":9107,"interventions":9108},[91],[1465,1466],[1468,346,1469]]